AU2022279441A1 - Novel multivalent nanoparticle-based vaccines - Google Patents
Novel multivalent nanoparticle-based vaccines Download PDFInfo
- Publication number
- AU2022279441A1 AU2022279441A1 AU2022279441A AU2022279441A AU2022279441A1 AU 2022279441 A1 AU2022279441 A1 AU 2022279441A1 AU 2022279441 A AU2022279441 A AU 2022279441A AU 2022279441 A AU2022279441 A AU 2022279441A AU 2022279441 A1 AU2022279441 A1 AU 2022279441A1
- Authority
- AU
- Australia
- Prior art keywords
- insdqualifier
- insdseq
- insdfeature
- name
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940039328 nanoparticle-based vaccine Drugs 0.000 title claims abstract description 7
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 357
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 341
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 326
- 239000002105 nanoparticle Substances 0.000 claims abstract description 270
- 230000002163 immunogen Effects 0.000 claims abstract description 192
- 241000894007 species Species 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 56
- 230000028993 immune response Effects 0.000 claims abstract description 48
- 101710154606 Hemagglutinin Proteins 0.000 claims description 297
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 297
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 297
- 101710176177 Protein A56 Proteins 0.000 claims description 297
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 211
- 150000001413 amino acids Chemical class 0.000 claims description 70
- 239000000185 hemagglutinin Substances 0.000 claims description 65
- 230000003472 neutralizing effect Effects 0.000 claims description 31
- 241001502567 Chikungunya virus Species 0.000 claims description 26
- 101710157275 Ferritin subunit Proteins 0.000 claims description 23
- 241000270934 Rana catesbeiana Species 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 241000590002 Helicobacter pylori Species 0.000 claims description 9
- 101710201961 Virion infectivity factor Proteins 0.000 claims description 9
- 229940037467 helicobacter pylori Drugs 0.000 claims description 9
- 241000893512 Aquifex aeolicus Species 0.000 claims description 5
- 241000204666 Thermotoga maritima Species 0.000 claims description 5
- 241000205069 Acidianus ambivalens Species 0.000 claims description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 abstract description 193
- 102000037865 fusion proteins Human genes 0.000 abstract description 193
- 238000008416 Ferritin Methods 0.000 abstract description 117
- 150000007523 nucleic acids Chemical class 0.000 abstract description 110
- 239000012678 infectious agent Substances 0.000 abstract description 82
- 108050000784 Ferritin Proteins 0.000 abstract description 75
- 102000008857 Ferritin Human genes 0.000 abstract description 75
- 108020004707 nucleic acids Proteins 0.000 abstract description 59
- 102000039446 nucleic acids Human genes 0.000 abstract description 59
- 208000015181 infectious disease Diseases 0.000 abstract description 10
- 101710159527 Maturation protein A Proteins 0.000 abstract 1
- 101710091157 Maturation protein A2 Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 212
- 241000700605 Viruses Species 0.000 description 83
- 235000001014 amino acid Nutrition 0.000 description 79
- 206010022000 influenza Diseases 0.000 description 73
- 229940024606 amino acid Drugs 0.000 description 71
- 102220417854 c.293A>T Human genes 0.000 description 68
- 238000001338 self-assembly Methods 0.000 description 60
- 108091028043 Nucleic acid sequence Proteins 0.000 description 51
- 229960005486 vaccine Drugs 0.000 description 47
- 230000000295 complement effect Effects 0.000 description 44
- 208000037798 influenza B Diseases 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 39
- 125000000539 amino acid group Chemical group 0.000 description 33
- 241000287828 Gallus gallus Species 0.000 description 31
- 235000013330 chicken meat Nutrition 0.000 description 31
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 239000000203 mixture Substances 0.000 description 25
- 108010068996 6,7-dimethyl-8-ribityllumazine synthase Proteins 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 210000003719 b-lymphocyte Anatomy 0.000 description 17
- 238000006467 substitution reaction Methods 0.000 description 17
- 101000868165 Acidianus ambivalens Sulfur oxygenase/reductase Proteins 0.000 description 16
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 16
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 230000003053 immunization Effects 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108091008875 B cell receptors Proteins 0.000 description 15
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- 230000000890 antigenic effect Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 238000006386 neutralization reaction Methods 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 241000701806 Human papillomavirus Species 0.000 description 11
- 241001482238 Pica pica Species 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- -1 encapsulin Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000000234 capsid Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 8
- 241000709661 Enterovirus Species 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 208000037797 influenza A Diseases 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000712907 Retroviridae Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229960003971 influenza vaccine Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 6
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 6
- 101710091045 Envelope protein Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 108010001267 Protein Subunits Proteins 0.000 description 6
- 102000002067 Protein Subunits Human genes 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- 101710172711 Structural protein Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 6
- 239000013638 trimer Substances 0.000 description 6
- 241000710929 Alphavirus Species 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 241000710831 Flavivirus Species 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 108010006232 Neuraminidase Proteins 0.000 description 5
- 102000005348 Neuraminidase Human genes 0.000 description 5
- 241000702437 Parvovirus H3 Species 0.000 description 5
- 108010076039 Polyproteins Proteins 0.000 description 5
- 241000710960 Sindbis virus Species 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 229940023064 escherichia coli Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 241000725619 Dengue virus Species 0.000 description 4
- 241001115402 Ebolavirus Species 0.000 description 4
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 4
- 108090001126 Furin Proteins 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 4
- 241000342334 Human metapneumovirus Species 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001115401 Marburgvirus Species 0.000 description 4
- 241000608292 Mayaro virus Species 0.000 description 4
- 230000004988 N-glycosylation Effects 0.000 description 4
- 241000712464 Orthomyxoviridae Species 0.000 description 4
- 241001505332 Polyomavirus sp. Species 0.000 description 4
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 4
- 241000710942 Ross River virus Species 0.000 description 4
- 241000710961 Semliki Forest virus Species 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001806 memory b lymphocyte Anatomy 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000726121 Acidianus Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 101900351172 Chikungunya virus Structural polyprotein Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000711950 Filoviridae Species 0.000 description 3
- 241000710781 Flaviviridae Species 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- 241000711504 Paramyxoviridae Species 0.000 description 3
- 241001631648 Polyomaviridae Species 0.000 description 3
- 241001112090 Pseudovirus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 241000710924 Togaviridae Species 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- SFIHWLKHBCDNCE-UHFFFAOYSA-N uranyl formate Chemical compound OC=O.OC=O.O=[U]=O SFIHWLKHBCDNCE-UHFFFAOYSA-N 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101000611570 Bos taurus Prolactin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 206010017914 Gastroenteritis salmonella Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100273730 Homo sapiens CD5 gene Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 241000283216 Phocidae Species 0.000 description 2
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 241000204652 Thermotoga Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 238000002439 negative-stain electron microscopy Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CSAHOYQKNHGDHX-ACZMJKKPSA-N Ala-Gln-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CSAHOYQKNHGDHX-ACZMJKKPSA-N 0.000 description 1
- IVKWMMGFLAMMKJ-XVYDVKMFSA-N Ala-His-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N IVKWMMGFLAMMKJ-XVYDVKMFSA-N 0.000 description 1
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 1
- OOIMKQRCPJBGPD-XUXIUFHCSA-N Arg-Ile-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O OOIMKQRCPJBGPD-XUXIUFHCSA-N 0.000 description 1
- RCENDENBBJFJHZ-ACZMJKKPSA-N Asn-Asn-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCENDENBBJFJHZ-ACZMJKKPSA-N 0.000 description 1
- AEZCCDMZZJOGII-DCAQKATOSA-N Asn-Met-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O AEZCCDMZZJOGII-DCAQKATOSA-N 0.000 description 1
- RATOMFTUDRYMKX-ACZMJKKPSA-N Asp-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N RATOMFTUDRYMKX-ACZMJKKPSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- WTXCNOPZMQRTNN-BWBBJGPYSA-N Cys-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)O WTXCNOPZMQRTNN-BWBBJGPYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- YOTNPRLPIPHQSB-XUXIUFHCSA-N Ile-Arg-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOTNPRLPIPHQSB-XUXIUFHCSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-DKIMLUQUSA-N Ile-Phe-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(O)=O XLXPYSDGMXTTNQ-DKIMLUQUSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 101710199771 Matrix protein 1 Proteins 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 101100086490 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rbd-2 gene Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- CDBXVDXSLPLFMD-BPNCWPANSA-N Tyr-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDBXVDXSLPLFMD-BPNCWPANSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 244000156473 Vallaris heynei Species 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VLYUGYAKYZETRF-UHFFFAOYSA-N dihydrolipoamide Chemical compound NC(=O)CCCCC(S)CCS VLYUGYAKYZETRF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 108010019701 influenza virus M-protein Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960001226 live attenuated influenza Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000004160 naive b lymphocyte Anatomy 0.000 description 1
- 239000002091 nanocage Substances 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012562 protein A resin Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Novel, nanoparticle-based vaccines are provided that elicit an immune response to a
broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a
heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self
5 assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from
an infectious agent, such as influenza virus. The fusion proteins self-assemble to form
nanoparticles that display a heterogeneous population of immunogenic portions on their surface.
When administered to an individual, such nanoparticles elicit an immune response to different
strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles
0 can be used to vaccinate an individual against infection by different Types, subtypes and/or
strains of infectious agents. Also provided are specific fusion proteins, nucleic acid molecules
encoding such fusion proteins and methods of using nanoparticles of the invention to vaccinate
individuals.
Description
This application claims the benefit of U.S. Provisional Application No. 62/098,755, filed December 31, 2014, the entire contents of which is incorporated herein by reference. This application is a divisional of Australian Patent Application No. 2020200303 filed January 15, 2020, which is a divisional of Australian Patent Application No. 2015373928 filed December 31, 2015, the entire contents of which are incorporated herein by reference.
The present invention provides novel, nanoparticle-based vaccines that are easily manufactured, potent, and which elicit broadly neutralizing antibodies against infectious agents, such as influenza virus, HIV and human papilloma virus. In particular, the present invention provides novel nanoparticles (nps), the surfaces of which display a heterogeneous population of immunogenic portions of proteins from infectious agents. Such nanoparticles comprise fusion proteins, each of which comprises a monomeric subunit of ferritin joined to one or more immunogenic portions of proteins from infectious agents. When such nanoparticles are administered to an individual, they elicit an immune response to proteins from a broad range of '0 infectious agents. In a first embodiment, there is provided a nanoparticle, comprising: at least four species of immunogenic portions of influenza virus hemagglutinin (HA) proteins from at least four different strains of influenza virus; wherein each species of the immunogenic portions of the HA proteins comprises an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 32-62; wherein each species of the immunogenic portions of the HA proteins is joined to subunits of the nanoparticle; and wherein the nanoparticle displays on its surface each species of the immunogenic portions of the HA proteins. In certain aspects, the subunits of the nanoparticle are selected from the group consisting of a monomeric ferritin subunit protein, a monomeric encapsulin protein, a monomeric 03-33 protein, a monomeric SOR protein, a monomeric LS protein, and a monomeric PDC protein.
In a second embodiment, there is provided kit comprising the nanoparticle of the disclosure. In a third embodiment, there is provided a method of eliciting in an individual, an immune response against influenza virus, comprising administering to the individual the nanoparticle of the disclosure. In certain aspects, the immune response is a broadly neutralizing immune response. In a fourth embodiment, there is provided a method of vaccinating an individual against influenza virus, comprising administering to the individual the nanoparticle of the disclosure. In one embodiment, the invention is a nanoparticle comprising fusion proteins, wherein the surface of the nanoparticle displays immunogenic portions of corresponding proteins from at least two infectious agents, wherein the at least two infectious agents are from different corresponding taxonomic groups within the same taxonomic family. In certain aspects of the invention, the fusion proteins comprise at least a portion of a self-assembling, monomeric subunit joined to at least one immunogenic portion of a protein from an infectious agent. In one embodiment, the invention is a nanoparticle comprising at least a first fusion protein and a second fusion protein, each fusion protein comprising at least a portion of a self assembling, monomeric subunit joined to at least one immunogenic portion of a protein from an infectious agent, wherein the immunogenic portion of the first fusion protein is from a protein from a first infectious agent; wherein the immunogenic portion of the second fusion protein is '0 from a protein from a second infectious agent; wherein the proteins from the first and second infectious agents are corresponding proteins; and wherein the first and second infectious agents are from different corresponding taxonomic groups within the same taxonomic family. In the above embodiments, the corresponding taxonomic groups can be genera, types, subtypes, species or strains. In certain aspects, the monomeric subunit can be a monomeric ferritin subunit protein, a monomeric encapsulin protein, a monomeric 03-33 protein, a monomeric SOR protein, a monomeric LS protein, a monomeric PDC protein or a Chikungunya virus structural polyprotein. In certain aspects the infectious agents are viruses. In certain aspects, the infectious agents can be, for example, influenza viruses, human immunodeficiency viruses (HIV), flaviviruses (e.g., hepatitis virus, dengue virus, etc.), human papillomaviruses (HPV), rhinoviruses, coronaviruses, enteroviruses, polyomaviruses, respiratory synctial viruses (RSV), human metapneumoviruses, ebola viruses, Marburg viruses, alphaviruses (e.g.,
Chikungunya virus, Ross River virus, Semliki Forest virus, Sindbis virus, Mayaro virus, etc), Porcine Epidemic Diarrhea, Porcine reproductive and respiratory syndrome virus and foot and mouth disease virus. In one embodiment, nanoparticles of the above embodiments can be produced by introducing into a cell one or more nucleic acid molecules encoding fusion proteins comprising at least a portion of a self-assembling, monomeric subunit joined to at least one immunogenic portion of a protein from an infectious agent, and incubating the cell under conditions suitable for expression of the encoded proteins to form nanoparticles. In certain embodiments, such a method can comprise further purification and/or isolation of the nanoparticles. In one embodiment of the invention, nanoparticles of the embodiments listed above are used to prepare a medicament for protecting an individual from an infectious agent. In such embodiments, the nanoparticles comprise immunogenic portions of proteins from infectious agents in the same taxonomic family as the infectious agent against which the individual is being protected. In certain embodiments, the medicament is used to vaccinate the individual. One embodiment of the invention is a method to elicit a protective immune response against an infectious agent, the method comprising administering to an individual a nanoparticle of the embodiments of the invention, or a composition or medicament comprising embodiments of the invention, wherein the nanoparticles comprise immunogenic portions of proteins from infectious agents in the same taxonomic family as the infectious agent against which the '0 protective immune response is being elicited. One embodiment of the invention is a method to elicit neutralizing antibodies against an infectious agent, the method comprising administering to an individual a nanoparticle of the embodiments of the invention, or a composition or medicament comprising embodiments of the invention, wherein the nanoparticles comprise immunogenic portions of proteins from infectious agents in the same taxonomic family as the infectious agent against which the neutralizing antibodies are desired. In one embodiment, the invention is a nanoparticle that comprises self-assembling fusion proteins, and in this embodiment the nanoparticle displays on its surface a heterogeneous population of immunogenic portions from HA proteins from one or more Type, Group, subtype and/or strain of influenza virus.
In another embodiment, the invention is a nanoparticle that comprises a heterogeneous population of fusion proteins, and in this embodiment each fusion protein comprises at least a portion of a monomeric subunit protein capable of self-assembling into a nanoparticle joined to at least one immunogenic portion from an influenza virus hemagglutinin protein, such that the heterogeneous population comprises at least two different species of fusion proteins, and such that the difference between two species of fusion proteins is due, at least in part, to sequence differences in the immunogenic portion from an influenza virus HA protein. In yet another embodiment, the invention is a nanoparticle that comprises at least two species of fusion proteins, and in this embodiment each fusion protein comprises at least a portion of a monomeric subunit protein capable of self-assembling into a nanoparticle joined to at least one immunogenic portion from an influenza virus HA protein, such that the species of fusion protein differ from one another due, at least in part, to differences in the sequences of the immunogenic portion from an influenza virus hemagglutinin protein. In still another embodiment, the invention is a nanoparticle that comprises at least a first species of fusion protein and a second species of fusion protein, and in this embodiment the fusion proteins comprise at least a portion of a monomeric subunit protein capable of self assembling into a nanoparticle joined to at least one immunogenic portion from an influenza virus hemagglutinin protein, such that the species of fusion proteins differ from one another due, at least in part, to differences in the sequences of the immunogenic portion from an influenza '0 virus hemagglutinin protein. In the above embodiments, the different species of fusion proteins contain immunogenic portions from HA proteins of influenza viruses in different taxonomic groups within the orthomyxoviridae family. In the above embodiments, ferritin-based nanoparticle can form an octahedron, which can consist of 24 subunits. Further, the immunogenic portions of the influenza HA proteins can be displayed on the surface of the nanoparticle with a spacing range in the range of about 50 A to about 100 k Additionally, the monomeric subunit protein can be selected from a monomeric ferritin subunit protein, a monomeric encapsulin protein, a monomeric 03-33 protein, a monomeric SOR protein, a monomeric LS protein, a monomeric PDC protein and Chikungunya virus envelope protein. The monomeric ferritin subunit protein can be selected from the a bacterial ferritin, a plant ferritin, an algal ferritin, an insect ferritin, a fungal ferritin and a mammalian ferritin and in preferred embodiments, is selected from a monomeric subunit of a Helicobacterpylori ferritin protein, a monomeric subunit of a Escherichia coli ferritin protein and a monomeric subunit of a bullfrog ferritin protein. In still another preferred embodiment, the monomeric ferritin subunit protein can be a hybrid protein that comprises at least a portion of a bullfrog ferritin protein joined to at least a portion of a ferritin protein selected from a Helicobacterpyloriferritin protein and an Escherichiacoli ferritin protein. In one aspect of the embodiments of the invention, the monomeric subunit protein can comprise at least 25 contiguous amino acids from a protein selected from a monomeric ferritin subunit protein, a monomeric encapsulin protein, a monomeric 03-33 protein, a monomeric SOR protein, a monomeric LS protein, a monomeric PDC protein and Chikungunya virus envelope protein. In still another aspect of the embodiments of the invention, the monomeric subunit protein can comprise at least 25 contiguous amino acids from an amino acid sequence selected from a sequence selected from SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:79, SEQ ID NO:82, SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:91 and SEQ ID NO:94. Alternatively, the monomeric subunit protein can comprise an amino acid sequence at least about 80% identical to an amino acid sequence selected from SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:79, SEQ ID NO:82, SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:91 and SEQ ID NO:94. Also, the '0 monomeric subunit protein can comprise an amino acid sequence selected from SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:79, SEQ ID NO:82, SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:91 and SEQ ID NO:94. In one aspect of the embodiments of the invention, the HA protein can be from a virus selected from A/New Caledonia/20/1999 (HIN1), A/California/04/2009 (HIN1), A/Singapore/1/1957 (H2N2), A/Hong Kong/1/1968 (H3N2), A/Brisbane/10/2007 (H3N2), A/Indonesia/05/2005 (H5N1), B/Florida/4/2006 (influenza B), A/Perth/16/2009 (H3N2), A/Brisbane/59/2007 (HIN1), B/Brisbane/60/2008 (influenza B), A/Wilson-Smith/33 (HIN1), A/Tientsin/78/77 (HIN1), A/Texas/36/91 (HIN1), A/Singapore/6/86 (HIN1), A/Memphis/39/83 (HINI), A/Malaysia/54 (HINI), A/Iowa/43 (HINI), A/Hong Kong/117/77 (HINI), A/Fort Monmouth/l/47 (HIN1), A/Brisbane/59/07 (HIN1), A/Baylor/4052/81 (HIN1), A/Albany/4835/48 (HIN1), A/Hong Kong/156/97 (H5N1), A/common magpie/Hong
Kong/5052/07 (H5N1), A/chicken/Shanxi/2/06 (H5N1), A/silky chicken/Hong Kong/SF189/01 (H5N1), A/chicken/Henan/16/04 (H5N1), A/Victoria/361/11 (H3N2), B/Massachusetts/2/12 (influenza B), B/Brisbane/60/08 (influenza B) and A/Texas/50/12 (H3N2). In yet another aspect of the embodiments of the invention, the HA protein can comprise at least 25 contiguous amino acids from the hemagglutinin protein of an influenza virus selected from the group consisting of A/New Caledonia/20/1999 (HiNi), A/Califomia/04/2009 (HiNi), A/Singapore/1/1957 (H2N2), A/Hong Kong/1/1968 (H3N2), A/Brisbane/10/2007 (H3N2), A/Indonesia/05/2005 (H5N1), B/Florida/4/2006 (influenza B), A/Perth/16/2009 (H3N2), A/Brisbane/59/2007 (HiN1), B/Brisbane/60/2008 (influenza B), A/Wilson-Smith/33 (HiN1), A/Tientsin/78/77 (HiN1), A/Texas/36/91 (HiN1), A/Singapore/6/86 (HN1), A/Memphis/39/83 (HiNi), A/Malaysia/54 (HiNi), A/Iowa/43 (HiNi), A/Hong Kong/117/77 (HiNi), A/Fort Monmouth/l/47 (HIN1), A/Brisbane/59/07 (HiN1), A/Baylor/4052/81 (HiN1), A/Albany/4835/48 (HiN1), A/Hong Kong/156/97 (H5N1), A/common magpie/Hong Kong/5052/07 (H5N1), A/chicken/Shanxi/2/06 (H5N1), A/silky chicken/Hong Kong/SF189/01 (H5N1), A/chicken/Henan/16/04 (H5N1), A/Victoria/361/11 (H3N2), B/Massachusetts/2/12 (influenza B), B/Brisbane/60/08 (influenza B) and A/Texas/50/12 (H3N2). In yet another aspect of the embodiments of the invention, the HA protein can comprise at least 25 contiguous amino acids from a sequence selected from SEQ ID NOs: 1-62. The HA protein can comprise an amino acid sequence at least about 80% identical to an amino acid '0 sequence selected from SEQ ID NOs: 1-62. Also, the hemagglutinin protein can comprise an amino acid sequence selected from SEQ ID NOs: 1-62. In still another aspect of the embodiments of the invention, the HA protein can be capable of eliciting an immune response to a protein comprising an amino acid sequence selected from SEQ ID NOs: 1-62. In another aspect of the embodiments of the invention, the immunogenic portion can comprise the receptor-binding domain of an influenza HA protein. Further, the immunogenic portion can be selected from amino acid residues 56-264 of a sequence selected from SEQ ID NOs: 1-62. In yet another aspect of the embodiments of the invention, the at least two species of fusion proteins can comprise immunogenic portions obtained from HA proteins from two different strains of influenza virus. Also, the at least two species of fusion proteins can comprise immunogenic portions obtained from HA protein from two different subtypes of influenza virus. In still another aspect of the embodiments of the invention, at least one species of fusion protein can comprise a linker sequence. In another aspect of the embodiments of the invention, the nanoparticle can elicit an immune response against the RBD region of an influenza HA protein. In one aspect, the nanoparticle can elicit an immune response to an influenza virus strain that is heterologous to the strains of influenza viruses from which the HA immunogenic portions were obtained. In still another aspect, the nanoparticle can elicit an immune response to an influenza virus that is antigenically divergent from the influenza virus from which the hemagglutinin proteins were obtained. In still another aspect of the embodiments of the invention, the heterogeneous population can comprise between 2 and 60 species of fusion proteins. In still another aspect of the embodiments of the invention, the heterogeneous population can comprise between 2 and 240 species of fusion proteins. Another embodiment of the present invention is a fusion protein comprising an amino acid sequence at least 80% identical to a sequence selected from SEQ ID NO:97, SEQ ID NO:100, SEQ ID NO:103, SEQ ID NO:106, SEQ ID NO:109, SEQ ID NO:112, SEQ ID NO:115, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:124, SEQ ID NO:127, SEQ ID '0 NO:130, SEQ ID NO:133, SEQ ID NO:136, SEQ ID NO:139, SEQ ID NO:142, SEQ ID NO:145, SEQ ID NO:148, SEQ ID NO:151, SEQ ID NO:154, SEQ ID NO:157, SEQ ID NO:160, SEQ ID NO:163, SEQ ID NO:166, SEQ ID NO:169, SEQ ID NO:172, SEQ ID NO:175, SEQ ID NO:178, SEQ ID NO:181, SEQ ID NO:184, SEQ ID NO:187 and SEQ ID NO:190. The fusion protein can also comprise an amino acid sequence selected from SEQ ID NO:97, SEQ ID NO:100, SEQ ID NO:103, SEQ ID NO:106, SEQ ID NO:109, SEQ ID NO:112, SEQ ID NO:115, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:124, SEQ ID NO:127, SEQ ID NO:130, SEQ ID NO:133, SEQ ID NO:136, SEQ ID NO:139, SEQ ID NO:142, SEQ ID NO:145, SEQ ID NO:148, SEQ ID NO:151, SEQ ID NO:154, SEQ ID NO:157, SEQ ID NO:160, SEQ ID NO:163, SEQ ID NO:166, SEQ ID NO:169, SEQ ID NO:172, SEQ ID NO:175, SEQ ID NO:178, SEQ ID NO:181, SEQ ID NO:184, SEQ ID NO:187 and SEQ ID NO:190.
A further embodiment is a nucleic acid molecule encoding any of the fusion proteins described above. In this embodiment, the nucleic acid sequence can be at least 80% identical to a sequence selected from SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:126, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171, SEQ ID NO:174, SEQ ID NO:177, SEQ ID NO:180, SEQ ID NO:183, SEQ ID NO:186 and SEQ ID NO:189. In still another aspect, the nucleic acid sequence can comprise a sequence selected from SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:126, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171, SEQ ID NO:174, SEQ ID NO:177, SEQ ID NO:180, SEQ ID NO:183, SEQ ID NO:186 and SEQ ID NO:189. Further in this embodiment, a plasmid can comprise the nucleic acid molecule of any of the nucleic acid molecules described above. Another embodiment of the present invention is a method for producing a nanoparticle of '0 any of the nanoparticles described above, the method comprising introducing one or more nucleic acid molecules encoding fusion proteins, wherein each fusion protein can comprise at least a portion of a monomeric subunit protein capable of self-assembling into a nanoparticle joined to at least one immunogenic portion from an influenza virus hemagglutinin protein; and incubating the cell under conditions suitable for expressing the encoded proteins and forming nanoparticles. A further aspect of this embodiment can comprise isolating the nanoparticles from the cell. Another embodiment of the present invention is a method of eliciting an immune response against influenza virus, the method comprising administering to an individual a nanoparticle as described above. Another embodiment of the present invention is a method of vaccinating an individual against influenza virus, such that the method can comprise administering to the individual a nanoparticle as described above. Accordingly, another embodiment of the present invention is an immunogenic composition comprising a nanoparticle of the invention. Another embodiment of the invention is a medicament for use in vaccinating an individual, or electing an immune response, against influenza virus, the medicament comprising a nanoparticle of the present invention. A further embodiment of the present invention is a kit. The kit can comprise a nanoparticle as described above, compositions and medicaments comprising such nanoparticles, a fusion protein and/or a nucleic acid molecule as described above. BACKGROUND Protective immune responses induced by vaccination against influenza virus are primarily directed to the viral hemagglutinin (HA) protein, which is a glycoprotein on the surface of the virus responsible for interaction of the virus with host cell receptors. HA proteins on the virus surface are trimers of hemagglutinin protein monomers that are enzymatically cleaved to yield amino-terminal HA1 and carboxy-terminal HA2 polypeptides. The globular head consists exclusively of the major portion of the HA1 polypeptide, whereas the stem that anchors the hemagglutinin protein into the viral lipid envelope is comprised of HA2 and part of HA1. The globular head of a hemagglutinin protein includes two domains: the receptor binding domain (RBD), an -148-amino acid residue domain that includes the sialic acid-binding site, and the vestigial esterase domain, a smaller -75-amino acid residue region just below the RBD. The top '0 part of the RBD adjacent to the 2,6-sialic acid recognition sites includes a large region (amino acids 131-143, 170-182, 205-215 and 257-262, 1918 numbering) (referred to herein as the RBD A region) of over 6000 A 2 per trimer that is 95% conserved between A/South Carolina/1/1918 (1918 SC) and A/Califomia/04/2009 (2009 CA) pandemic strains. The globular head includes several antigenic sites that include immunodominant epitopes. Examples include the Sa, Sb, Cai, Ca2 and Cb antigenic sites (see, for example, Caton AJ et al, 1982, Cell 31, 417-427). The RBD-A region includes the Sa antigenic site and part of the Sb antigenic site. Antibodies against influenza often target variable antigenic sites in the globular head of HA, which surround a conserved sialic acid binding site, and thus, neutralize only antigenically closely related viruses. The variability of the HA head is due to the constant antigenic drift of influenza viruses and is responsible for seasonal endemics of influenza. In contrast, gene segments of the viral genome can undergo reassortment (antigenic shift) in host species, creating new viruses with altered antigenicity that are capable of becoming pandemics [Salomon, R. et al. Cell 136, 402-410 (2009)]. Until now, each year, influenza vaccine is updated to reflect the predicted HA and neuraminidase (NA) for upcoming circulating viruses. Current vaccine strategies for influenza use either a chemically inactivated or a live attenuated influenza virus. Both vaccines are generally produced in embryonated eggs which present major manufacturing limitations due to the time consuming process and limited production capacity. Another more critical limitation of current vaccines is its highly strain specific efficacy. These challenges became glaring obvious during emergence of the 2009 HiNi pandemic, thus validating the necessity for new vaccine platforms capable of overcoming these limitations. Virus-like particles represent one of such alternative approaches and are currently being evaluated in clinical trials [Roldao, A. et al. Expert Rev Vaccines 9, 1149-1176 (2010); Sheridan, C. Nat Biotechnol 27, 489-491 (2009)]. Instead of embryonated eggs, VLPs comprising HA, NA and matrix protein 1 (M1) can be mass-produced in mammalian or insect cell expression systems [Haynes, J.R. Expert Rev Vaccines 8, 435-445 (2009)]. The advantages of this approach are its particulate, multivalent nature and the authentic display of properly folded HA proteins that faithfully mimic the infectious virion. In contrast, by the nature of its assembly, the enveloped VLPs contain a small but finite host cell component that may present potential safety, immunogenicity challenges following repeated use of this platform [Wu, C.Y. et al. PLoS One 5, e9784 (2010)]. Moreover, the immunity induced by the VLPs is essentially the '0 same as the immunity induced by current vaccines, and thus, does not likely improve both potency and breadth of vaccine-induced protective immunity. In addition to VLPs, a recombinant HA protein has also been evaluated in humans [Treanor, J.J. et al. Vaccine 19, 1732-1737 (2001); Treanor, J.J. JAMA 297, 1577-1582 (2007)], though the ability to induce protective neutralizing antibody titers are limited. The recombinant HA proteins used in those trials were produced in insect cells and might not form native trimer preferentially [Stevens, J. Science 303, 1866-1870 (2004)]. Recently, entirely new classes of broadly neutralizing antibodies against influenza viruses were isolated. One class of antibodies recognizes the highly conserved HA stem [Corti, D. et al. J Clin Invest 120, 1663-1673 (2010); Ekiert, D.C. et al. Science 324, 246-251 (2009); Kashyap, A.K. et al. Proc Natl Acad Sci USA 105, 5986-5991 (2008); Okuno, Y. et al. J Virol 67, 2552 2558 (1993); Sui, J. et al. Nat Struct Mol Biol 16, 265-273 (2009); Ekiert, D.C. et al. Science
333, 843-850 (2011); Corti, D. et al. Science 333, 850-856 (2011)], and another class of antibodies precisely recognizes the sialic acid binding site of the RBD on the variable HA head
[Whittle, J.R. et al. Proc Natl Acad Sci USA 108, 14216-14221 (2011); Krause, J.C. et al. J Virol 85, 10905-10908 (2011)]. Unlike strain-specific antibodies, those antibodies are capable of neutralizing multiple antigenically distinct viruses, and hence inducing such antibodies has been a focus of next generation universal vaccine [Nabel, G.J. et al. Nat Med 16, 1389-1391 (2010)]. However, robustly eliciting these antibodies with such heterologous neutralizing profile by vaccination has been difficult [Steel, J. et al. MBio 1, e0018 (2010); Wang, T.T. et al. PLoS Pathog6, e1000796 (2010); Wei, C.J. et al. Science 329, 1060-1064 (2010)]. Despite several alternatives to conventional influenza vaccines, advances in biotechnology in past decades have allowed engineering of biological materials to be exploited for the generation of novel vaccine platforms. Ferritin, an iron storage protein found in almost all living organisms, is an example which has been extensively studied and engineered for a number of potential biochemical/biomedical purposes [Iwahori, K. U.S. Patent 2009/0233377 (2009); Meldrum, F.C. et al. Science 257, 522-523 (1992); Naitou, M. et al. U.S. Patent Publication No. 2011/0038025 (2011); Yamashita, I. Biochim Biophys Acta 1800, 846-857 (2010)], including a potential vaccine platform for displaying exogenous epitope peptides
[Carter, D.C. et al. U.S. Patent Publication No. 2006/0251679 (2006); Li, C.Q. et al. Industrial Biotechnol 2, 143-147 (2006)]. Its use as a vaccine platform is particularly interesting because '0 of its self-assembly and multivalent presentation of antigen which induces stronger B cell responses than monovalent form as well as induce T-cell independent antibody responses
[Bachmann, M.F. et al. Annu Rev Immunol 15, 235-270 (1997); Dintzis, H.M. et al. Proc Nat Acad Sci USA 73, 3671-3675 (1976)]. Further, the molecular architecture of ferritin, which consists of 24 subunits assembling into an octahedral cage with 432 symmetry has the potential to display multimeric antigens on its surface. There remains a need for an efficacious influenza vaccine that provides robust protection against influenza virus. There particularly remains a need for an influenza vaccine that elicits broadly a neutralizing immune response, thereby protecting individuals from heterologous strains of influenza virus, including evolving seasonal and pandemic influenza virus strains of the future. The present invention meets this need by providing a novel, multivalent nanoparticle based, influenza vaccine that is easily manufactured, potent, and elicits broadly neutralizing influenza antibodies.
BRIEF DESCRIPTION OF THE FIGURES Figure 1. Theoretical model of immune triggering by a supernatural heterogeneous antigen array on particulate immunogen. (Left Images) Immune triggering upon natural homogeneous antigen array. Particulate homogeneous antigens are built by an antigenically identical subunit and thereby displaying antigenically homogeneous antigens to immune system. B cells harboring B cell receptor (BCR) specific to an antigen displayed on the homogeneous array are stimulated strongly upon encountering the "matched" antigenic stimulation (left middle). B cells harboring more BCR with broader specificity are also stimulated by the homogeneous antigen array but lesser extent presumably the binding affinity of broader specific BCR to the antigen is not as tight as narrower specific BCR to the "matched" antigen (left bottom). The weaker affinity of broader specific BCR to antigen may partly be due to its cross-reactivity because the BCR recognizes other antigenically distinct antigens and thus avoids contacting antigenically heterogeneous parts on antigens (smaller antibody footprint on antigens). (Right Images) Immune triggering upon supernatural heterogeneous antigen array. Particulate heterogeneous antigens are synthetically built using antigenically heterogeneous subunits, which display antigenically heterogeneous '0 antigens to immune system. Upon stimulation with the heterogeneous antigen array, BCRs having narrow specificity only recognize a subset of antigens on the particulate antigen and thus are not stimulated by this antigen (middle right); BCRs having broader specificity recognize larger numbers of antigens on the particulate antigen and thus are stimulated by this antigen (bottom right). In this situation, the B cells harboring BCR with broader specificity have a better chance to outcompete B cells harboring BCR with narrower specificity, therefore selecting cross reactive B cells otherwise being overcast by others. Figure 2. Schematic representation of HA RBD-ferritin single polypeptide design. HA RBD-ferritin construct without Furin-2A (F2A) self cleavage module (top). Two or three HA RBD-ferritin constructs are connected with F2A self cleavage module (middle or bottom, respectively). As the fusion proteins are produced in producer cells, the cellular protease furin cleaves its cleavage site at the N-terminus of F2A module, and 2A protease cleaves the second
(and third) HA RBD-ferritin from the F2A module. As the result, equimolar amount of each HA-RBD-ferritin is produced. Figure 3. Electron microscopic analysis of HA RBD-nanoparticles. (A) Negative stain electron micrographs of NC99 RBD-nanoparticles; (B) Negative stain electron micrographs of CA09 RBD-nanoparticles; (C) Negative stain electron micrographs of co-assembled (CoAsmbl 2) RBD-nanoparticles. Purified particles were adsorbed to freshly glow-discharged carbon coated grids and stained with uranyl formate. Figure 4. Two-dimension classifications of NC99 RBD-nanoparticles were calculated using images stained with ammonium molybdate instead of uranyl formate
. Figure 5. Characterization of HA RBD-nanoparticles. Monovalent (NC99= A/New Caledonia/20/1999 and CA09 A/Califomia/04/2009) and co-assembled (CoAsmbl2= A/New Caledonia/20/99 (NC99) + A/Califomia/04/09 (CA09)) nanoparticles were immunoprecipitated using either anti-NC99 (3u-u)(left), anti-pandemic HINI HA (2D1)(center) or anti-HA stem (C179) (right) monoclonal antibodies. The precipitated material was then analyzed by SDS PAGE Protein bands at -150 and -50 kDa correspond to IgG, RBD-nanoparticle subunits, respectively. Figure 6. SDS-PAGE analysis of purified HA RBD-nanoparticles from different HiNi strains and co-assembled RBD-nanoparticles with different combinations of HA. NC99=ANew Caledonia/20/1999; CA09=A/California/04/2009; WS33=A/Wilson-Smith/1933; '0 AB48=A/Albany/4835/1948; BR07=A/Brisbane/59/2007; IA43=A/Iowa/1943; HK77=A/Hong Kong/117/1977; FM47=A/Fort Monmouth/1/1947. CoAsmbl 2= A/New Caledonia/20/99 (NC99) + A/Califomia/04/09 (CA09); CoAsmbl 4= CoAsmbl 2 + A/Wilson-Smith/33 (WS33) + A/Albany/4835/48 (AB48); CoAsmbl 6 = CoAsmbl 4 + A/Brisbane/59/07 (BR07) + A/Iowa/43 (IA43); CoAsmbl 8 = CoASmbl 6 + A/Hong Kong/117/77 (HK77) + A/Fort Monmouth/l/47 (FM47) Figure 7. Hemagglutination inhibitory (HAI) titers against influenza A/New Caledonia/20/1999 virus. (Left panel) Hemagluttination inhibition titers of sera from mice immunized with monovalent nanoparticles (NC99) or mixtures of monovalent nanoparticles (Admix 2, 4 or 6). (Middle panel) Hemagluttination inhibition titers of sera from mice immunized with monovalent nanoparticles (NC99) or multivalent nanoparticles (CoAsmbl2, 4, 6 or 8). (Right panel) Side by side comparison, using the data from the left and middle panels, comparing the HAI titers generated by immunizing mice with either admixed monovalent nanoparticles or multivalent nanoparticles displaying corresponding influenza HA proteins. All sera was collected at 2 weeks following the second immunization and tested for hemagluttination inhibition activity. Each dot indicates individual serum sample and is plotted as box-and whiskers graph. P values were calculated by Student's t-test. Figure 8. Neutralization titers against NC99 pseudotyped lentivirus. (Left panel) Neutralization titer of sera from mice immunized with monovalent nanoparticles (NC99) or mixtures of monovalent nanoparticles (Admix 2, 4 or 6). (Middle panel) Neutralization titer of sera from mice immunized with monovalent nanoparticles (NC99) or multivalent nanoparticles (CoAsmbl2, 4, 6, or 8). (Right panel) Side by Side comparison, using the data from the left and middle panels, comparing the neutralization titers generated by immunizing mice with either admixed monovalent nanoparticles or multivalent nanoparticles displaying corresponding influenza HA proteins. All sera was collected at 2 weeks following the second immunization and tested for hemagluttination inhibition activity. Each dot indicates individual serum sample and is plotted as box-and-whiskers graph. P values were calculated by Student's t-test. Figure 9. Neutralization breadth of immune serum. Heatmap representation of HAI titers from mice immunized with either monovalent nanoparticles against NC99 or CA09, admixed monovalent nanoparticles (Admix 4), or multivalent, co-assembled nanoparticles '0 (CoAsmbl 4 or CoAsmbl 8). Each row indicates an individual mouse. Figure 10. Detection of HA-specific cross-reactive B cells in peripheral blood cells in HA RBD-nanoparticle-immunized mice. (Upper panels). Gating strategy of mouse whole blood cells. (Bottom panel) FACs analysis using anti-CD3, anti-CD14, anti-CD19, anti-IgD to identify non-naive B-cell populations in peripheral blood from mice immunized with monovalent nanoparticles against NC99 or CA09, admixed particles (Admix 2, Admix 4 or Admix 6), or multivalent (CoAsmbl 2, CoAsmbl 4, CoAsmbl 6 or CoAsmbl 8). Each dot indicates individual sample. Figure 11. Box-and-whiskers plot of FACS data from lower panel in Figure 10. Figure 12. Correlation of NC99/CA09 cross-reactive B cell frequency and antigenic heterogeneity of co-assembled RBD-nanoparticles. X-axis represents antigenic heterogeneity
(number of different HA RBD on a single RBD-nanoparticle). Y-axis represents cross-reactive B cell frequency. Pearson correlation was calculated using GraphPad Prism 6. Figure 13. Three dimensional reconstruction model of HA trimer in complex with Fab 441D6. (Upper panels) Rotational and top views for reconstructed model of HA:Fab441D6 complex. (Lower panels) Electron microscopy density maps of HA:Fab441D6 complex. Resolution of the final model was-~18.5 A.
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel, nanoparticle-based, multivalent vaccine that can be used to produce a broadly neutralizing immune response to various infectious agents, such as influenza virus and human immunodeficiency virus (HIV). The present invention builds on previous work showing that monovalent, nanoparticle-based vaccines can be used to induce a protective immune response against a limited number of closely related infectious agents. For example, previous work in the field of influenza vaccines demonstrated that fusion proteins comprising an immunogenic portion of an influenza virus hemagglutinin (HA) protein joined to a self-assembly (SA) protein, to produce an HA-SA fusion protein, will self-assemble into nanoparticles displaying the immunogenic portion of the influenza HA protein on their surface. Moreover, when such nanoparticles are administered to an individual, they elicit a robust, neutralizing immune response to influenza virus. The construction and use of such nanoparticles '0 has been described in U.S. Patent Publication No. 2014-0302079A1, which is incorporated herein by reference in its entirety. Similarly, nanoparticle-based vaccines for Epstein-Barr Virus have been described in International Patent Application No. PCT/US14/60142, which is incorporated herein by reference in its entirety. The present inventors have now discovered that nanoparticles displaying immunogenic portions of proteins from more than one genera, Type, Group, subtype or strain of infectious agent (e.g., influenza virus) can be used as a vaccine to elicit an immune response that neutralizes a variety, including a heterogeneous population, of different, but related, infectious agents. Moreover, the inventors have found that, surprisingly, such multivalent nanoparticles elicit a greater immune response than do vaccines comprising a single species of monovalent nanoparticles, or a mixture of two or more species of monovalent nanoparticles. Thus, a general embodiment of the invention is a nanoparticle made from self assembling fusion proteins, wherein the surface of the nanoparticle displays a heterogeneous population of immunogenic portions of proteins from two or more infectious agents of the same taxonomic family. In specific embodiments, the two or more infectious agents are divergent enough such that the amino acid sequence of the immunogenic portions of corresponding proteins from the two or more infectious agents differ by at least one amino acid. In certain embodiments, the infectious agents are from different taxonomic groups within the same taxonomic family. Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described herein, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting on the finally claimed invention, since the scope of the invention will be limited only by the claims. It should also be understood that while elements of the invention appear in specific locations in the application, the present invention encompasses any combination of the elements disclosed herein. It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, a nucleic acid molecule refers to one or more nucleic acid molecules. As such, the terms "a", "an", "one or more" and "at least one" can be used interchangeably. Similarly the terms "comprising", "including" and "having" can be used interchangeably. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is '0 intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like, in connection with the recitation of claim elements, or use of a "negative" limitation. Throughout the specification and the claims that follow, unless the context requires otherwise, the words "comprise" and "include" and variations such as "comprising" and "including" will be understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers. The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement of any form of suggestion that such prior art forms part of the common general knowledge. As used herein, a nanoparticle refers to a particle formed from self-assembling, monomeric subunit proteins. For example, ferritin subunit proteins self-assemble into ferritin nanoparticles. Nanoparticles of the present invention are generally spherical, or spheroid, in shape, although other shapes, for example, rod, cube, sheet, oblong, ovoid, and the like, are also useful for practicing the present invention. While nanoparticles of the present invention can vary in size, preferred nanoparticles are those in which the distance between the displayed immunogenic portions of the HA protein globular head region is such that two adjacent immunogenic portions displayed on the nanoparticle can fit the distance of the two antigenic-binding sites of a single B cell receptor, or about 50-100A apart. Such spacing allows each of the two adjacent immunogenic portions to interact with one of the two, identical antigen-binding sites in the same B-cell receptor. Binding of a single B-cell receptor to heterologous immunogenic portions that are adjacent on the surface of the nanoparticle is desirable since it allows for the selection of cross-reactive immune responses. While not intending to be bound by theory, the inventors believe that this is due to the fact that high affinity binding of one antigenic site to an immunogenic portion allows stabilization of low-affinity binding of the other antigenic binding site to a heterologous immunogenic portion. Thus, B-cells are selected that produce cross reactive antibodies. This concept is illustrated in Figure 1. It is understood by those skilled in the art that the antigenic binding sites of a B-cell receptor are approximately 50-100 angstroms (Ak) apart. Thus, in certain embodiments, the immunogenic portions displayed on the surface of the nanoparticle are separated by about 50 -100 k In specific embodiment, the immunogenic portions displayed on the surface of the nanoparticle are separated by about 50 k, by about 60 k, by about 70 k, by about 80 k, by about 90 k, by about 100 k With respect to the spacing of '0 immunogenic portions on the surface of a nanoparticle, the term about refers to a variation of no more than 20%. According to the present invention, a self-assembling monomeric subunit protein, monomeric subunit protein, self-assembly(SA) protein, self-assembling subunit protein, and the like, of the present invention is a full length, monomeric polypeptide, or any portion or variant thereof, which, is capable of directing self-assembly of monomeric self-assembling subunit proteins into a nanoparticle. Such proteins are known to those skilled in the art. Examples of self-assembly proteins useful for producing nanoparticles of the present invention include, but are not limited to, ferritin, encapsulin, sulfur oxygenase reductase (SOR), lumazine synthase (LS), pyruvate dehydrogenase complex (PDC) dihydrolipoamide acetyltransferase (E2) and the envelope (Env) proteins of alphaviruses such as Chikungunya virus. Representative examples of such proteins are listed below in Table 1.
As used herein, a fusion protein is a recombinant protein containing amino acid sequences from at least two unrelated proteins that have been joined together, via a peptide bond, to make a single protein. The unrelated amino acid sequences can be joined directly to each other or they can be joined using a linker sequence. As used herein, proteins are unrelated, if their amino acid sequences are not normally found joined together via a peptide bond in their natural environment (e.g., inside a cell). For example, the amino acid sequences of monomeric subunits of ferritin, and the amino acid sequences of influenza hemagglutinin proteins are not normally found joined together via a peptide bond and thus, these two proteins would be considered unrelated. Similarly, the amino acid sequences of monomeric subunits of encapsulin and the amino acid sequences of influenza hemagglutinin proteins or HIV envelope proteins are not normally found joined together via a peptide bond and thus, encapsulin and influenza HA, or encapsulin and HIV envelope protein, would be considered unrelated. As used herein, a heterogeneous population of immunogenic portions refers a nanoparticle that displays more than one species of immunogenic portion of a protein on its surface. A species of immunogenic portion of a protein of the invention is defined by the specific amino acid sequence of the immunogenic portion. Accordingly, two immunogenic portions having identical amino acid sequences would be considered the same species of immunogenic portion. It should be noted that two fusion proteins comprising the same species of immunogenic portions may or may not vary in regions of amino acid sequences other than the '0 immunogenic portion. If such fusion proteins are identical throughout their entire sequence, they would be considered the same species of fusion protein. Thus, it should be apparent that species of immunogenic portions are defined by variations in their immunogenic portions. Such variation can be due to natural or man-made changes in the amino acid sequence of the immunogenic portion. For example, a new species of immunogenic portion can be made by altering (mutating) the sequence of an existing immunogenic portion through means such as recombinant DNA technology. Methods of making such alterations are known to those skilled in the art. Alternatively, fusion proteins having different species of immunogenic portions can be made using corresponding proteins, or useful portions thereof, (or nucleic acid molecules encoding such proteins or portions) from unique, but related, infectious agents. For example, it is known that viruses often produce progeny virus having mutations in their envelope (or capsid) protein, the result being that some percentage of the progeny virus avoid detection by the host immune system. Similarly repeated cycles of progeny production result in a heterogeneous population of viruses, with various individual viruses in the population differing in the sequence of their envelope (or capsid) proteins. Such a process eventually results in the production of closely related, but genetically divergent viruses. These divergent viruses are referred to strains, species and subtypes. As these strains, species and subtypes become more divergent, they are further classified into types, generas and/or families. Such classifications can be referred to as taxonomic groups. For examples, a taxonomic group can be a family, a genus, a type, a subtype, a strain or a species. Classification of viruses into various taxonomic groups is well understood by those skilled in the art. With regard to the present invention, preferred nanoparticles are those comprising immunogenic portions from two or more infectious agents within the same family. As used herein, corresponding proteins are proteins having a similar function in two (or more) different organisms. Corresponding proteins may or may not have identical amino acid sequences, but generally share some sequence homology. In the examples above, the envelope (or capsid) proteins from two closely related viruses are corresponding proteins. As a further example, envelope proteins from different strains of HIV would be considered corresponding proteins, as would hemagglutinin (HA) protein from different strains, subtypes, or genera of influenza virus. In certain embodiments, proteins having the same function in two different infectious agents from the same taxonomic family would be considered corresponding proteins. '0 In certain embodiments, such proteins have at least 50% sequence homology. In certain embodiments, such proteins have at least 50% sequence identity, at least 60% sequence identity, at least 70% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 95% sequence identity, at least 97% sequence identity, or at least 99% sequence identity. As used herein, the term infectious agent refers to any microorganism capable of infecting a mammal. Preferred infectious agents are those which cause illness. Examples of infectious agents include, but are not limited to, viruses, bacteria and parasites. Examples of useful viruses for practicing methods of the present invention include, but are not limited to, viruses from a family selected from the group consisting of orthomyxoviridae, retroviridae, flaviviridae, filoviridae, coronoviridae, paramyxoviridae, picomoviridae, retroviridae, papillomaviridae, togaviridae, and polyomaviridae. More specific examples of useful viruses for practicing methods of the present invention include, but are not limited to, influenza viruses, human immunodeficiency viruses (HIV), flaviviruses (e.g., hepatitis virus, dengue virus, etc.), human papillomaviruses (HPV), rhinoviruses, coronaviruses, enteroviruses, polyomaviruses, respiratory synctial viruses (RSV), human metapneumoviruses, ebola viruses, Marburg viruses, alphaviruses (e.g., Chikungunya virus, Ross River virus, Semliki Forest virus, Sindbis virus, Mayaro virus, etc), Porcine Epidemic Diarrhea virus, Porcine reproductive and respiratory syndrome virus, and foot and mouth disease virus. Proteins from infectious agents can be any protein useful for generating an immune response against an infectious agent comprising the protein. Useful proteins are those that elicit a protective immune response, such as the production of neutralizing antibodies. A particularly desirable protein is one that elicits the production of broadly neutralizing antibodies. One example of a useful protein with which to practice the present invention is the HIV envelope glycoprotein protein (Gp120). The ability of GP120 to elicit an antibody response, as well as useful mutants thereof, as well as other useful HIV proteins are described in U.S. Patent Publication Nos. US20140322269, US 20040052821, US20030064361, US20030158134, all of which are incorporated herein by reference in their entirety. Another example of a useful protein with which to practice the present invention is the flavivirus envelope protein, which is described in U.S. Patent Publication No. 20110059131, U.S. Patent Publication No. 20090311287, and U.S. Patent Publication No. 20040009469, all of which are incorporated herein by reference in their entirety. Another example of a useful protein with which to practice the present invention '0 is the HCV capsid protein, which is described in U.S. Patent Publication No. 20020107360, U.S. Patent Publication No. 20020119495, and U.S. Patent Publication No. 20050233316, all of which are incorporated herein by reference in their entirety. Other useful proteins with which to practice the present invention are human Papillomavirus (HPV) proteins such as E2. The use of such proteins is described in U.S. Patent Publication No. 20100143408 and U.S. Patent Publication No. 20100183648, both of which are incorporated herein by reference in their entirety. Other useful proteins are disclosed in U.S. Patent Publication No. 20140161833, U.S. Patent Publication No. 20090202583, U.S. Patent Publication No. 20060182762, U.S. Patent Publication No. 20050053622, U.S. Patent Publication No. 20040175395, U.S. Patent Publication No. 20090162395, U.S. Patent Publication No. 20030224015, U.S. Patent Publication No. 20050255123, U.S. Patent Publication No.US 2012-0003266 and U.S. Patent Publication No.20120315270, all of which are incorporated herein by reference in their entirety.
As used herein, broadly neutralizing antibodies are antibodies that neutralize an infectious agent from a taxonomic group that differs from the taxonomic groups of the infectious agents from which the immunogenic portions used to elicit the antibodies (used produce the nanoparticles) were derived. In preferred embodiments, nanoparticles of the invention elicit broadly neutralizing antibodies that neutralize at least one infectious agent from a genera, type, subtype, species and/or strain that differs from the genera, type, subtype, species and/or strain of the infectious agents from which imunogenic portions were derived in order to produce the nanoparticle. For example, if a nanoparticle is constructed using immunogenic portions of HA proteins from influenza A/Hong Kong/1/1968 (H3N2) and influenza A/Indonesia/05/2005 (H5N1), antibodies elicited by such nanoparticle and that that are broadly neutralizing would be able to neutralize one or more influenza viruses of genera, types, subtypes, species and/or strains other than influenza A/Hong Kong/1/1968 (H3N2) and influenza A/Indonesia/05/2005 (H5N1). One embodiment of the present invention is a nanoparticle comprising fusion proteins, wherein the surface of the nanoparticle displays immunogenic portions of corresponding proteins from at least two infectious agents, wherein the at least two infectious agents are from different corresponding taxonomic groups within the same taxonomic family. In on embodiment, each fusion protein comprises at least a portion of a self-assembling, monomeric subunit joined to at least one portion of an immunogenic portion of a protein from an infectious agent. In one embodiment, the portion of the self-assembling, monomeric subunit comprises at least 25 amino '0 acids, at least 50 amino acids, at least 75 amino acids, at least 100 amino acids or at least 150 amino acids from a monomeric subunit protein selected from the group consisting of a monomeric ferritin subunit protein, a monomeric encapsulin protein, a monomeric 03-33 protein, a monomeric SOR protein, a monomeric LS protein, a monomeric PDC protein and a Chikungunya virus structural polyprotein. In one embodiment, each fusion protein comprises a monomeric subunit protein selected from the group consisting of a monomeric ferritin subunit protein, a monomeric encapsulin protein, a monomeric 03-33 protein, a monomeric SOR protein, a monomeric LS protein, a monomeric PDC protein and a Chikungunya virus structural polyprotein. In one embodiment, the infectious agents are viruses. Any virus capable of infecting a mammal can be used in constructing nanoparticles of the present invention. Examples of useful viruses for practicing methods of the present invention include, but are not limited to, viruses from a family selected from the group consisting of orthomyxoviridae, retroviridae, flaviviridae, filoviridae, coronoviridae, paramyxoviridae, picomoviridae, retroviridae, papillomaviridae, togaviridae, and polyomaviridae. Examples of useful viruses include, but are not limited to, influenza viruses, human immunodeficiency viruses (HIV), flaviviruses (e.g., hepatitis virus, dengue virus, etc.), human papillomaviruses (HPV), rhinoviruses, coronaviruses, enteroviruses, polyomaviruses, respiratory synctial viruses (RSV), human metapneumoviruses, ebola viruses, Marburg viruses, alphaviruses (e.g., Chikungunya virus, Ross River virus, Semliki Forest virus, Sindbis virus, Mayaro virus, etc), Porcine Epidemic Diarrhea virus, Porcine reproductive and respiratory syndrome virus and foot and mouth disease virus. In one embodiment, the at least two infectious agents are from different genera within the same family. In one embodiment, the at least two infectious agents are from different species within the same family. In one embodiment, the at least two infectious agents are from different Types within the same family. In one embodiment, the at least two infectious agents are from different subtypes within the same family. In one embodiment, the at least two infectious agents are different strains within the same family. One embodiment of the present invention is a nanoparticle comprising a first fusion protein and a second fusion protein, each fusion protein comprising at least a portion of a self assembling, monomeric subunit joined to at least one immunogenic portion of a protein from an infectious agent, wherein the immunogenic portion of the first fusion protein is from a protein '0 from a first infectious agent; wherein the immunogenic portion of the second fusion protein is from a protein from a second infectious agent; wherein the proteins from the first and second infectious agents are corresponding proteins; and wherein the first and second infectious agents are from different corresponding taxonomic groups within the same taxonomic family. In one embodiment, the infectious agents are viruses. Any virus capable of infecting a mammal can be used in constructing nanoparticles of the present invention. Examples of useful viruses for practicing methods of the present invention include, but are not limited to, viruses from a family selected from the group consisting of orthomyxoviridae, retroviridae, flaviviridae, filoviridae, coronoviridae, paramyxoviridae, picomoviridae, retroviridae, papillomaviridae, togaviridae, and polyomaviridae. Examples of useful viruses include, but are not limited to, influenza viruses, human immunodeficiency viruses (HIV), flaviviruses (e.g., hepatitis virus, dengue virus, etc.), human papillomaviruses (HPV), rhinoviruses, coronaviruses, enteroviruses, polyomaviruses, respiratory synctial viruses (RSV), human metapneumoviruses, ebola viruses, Marburg viruses, alphaviruses (e.g., Chikungunya virus, Ross River virus, Semliki Forest virus, Sindbis virus, Mayaro virus, etc), Porcine Epidemic Diarrhea, Porcine reproductive and respiratory syndrome virus and foot and mouth disease virus. In one embodiment, the at least two infectious agents are from different genera within the same family. In one embodiment, the at least two infectious agents are from different species within the same family. In one embodiment, the at least two infectious agents are from different Types within the same family. In one embodiment, the at least two infectious agents are from different subtypes within the same family. In one embodiment, the at least two infectious agents are different strains within the same family. One embodiment of the present invention is a nanoparticle comprising at least two species of fusion protein, each species of fusion protein comprising at least a portion of a self assembling, monomeric subunit joined to at least one immunogenic portion of a protein from a unique infectious agent, wherein the proteins in the unique infectious agents correspond to one another, and; wherein each unique infectious agent is from a different corresponding taxonomic group within the same taxonomic family. As used herein, a unique infectious agent refers to infectious agents from the same taxonomic family, such as orthomyoviridae or retroviridae, which are genetically distinct from one another. Thus, infectious agents that are unique from one another would belong to different '0 taxonomic groups. For example, two different strains of influenza virus would be considered unique from one another. Likewise, two different subtypes of influenza virus would be considered unique from one another. While not intending to be limited to a specific embodiment, the inventors have chosen to utilize influenza virus to demonstrate the general principles and concepts of the present invention. Thus, with regard to certain embodiments of the present invention, all nomenclature used herein to classify influenza virus is that commonly used by those skilled in the art. Thus, a Type of influenza virus refers to influenza Type A, influenza Type B or influenza type C. It is understood by those skilled in the art that the designation of a virus as a specific Type relates to sequence difference in the respective M1 (matrix) protein or NP (nucleoprotein). Type A influenza viruses are further divided into Group1 and Group 2. These Groups are further divided into subtypes, a designation that refers to classification of a virus based on the sequence of its
HA protein. Examples of current commonly recognized subtypes are HI, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17 or H18. Group 1 influenza subtypes are HI, H2, H5, H6, H8, H9, HI1, H12, H13, H16, H17 and H18. Group 2 influenza subtypes are H3, H4, H7, H1O, H14 and H15. Finally, the term strain refers to viruses within a subtype that differ from one another due to small, genetic variations in their genome. Such genetic variations may, or may not, result in amino acid changes in the encoded influenza protein(s). As used herein, an influenza hemagglutinin protein, or HA protein, refers the hemagglutinin glycoprotein present on the surface of influenza virus. Influenza virus HA proteins are able to bind sialic acid on the surface of cells, an activity responsible for the viruses ability to cause red blood cells to agglutinate. Influenza virus HA proteins are also responsible for fusion of the influenza virus membrane with the endosome membrane following infection of a cell by influenza virus. Such proteins, and their activities, are known to those skilled in the art. With specific regard to the present invention, an HA protein refers to a full-length influenza virus hemagglutinin protein or any portion thereof, that is, at least, capable of eliciting an immune response. Exemplary influenza proteins useful for producing nanoparticles of the present invention are listed below in Table 1.
Table 1 SEQ ID ORGANISM DESCRIPTION NOs. Ectodomains 1 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/New Caledonia/20/1999 (HIN1). 2 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Califomia/04/2009 (HIN1) 3 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Singapore/i/1957 (H2N2) 4 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Hong Kong/1/1968 (H3N2) 5 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Brisbane/10/2007 (H3N2) 6 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Indonesia/05/2005 (H5N1) 7 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from B/Florida/4/2006 (influenza B) 8 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Perth/16/2009 (H3N2) 9 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Brisbane/59/2007 (HIN1)
SEQ ID ORGANISM DESCRIPTION NOs. Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from B/Brisbane/60/2008 (influenza B) II Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Wilson-Smith/33 (HIN1) 12 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Tientsin/78/77 (HIN1) 13 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Texas/36/91 (H IN1) 14 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Singapore/6/86 (HIN1) Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Memphis/39/83 (HIN1) 16 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Malaysia/54 (HIN1) 17 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Iowa/43 (HIN1) 18 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Hong Kong/117/77 (HIN1) 19 Influenza virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Fort Monmouth/1/47 (HIN1) Influenza virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Brisbane/59/07 (HIN1) 21 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Baylor/4052/81 (HIN1) 22 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Albany/4835/48 (HIN1) 23 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Hong Kong/156/97 (H5N1) 24 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/common magpie/Hong Kong/5052/07 (H5N1) Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/chicken/Shanxi/2/06 (H5N1) 26 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/silky chicken/Hong Kong/SF189/01 (H5N1) 27 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/chicken/Henan/16/04 (H5N1) 28 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Victoria/361/11 (H3N2) 29 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from B/Massachusetts/2/12 (Influenza B) Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from B/Brisbane/60/08 (Influenza B) 31 Influenza Virus Amino acid sequence of ectodomain from the hemagglutinin protein from A/Texas/50/12 (H3N2) Receptor Binding Domains 32 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/New Caledonia/20/1999 (HiNi); (56-264, F264A) 33 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of
SEQ ID ORGANISM DESCRIPTION NOs. A/New Caledonia/20/1999 (HiN1); (56-264, Y98F, F264A) 34 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Califomia/04/2009 (HiN1); (56-264) Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Califomia/04/2009 (HiN1); (56-264, Y98F) 36 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Singapore/i/1957 (H2N2) 37 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Hong Kong/1/1968 (H3N2) 38 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Brisbane/10/2007 (H3N2) 39 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of B/Florida/4/2006 (influenza B) Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Perth/16/2009 (H3N2) 41 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Wilson-Smith/33 (HINi) (56-264, Y98F, F264A) 42 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Tientsin/78/77 (HiNi) (56-264, Y98F, F264A) 43 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Texas/36/91 (HINi) (56-264, Y98F, F264A) 44 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Singapore/6/86 (HiNi) (56-264, Y98F, F264A) Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Memphis/39/83 (HINi) (56-264, Y98F, F264A) 46 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Malaysia/54 (HiNi) (56-264, Y98F) (56-264, Y98F) 47 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Iowa/43 (HINi) (56-264, Y98F, F264A) 48 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Hong Kong/i17/77 (HiN1) (56-264, Y98F, F264A) 49 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of Fort Monmouth/1/47 (HIN1) (56-264, Y98F, F264A) Influenza virus Amino acid sequence of RBD from hemagglutinin protein of Brisbane/59/07 (HiNi) (56-264, Y98F, F264A) 51 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Baylor/4052/81 (HINi) (56-264, Y98F, F264A) 52 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Albany/4835/48 (HiN1) (56-264, Y98F, F264A) 53 Influenza virus Amino acid sequence of RBD from hemagglutinin protein of Indonesia/05/05 (H5N1) (56-264, Y98F) 54 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/HongKong/156/97(H5Ni) (56-264,Y98F) Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/common magpie/Hong Kong/5052/07 (H5N1) (56-264, Y98F) 56 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/chicken/Shanxi/2/06 (H5N1) (56-264, Y98F) 57 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of
SEQ ID ORGANISM DESCRIPTION NOs. A/silky chicken/Hong Kong/SF189/01 (H5N1) (56-264, Y98F) 58 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/chicken/Henan/16/04 (H5N1) (56-264, Y98F) 59 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Victoria/361/11 (H3N2) (56-264, Y98F, K264A)) Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of B/Massachusetts/2/12 (Influenza B) (63-294) 61 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of B/Brisbane/60/08 (Influenza B) (63-294) 62 Influenza Virus Amino acid sequence of RBD from hemagglutinin protein of A/Texas/50/12 (H3N2) Self-Assembly Proteins Ferritin Proteins 63 Helicobacter pylori Coding sequence for ferritin monomeric subunit protein from H. pylori 64 Helicobacter pylori Amino acid sequence encoded by SEQ ID NO:63 Helicobacter pylori Complement of SEQ ID NO:63 66 Escherichia coli Coding sequence for ferritin monomeric subunit protein from E. coli(gi446839951_WP_000917207.1) 67 Escherichia coli Amino acid sequence encoded by SEQ ID NO:66 68 Escherichia coli Complement of SEQ ID NO:66 69 Rana catesbeiana Coding sequence for bullfrog ferritin monomeric subunit protein (gi 13675gbAAA49524.1) Rana catesbeiana Amino acid sequence encoded by SEQ ID NO:69 SEQ ID NO:8 from 6137NIAID-34-PCT 71 Rana catesbeiana Complement of SEQ ID NO:69 Hybrid Ferritin Proteins 72 Artificial Sequence Coding sequence for H. pylori-ferritin/bullfrog-ferritin fusion protein 73 Artificial Sequence Amino acid sequence encoded by SEQ ID NO:72 74 Artificial Sequence Complement of SEQ ID NO:72 Artificial Sequence Coding sequence for E. coli-ferritin/bullfrog-ferritin fusion protein 76 Artificial Sequence Amino acid sequence encoded by SEQ ID NO:75 77 Artificial Sequence Complement of SEQ ID NO:75 Other Self-Assembling Monomeric Subunits 78 Thermotoga maritima Coding sequence for encapsulin protein 79 Thermotoga maritime Amino acid sequence encoded by SEQ ID NO:78 Thermotoga maritime Complement of SEQ ID NO:78 81 Artificial Sequence Coding sequence for Salmonella enteritis 03-33 protein (gi 390136278 pdb 3VCD) 82 Artificial Sequence Amino acid sequence encoded by SEQ ID NO:81 83 Artificial Sequence Complement of SEQ ID NO:81 84 Acidianus Coding sequence for sulfur oxygenase reductase protein from ambivalens Acidianus ambivalens (gi 93279016 pdb 2CB2) Acidianus Amino acid sequence encoded by SEQ ID NO:84 ambivalens
SEQ ID ORGANISM DESCRIPTION NOs. 86 Acidianus Complement of SEQ ID NO:84 ambivalens 87 Aquifex aeolicus Coding sequence for lumazine synthase protein from Aquifex aeolicus (gi 18159011 pdblHQK) 88 Aquifex aeolicus Amino acid sequence encoded by SEQ ID NO:87 89 Aquifex aeolicus Complement of SEQ ID NO:87 Bacillus Coding sequence for dihydrolipoamide acetyltransferase (E2p) stearothermophilus protein from Bacillus stearothermophilus (gi 4558102 pdbIB5S 91 Bacillus Amino acid sequence encoded by SEQ ID NO:90 stearothermophilus 92 Bacillus Complement of SEQ ID NO:90 stearothermophilus 93 Chikungunya virus Coding sequence for Chikungunya virus capsid, envelope E3, E2, 6K, and El polyprotein 94 Chikungunya virus Amino acid sequence encoded by SEQ ID NO:93 Chikungunya virus Complement of SEQ ID NO:93 Ferritin Fusion Proteins 96 Artificial Sequence Nucleic acid sequence of HI NC99 RBD-Ferritin (56-264, F264A) 97 Artificial Sequence Amino acid sequence of HI NC99 RBD-Ferritin (56-264, F264A) 98 Artificial Sequence Complement of SEQ ID NO:96 99 Artificial Sequence Nucleic acid sequence of HI NC99 RBD-Ferritin (56-264, Y98F, F264A) 100 Artificial Sequence Amino acid sequence of HI NC99 RBD-Ferritin (56-264, F264A) 101 Artificial Sequence Complement of SEQ ID NO:99 102 Artificial Sequence Nucleic acid sequence of HI CA09 RBD-Ferritin (56-264) 103 Artificial Sequence Amino acid sequence of HI CA09 RBD-Ferritin (56-264) 104 Artificial Sequence Complement of SEQ ID NO:102 105 Artificial Sequence Nucleic acid sequence of HI CA09 RBD-Ferritin (56-264, Y98F) 106 Artificial Sequence Amino acid sequence of H1 CA09 RBD-Ferritin (56-264, Y98F) 107 Artificial Sequence Complement of SEQ ID NO:105 108 Artificial Sequence Nucleic acid sequence of HI WS33 RBD-Ferritin (56-264, Y98F,F264A) 109 Artificial Sequence Amino acid sequence of HI WS33 RBD-Ferritin (56-264, Y98F, F264A) 110 Artificial Sequence Complement of SEQ ID NO:108 111 Artificial Sequence Nucleic acid sequence of HI Tien 77 RBD-Ferritin (56-264, Y98F,F264A) 112 Artificial Sequence Amino acid sequence of HI Tien 77 RBD-Ferritin (56-264, Y98F,F264A) 113 Artificial Sequence Complement of SEQ ID NO:111 114 Artificial Sequence Nucleic acid sequence of HI TX91 RBD-Ferritin (56-264, Y98F, F264A)
SEQ ID ORGANISM DESCRIPTION NOs. 115 Artificial Sequence Amino acid sequence of HI TX91 RBD-Ferritin (56-264, Y98F, F264A) 116 Artificial Sequence Complement of SEQ ID NO:114 117 Artificial Sequence Nucleic acid sequence of HI SG86 RBD-Ferritin (56-264, Y98F, F264A) 118 Artificial Sequence Amino acid sequence of HI SG86 RBD-Ferritin (56-264, Y98F, F264A) 119 Artificial Sequence Complement of SEQ ID NO:117 120 Artificial Sequence Nucleic acid sequence of HI Mem83 RBD-Ferritin (56-264, Y98F,F264A) 121 Artificial Sequence Amino acid sequence of HI Mem83 RBD-Ferritin (56-264, Y98F,F264A) 122 Artificial Sequence Complement of SEQ ID NO:120 123 Artificial Sequence Nucleic acid sequence of HI Ma54 RBD-Ferritin (56-264, Y98F) 124 Artificial Sequence Amino acid sequence of HI Ma54 RBD-Ferritin (56-264, Y98F) 125 Artificial Sequence Complement of SEQ ID NO:123 126 Artificial Sequence Nucleic acid sequence of HI IA43 RBD-Ferritin (56-264, Y98F, F264A) 127 Artificial Sequence Amino acid sequence of H1 IA43 RBD-Ferritin (56-264, Y98F, F264A) 128 Artificial Sequence Complement of SEQ ID NO:126 129 Artificial Sequence Nucleic acid sequence of HI HK77 RBD-Ferritin (56-264, Y98F, F264A) 130 Artificial Sequence Amino acid sequence of HI HK77 RBD-Ferritin (56-264, Y98F, F264A) 131 Artificial Sequence Complement of SEQ ID NO:129 132 Artificial Sequence Nucleic acid sequence of HI FM47 RBD-Ferritin (56-264, Y98F, F264A) 133 Artificial Sequence Amino acid sequence of HI FM47 RBD-Ferritin (56-264, Y98F, F264A) 134 Artificial Sequence Complement of SEQ ID NO:132 135 Artificial Sequence Nucleic acid sequence of HI BRO7 RBD-Ferritin (56-264, Y98F,F264A) 136 Artificial Sequence Amino acid sequence of HI BRO7 RBD-Ferritin (56-264, Y98F, F264A) 137 Artificial Sequence Complement of SEQ ID NO:135 138 Artificial Sequence Nucleic acid sequence of HI Bay81 RBD-Ferritin (56-264, Y98F,F264A) 139 Artificial Sequence Amino acid sequence of HI Bay81 RBD-Ferritin (56-264, Y98F, F264A) 140 Artificial Sequence Complement of SEQ ID NO:138 141 Artificial Sequence Nucleic acid sequence of HI Alb48 RBD-Ferritin (56-264, Y98F,F264A) 142 Artificial Sequence Amino acid sequence of HI Alb48 RBD-Ferritin (56-264, Y98F, F264A) 143 Artificial Sequence Complement of SEQ ID NO:141
SEQ ID ORGANISM DESCRIPTION NOs. 144 Artificial Sequence Nucleic acid sequence of H5 IN05 RBD-Ferritin (56-264, Y98F) 145 Artificial Sequence Amino acid sequence ofH51IN05 RBD-Ferritin (56-264, Y98F) 146 Artificial Sequence Complement of SEQ ID NO:144 147 Artificial Sequence Nucleic acid sequence of H5 HK97(cO) RBD-Ferritin (56-264, Y98F) 148 Artificial Sequence Amino acid sequence of H5 HK97(cO) RBD-Ferritin (56-264, Y98F) 149 Artificial Sequence Complement of SEQ ID NO:147 150 Artificial Sequence Nucleic acid sequence of H5 HK07(c2.3.2.1) RBD-Ferritin (56 264, Y98F) 151 Artificial Sequence Amino acid sequence of H5 HK07(c2.3.2.1) RBD-Ferritin (56 264, Y98F) 152 Artificial Sequence Complement of SEQ ID NO:150 153 Artificial Sequence Nucleic acid sequence of H5 SX06(c7.2) RBD-Ferritin (56-264, Y98F) 154 Artificial Sequence Amino acid sequence of H5 SX06(c7.2) RBD-Ferritin (56-264, Y98F) 155 Artificial Sequence Complement of SEQ ID NO:153 156 Artificial Sequence Nucleic acid sequence of H5 HK1(c3) RBD-Ferritin (56-264, Y98F) 157 Artificial Sequence Amino acid sequence of H5 HK1(c3) RBD-Ferritin (56-264, Y98F) 158 Artificial Sequence Complement of SEQ ID NO:156 159 Artificial Sequence Nucleic acid sequence of H5 HN04(c8) RBD-Ferritin (56-264, Y98F) 160 Artificial Sequence Amino acid sequence of H5 HN04(c8) RBD-Ferritin (56-264, Y98F) 161 Artificial Sequence Complement of SEQ ID NO:159 162 Artificial Sequence Nucleic acid sequence of H3 Vic11 RBD-Ferritin (56-264, Y98F, K264A) 163 Artificial Sequence Amino acid sequence of H3 Vic1 RBD-Ferritin (56-264, Y98F, K264A) 164 Artificial Sequence Complement of SEQ ID NO:162 165 Artificial Sequence Nucleic acid sequence of B MA12 RBD-Ferritin (63-294) 166 Artificial Sequence Amino acid sequence of B MA12 RBD-Ferritin (63-294) 167 Artificial Sequence Complement of SEQ ID NO:165 168 Artificial Sequence Nucleic acid sequence of B BRO8 RBD-Ferritin (63-295) 169 Artificial Sequence Amino acid sequence of B BRO8 RBD-Ferritin (63-295) 170 Artificial Sequence Complement of SEQ ID NO:168 Ferritin Single Polypeptide Design Fusion Proteins 171 Artificial Sequence Nucleic acid sequence H1/H3 CA09 TX12 F2A RBD-Ferritin 172 Artificial Sequence Amino acid sequence of Hl/H3 CA09 TX12 F2A RBD-Ferritin 173 Artificial Sequence Complement of SEQ ID NO:171 174 Artificial Sequence Nucleic acid sequence of B/B BRO8 MA12 F2A RBD-Ferritin 175 Artificial Sequence Amino acid sequence of B/B BRO8 MA12 F2A RBD-Ferritin 176 Artificial Sequence Complement of SEQ ID NO:174
SEQ ID ORGANISM DESCRIPTION NOs. 177 Artificial Sequence Nucleic acid sequence H1/H3/B CA09 TX12 MA12 F2A RBD Ferritin 178 Artificial Sequence Amino acid sequence of H1/H3 CA09 TX12 MA12 F2A RBD Ferritin 179 Artificial Sequence Complement of SEQ ID NO:177 Encapsulin Fusion Proteins 180 Artificial Sequence Nucleic acid sequence of HI NC99 RBD-Encapsulin (56-264, F264A) 181 Artificial Sequence Amino acid sequence of HI NC99 RBD-Encapsulin (56-264, F264A) 182 Artificial Sequence Complement of SEQ ID NO:180 183 Artificial Sequence Nucleic acid sequence of HI CA09 RBD-Encapsulin (56-264) 184 Artificial Sequence Amino acid sequence of HI CA09 RBD-Encapsulin (56-264) 185 Artificial Sequence Complement of SEQ ID NO:183 CHIK VLP Fusion Proteins 186 Artificial Sequence Nucleic acid sequence of HI NC99 RBD-CHIKVLP (59-264, Y98F,F264A) 187 Artificial Sequence Amino acid sequence of NC99 RBD-CHIKVLP (59-264, Y98F, F264A) 188 Artificial Sequence Complement of SEQ ID NO:186 189 Artificial Sequence Nucleic acid sequence of HI CA09 RBD-CHIKVLP (59-264, Y98F) 190 Artificial Sequence Amino acid sequence of HI CA09 RBD-CHIKVLP (59-264, Y98F) 191 Artificial Sequence Complement of SEQ ID NO:189
It is understood by those skilled in the art that HA proteins from different influenza viruses may have different lengths, due to insertions and/or deletions of amino acid residue in one or both of thee HA proteins. Thus, reference to a corresponding region refers to a region of another proteins that is identical, or nearly so (e.g., at least 95%, identical, at least 98% identical or at least 99% identical), in sequence, structure and/or function to the region being compared. For example, with regard to the globular head region or RBD of a hemagglutinin protein, the corresponding region in another hemagglutinin protein may not have the same residue numbers, but will have a very similar sequence and will perform the same function. To improve sequence comparisons between viruses, numbering systems are used by those in the field, which relate amino acid positions to a reference sequence. Thus, corresponding amino acid residues in hemagglutinin proteins from different strains of influenza may not have the same residue number with respect to their distance from the N-terminal amino acid of the mature protein. For example, using the H3 numbering system, reference to residue 100 in A/New Caledonia/20/1999
(1999 NC, HI) does not mean it is the1 0 0th residue from the N-terminal amino acid of the mature protein. Instead, residue 100 of A/New Caledonia/20/1999 (1999 NC, HI) HA protein aligns with residue 100 of the HA protein from influenza H3N2 strain. The use of such numbering systems is understood by those skilled in the art. Unless otherwise noted, reference to amino acid positions in hemagglutinin proteins herein is made using the H3 numbering system. As used herein, the term immunogenic refers to the ability of a specific protein, or a specific region thereof (i.e., a specific amino acid sequence), to elicit an immune response to the specific protein, or to proteins comprising an amino acid sequence having a high degree of identity with the specific protein. According to the present invention, two proteins having a high degree of identity have amino acid sequences at least 80% identical, at least 85% identical, at least 87% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical or at least 99% identical. Preferred immunogenic proteins, or portions thereof, are those that elicit neutralizing antibodies to influenza virus. As used herein, a heterogeneous population refers to a population of molecules in which at least one molecule in the population differs in sequence from at least one other molecule in the population. For example, with particular regard to the present invention, in a heterogeneous population of immunogenic portions from influenza HA proteins, the population is heterologous due to the fact that the amino acid sequence of at least one immunogenic portion in the '0 population differs from the amino acid sequence of at least one other immunogenic portion in the population. With regard to the present invention, each unique sequence is referred to as a species of molecule (e.g., a species of immunogenic portion, a species of fusion protein, etc.). The difference in sequence between two species of molecule can involve a single amino acid difference or it can involve more than one amino acid difference. Moreover, such differences may, or may not, result in different species having different epitopes. As used herein, epitopes are clusters of amino acid residues that are recognized by (e.g., bound by) components of the immune system, such as B-cell receptors, T-cell receptors, antibodies, and the like, thus forming an immune complex and eliciting an immune response. Such epitopes may consist of contiguous amino acids residues (i.e., amino acid residues that are adjacent to one another in the protein), or they may consist of non-contiguous amino acid residues (i.e., amino acid residues that are not adjacent one another in the linear protein) but which are in close spatial proximity in three-dimensional space in the finally folded protein. Thus, in one embodiment the immunogenic portion comprises at least one epitope from an influenza virus HA protein. As used herein, a monovalent nanoparticle refers to a nanoparticle that displays a single species of immunogenic portion from an HA protein on its surface. That is, all of the immunogenic portions have the same sequence. As used herein, Admixed nanoparticles refers to a population of nanoparticles that contains a mixture of monovalent nanoparticle species. In such a population, each monovalent nanoparticle is produced separately from other monovalent nanoparticles, and the monovalent nanoparticles are then mixed together to produce Admixed nanoparticles. It will be understood by those skilled in the art that while a population of Admixed nanoparticles comprises more than one species of immunogenic portion, each monovalent nanoparticle in the Admixed population comprises a single species of immunogenic portion. As used herein, a multivalent co-assembled nanoparticle, co-assembled nanoparticle, and the like, refers to a nanoparticle made by combining more than one species of fusion protein, wherein at least two fusion proteins differ in the sequence of their immunogenic portions. The result is a nanoparticle comprising a heterogeneous population of self-assembling fusion proteins, wherein the nanoparticle displays on its surface a heterogeneous population of immunogenic portions from HA proteins. Such multivalent nanoparticles can also be referred to as mosaic nanoparticles. One embodiment of the present invention is a nanoparticle comprising a heterologous population of fusion proteins, wherein each fusion protein comprises at least one immunogenic portion from an influenza HA protein joined to at least 25 contiguous amino acids from a monomeric subunit protein capable of assembling into a nanoparticle (i.e., a self-assembly (SA) protein), wherein the heterologous population of fusion proteins comprises at least two different species of fusion proteins. Nanoparticles of the present invention can be made from fusion proteins comprising immunogenic portions of HA proteins from any Type, sub-type, strain, or combinations thereof, of influenza virus. In certain embodiments, the immunogenic portions are from HA proteins from one or more influenza viruses selected from the group consisting of Type A influenza viruses, Type B influenza viruses and Type C influenza viruses. In one embodiment, the immunogenic portions are from HA proteins from one or more virus selected from the group consisting of Group I influenza viruses and Group II influenza virus. In one embodiment, the immunogenic portions are from HA proteins from one or more virus selected from the group consisting of an Hi influenza virus, an H2 influenza virus, an influenza H3 virus, an influenza H4 virus, an influenza H5 virus, an influenza H6 virus, an H7 influenza virus, an H8 influenza virus, an H9 influenza virus, an H10 influenza virus, an Hi1 influenza virus, an H12 influenza virus, an H13 influenza virus, an H14 influenza virus, an H15 influenza virus, an H16 influenza virus, an H17 influenza virus, an H18 influenza virus and an influenza B lineage virus. In certain embodiments, the immunogenic portions are from HA proteins from one or more influenza viruses selected from the group consisting of A/New Caledonia/20/1999 (, HiNi), A/Califomia/04/2009 (HiN), A/Singapore/1/1957 (H2N2), A/Hong Kong/1/1968 (H3N2), A/Brisbane/10/2007 (H3N2), A/Indonesia/05/2005 (H5N1), B/Florida/4/2006 (influenza B), A/Perth/16/2009 (H3N2), A/Brisbane/59/2007 (HiN1), B/Brisbane/60/2008 (influenza B), A/Wilson-Smith/33 (HiN1), A/Tientsin/78/77 (HiN1), A/Texas/36/91 (HiN1), A/Singapore/6/86 (HiN1), A/Memphis/39/83 (HiN1), A/Malaysia/54 (HiN1), A/Iowa/43 (HiNi), A/Hong Kong/117/77 (HN), A/Fort Monmouth/l/47 (HN), A/Brisbane/59/07 (HiNi), A/Baylor/4052/81 (HiNi), A/Albany/4835/48 (HiNi), A/Hong Kong/156/97 (H5Ni), A/common magpie/Hong Kong/5052/07 (H5Ni), A/chicken/Shanxi/2/06 (H5Ni), A/silky chicken/Hong Kong/SF189/01 (H5Ni), A/chicken/Henan/16/04 (H5Ni), A/Victoria/361/11 (H3N2), B/Massachusetts/2/12 (influenza B), B/Brisbane/60/08 (influenza B) and A/Texas/50/12 (H3N2). In certain embodiments, the immunogenic portions are from one or more HA proteins '0 Listed in Table 1. In certain embodiments, the immunogenic portions are from one or more HA proteins selected from the group consisting of HA proteins comprising SEQ ID NO:I-SEQ ID NO:62. In certain embodiments, the immunogenic portions are from one or more HA proteins selected from the group consisting of HA proteins consisting of SEQ ID NO:I-SEQ ID NO:62. Immunogenic portions useful for constructing nanoparticles of the present invention can also be obtained from variants of influenza virus HA proteins disclosed herein. As used herein, a variant refers to a protein, or nucleic acid molecule, the sequence of which is similar, but not identical to, a reference sequence, wherein the activity of the variant protein (or the protein encoded by the variant nucleic acid molecule) is not significantly altered. These variations in sequence can be naturally occurring variations or they can be engineered through the use of genetic engineering technique known to those skilled in the art. Examples of such techniques are found in Sambrook J, Fritsch E F, Maniatis T et al., in Molecular Cloning--A Laboratory
Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, pp. 9.31-9.57), or in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, both of which are incorporated herein by reference in their entirety. With regard to variants, any type of alteration in the amino acid, or nucleic acid, sequence is permissible so long as such alterations do not significantly affect the activity of the variant protein and the variant protein retains the desired activity. Examples of such variations include, but are not limited to, deletions, insertions, substitutions and combinations thereof. For example, with regard to proteins, it is well understood by those skilled in the art that one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10), amino acids can often be removed from the amino and/or carboxy terminal ends of a protein without significantly affecting the activity of that protein. Similarly, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acids can often be inserted into a protein without significantly affecting the activity of the protein. As noted, variant proteins of the present invention can contain amino acid substitutions relative to the influenza HA proteins disclosed herein. Any amino acid substitution is permissible so long as the activity of the protein is not significantly affected. In this regard, it is appreciated in the art that amino acids can be classified into groups based on their physical properties. Examples of such groups include, but are not limited to, charged amino acids, uncharged amino acids, polar uncharged amino acids, and hydrophobic amino acids. Preferred variants that contain substitutions are those in which an amino acid is substituted with an amino '0 acid from the same group. Such substitutions are referred to as conservative substitutions. Naturally occurring residues may be divided into classes based on common side chain properties: 1) hydrophobic: Met, Ala, Val, Leu, Ile; 2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; 3) acidic: Asp, Glu; 4) basic: His, Lys, Arg; 5) residues that influence chain orientation: Gly, Pro; and 6) aromatic: Trp, Tyr, Phe. For example, non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class.
In making amino acid changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. The hydropathic indices are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5). The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte et al., 1982, J. Mol. Biol. 157:105-31). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within 2 is preferred, those within 1 are particularly preferred, and those within 0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functionally equivalent protein or peptide thereby created is intended for use in immunological invention, as in the present case. The greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., with a biological property of the protein. The following hydrophilicity values have been '0 assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.01); glutamate (+3.01); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5+1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4). In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within 2 is preferred, those within 1 are particularly preferred, and those within 0.5 are even more particularly preferred. One may also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. For example, amino acid substitutions can be used to identify important residues of the HA protein, or to increase or decrease the immunogenicity, solubility or stability of the HA proteins described herein. Exemplary amino acid substitutions are shown below in Table 2.
Table 2 Amino Acid Substitutions Original Amino Acid Exemplary Substitutions Ala Val, Leu, Ile Arg Lys, Gln, Asn Asn Gln Asp Glu Cys Ser, Ala Gln Asn Glu Asp Gly Pro, Ala His Asn, Gln, Lys, Arg Ile Leu, Val, Met, Ala Leu Ile, Val, Met, Ala Lys Arg, Gln, Asn Met Leu, Phe, Ile Phe Leu, Val, Ile, Ala, Tyr Pro Ala Ser Thr, Ala, Cys Thr Ser Trp Tyr, Phe Tyr Trp, Phe, Thr, Ser Val Ile, Met, Leu, Phe, Ala
As used herein, the phrase significantly affect a proteins activity refers to a decrease in the activity of a protein by at least 10%, at least 20%, at least 30%, at least 40% or at least 50%. With regard to the present invention, such activity may be ability to elicit antibodies, including neutralizing antibodies, against an influenza virus. The determination of antibody production may be measured by measuring the titer of such antibodies against influenza virus, or by measuring the number of types, subtypes or strains bound by the elicited antibodies. Methods of determining antibody titers and methods of performing virus neutralization assays are known to those skilled in the art. In addition to the activities described above, examples of other activities that may be measured include the ability to agglutinate red blood cells, the ability to bind sialic acid or the binding affinity of the protein for a cell. Methods of measuring such activities are known to those skilled in the art.
Thus, in one embodiment, nanoparticles of the present invention comprise fusion proteins comprising immunogenic portions from HA proteins comprising amino acid sequences at least 80%, at least 8 5 %, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% identical to amino acid sequences from one or more HA proteins from any Type, sub-type, strain, or combinations thereof, of influenza virus. In certain embodiments, the immunogenic portions are from HA proteins from one or more influenza viruses selected from the group consisting of Type A influenza virus, Type B influenza virus and Type C influenza viruses. In certain embodiments, the immunogenic portions are from HA proteins from one or more influenza viruses selected from the group consisting of Group 1 influenza virus and Group 2 influenza viruses. In one embodiment, the immunogenic portions are from one or more HA proteins comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% identical to amino acid sequences of HA proteins from one or more viruses selected from the group consisting of an H1 influenza virus, an H2 influenza virus, an influenza H3 virus, an influenza H4 virus, an influenza H5 virus, an influenza H6 virus, an H7 influenza virus, an H8 influenza virus, an H9 influenza virus, an H10 influenza virus, an Hi1 influenza virus, an H12 influenza virus, an H13 influenza virus, an H14 influenza virus, an H15 influenza virus, an H16 influenza virus, an H17 influenza virus, an H18 influenza virus and an influenza lineage B virus. In certain embodiments, the immunogenic portions are from HA proteins comprising amino acid sequence at least 80%, at least 85%, at '0 least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% identical to amino acid sequences of HA proteins from one or more influenza viruses selected from the group consisting of A/New Caledonia/20/1999 (, HiNi), A/Califomia/04/2009 (HiNi), A/Singapore/1/1957 (H2N2), A/Hong Kong/1/1968 (H3N2), A/Brisbane/10/2007 (H3N2), A/Indonesia/05/2005 (H5N1), B/Florida/4/2006 (influenza B), A/Perth/16/2009 (H3N2), A/Brisbane/59/2007 (HiN1), B/Brisbane/60/2008 (influenza B), A/Wilson-Smith/33 (HiN1), A/Tientsin/78/77 (HiN1), A/Texas/36/91 (HiN1), A/Singapore/6/86 (HiN1), A/Memphis/39/83 (HiNi), A/Malaysia/54 (HiNi), A/Iowa/43 (HiNi), A/Hong Kong/117/77 (HiNi), A/Fort Monmouth/l/47 (HiN1), A/Brisbane/59/07 (HiN1), A/Baylor/4052/81 (HiN1), A/Albany/4835/48 (HiN1), A/Hong Kong/156/97 (H5N1), A/common magpie/Hong Kong/5052/07 (H5NI), A/chicken/Shanxi/2/06 (H5NI), A/silky chicken/Hong Kong/SF189/01 (H5NI), A/chicken/Henan/16/04 (H5NI), A/Victoria/361/11 (H3N2), B/Massachusetts/2/12
(influenza B), B/Brisbane/60/08 (influenza B) and A/Texas/50/12 (H3N2). In certain embodiments, the immunogenic portions are from HA proteins comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% identical to amino acid sequences of one or more HA proteins Listed in Table 1. In certain embodiments, the immunogenic portions are from HA proteins comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% identical to amino acid sequences of one or more HA proteins selected from the group consisting of HA proteins comprising SEQ ID NO:1-SEQ ID NO:62. In certain embodiments, the immunogenic portions are from HA proteins comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% identical to amino acid sequences of one or more HA proteins selected from the group consisting of HA proteins consisting of SEQ ID NO:1-SEQ ID NO:62. It is understood by those skilled in the art that the influenza HA protein contains different regions or domains. Examples of such regions include the stem region and the globular head region. Thus, while nanoparticle-based influenza vaccines can be made using immunogenic portions from any influenza HA proteins, in preferred embodiments the immunogenic portions are from a specific region or domain of the selected HA proteins. One embodiment of the present invention is a nanoparticle comprising a heterologous population of fusion proteins, wherein each fusion protein comprises at least one immunogenic portion from the globular head '0 region of an influenza HA protein joined to at least 25 contiguous amino acids from a monomeric subunit protein capable of assembling into a nanoparticle (i.e., a self-assembly (SA) protein), wherein the heterologous population of fusion proteins comprises at least two different species of fusion proteins. The globular head region, which comprises (approximately) amino acid residues 52-277 of influenza A HA protein (H3 numbering system), consists exclusively of the major portion of the HA1 polypeptide and includes two domains: the receptor binding domain (RBD and the vestigial esterase sub-domain. One example of a globular head region is represented by amino acids 52-277 from an HA protein comprising a region corresponding to an amino acid sequence selected from the group consisting of SEQ ID NO:1-62. In one embodiment, the immunogenic portions are from the globular head regions of HA proteins comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% at least 99%, or which are, identical to the amino acid sequences of HA proteins from one or more influenza viruses selected from the group consisting of Type A influenza viruses, Type B influenza viruses and Type C influenza viruses. In one embodiment, the immunogenic portions are from the globular head regions of HA proteins comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% at least 99%, or which are, identical to the amino acid sequences of HA proteins from one or more influenza viruses selected from the group consisting of Group I influenza viruses and Group II influenza viruses. In one embodiment, the immunogenic portions are from globular head regions of HA proteins comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, at least 99%, or which are, identical to the amino acid sequences of HA proteins from one or more viruses selected from the group consisting of an HI influenza virus, an H2 influenza virus, an influenza H3 virus, an influenza H4 virus, an influenza H5 virus, an influenza H6 virus, an H7 influenza virus, an H8 influenza virus, an H9 influenza virus, an H10 influenza virus, an Hi1 influenza virus, an H12 influenza virus, an H13 influenza virus, an H14 influenza virus, an H15 influenza virus, an H16 influenza virus, a H17 influenza virus, an H18 influenza virus and an influenza linage B virus. In one embodiment, the immunogenic portions are from the globular head regions of HA proteins comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% at least 99%, or which are, identical to the amino acid sequences of HA proteins from one or more influenza viruses selected from the group consisting '0 of A/New Caledonia/20/1999 (HiNi), A/Califomia/04/2009 (HiNi), A/Singapore/1/1957 (H2N2), A/Hong Kong/1/1968 (H3N2), A/Brisbane/10/2007 (H3N2), A/Indonesia/05/2005 (H5N1), B/Florida/4/2006 (influenza B), A/Perth/16/2009 (H3N2), A/Brisbane/59/2007 (HiN1), B/Brisbane/60/2008 (influenza B), A/Wilson-Smith/33 (HiN1), A/Tientsin/78/77 (HiN1), A/Texas/36/91 (HiN1), A/Singapore/6/86 (HiN1), A/Memphis/39/83 (HiN1), A/Malaysia/54 (HiNi), A/Iowa/43 (HiNi), A/Hong Kong/117/77 (HiNi), A/Fort Monmouth/l/47 (HiNi), A/Brisbane/59/07 (HiN1), A/Baylor/4052/81 (HiN1), A/Albany/4835/48 (HiN1), A/Hong Kong/156/97 (H5N1), A/common magpie/Hong Kong/5052/07 (H5N1), A/chicken/Shanxi/2/06 (H5Ni), A/silky chicken/Hong Kong/SF189/01 (H5Ni), A/chicken/Henan/16/04 (H5Ni), A/Victoria/361/11 (H3N2), B/Massachusetts/2/12 (influenza B), B/Brisbane/60/08 (influenza B) and A/Texas/50/12 (H3N2). In one embodiment, the immunogenic portions are from the globular head regions of HA proteins comprising amino acid sequences at least 80%, at least
85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% at least 99%, or which are, identical to the amino acid sequences of one or more HA proteins Listed in Table 1. As has been discussed, the globular head region comprises several other regions or domains. Thus, it will be appreciated by those skilled in the art that the immunogenic portions of the self-assembling fusion proteins can be fragments from the globular head regions from one or more influenza virus HA proteins. In one embodiment, the immunogenic portions comprise at least 10, atleast20, at least 30, at least40, atleast 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from globular head regions of influenza virus HA proteins. In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the globular head regions of HA proteins, or variant, thereof, from one or more influenza viruses selected form the group consisting of Type A influenza viruses, Type B influenza viruses and Type C influenza viruses. In one embodiment, the immunogenic portions comprise at least 10, atleast20, at least30, atleast40, atleast50, atleast60, atleast70, atleast 80, atleast90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the globular '0 head regions of HA proteins, or variants, thereof, from one or more influenza viruses selected from the group consisting of Group I influenza viruses and Group II influenza viruses. In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, atleast50, atleast60, atleast70, atleast 80, atleast90, atleast 100, atleast 110, atleast 120, at least 130, atleast 140, at least 150, at least 160, at least 170, at least 180, atleast 190 or at least 200 contiguous amino acid residues from the globular head regions of HA proteins, or variant thereof, from one or more viruses selected from the group consisting of an HI influenza virus, an H2 influenza virus, an influenza H3 virus, an influenza H4 virus, an influenza H5 virus, an influenza H6 virus, an H7 influenza virus, an H8 influenza virus, an H9 influenza virus, an H1O influenza virus, an Hi1 influenza virus, an H12 influenza virus, an H13 influenza virus, an H14 influenza virus, an H15 influenza virus, an H16 influenza virus, an H17 influenza virus, an H18 influenza virus and an influenza lineage B virus. In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the region corresponding to the globular head regions of HA proteins, or variant thereof, from one or more influenza viruses selected from the group consisting of A/New Caledonia/20/1999 (HIN1), A/California/04/2009 (HiN1), A/Singapore/i/1957 (H2N2), A/Hong Kong/i/1968 (H3N2), A/Brisbane/10/2007 (H3N2), A/Indonesia/05/2005 (H5N1), B/Florida/4/2006 (influenza B), A/Perth/16/2009 (H3N2), A/Brisbane/59/2007 (HiN1), B/Brisbane/60/2008 (influenza B), A/Wilson-Smith/33 (HiN1), A/Tientsin/78/77 (HiN1), A/Texas/36/91 (HiN1), A/Singapore/6/86 (HiN1), A/Memphis/39/83 (HiN1), A/Malaysia/54 (HiNi), A/Iowa/43 (HiNi), A/Hong Kong/117/77 (HiNi), A/Fort Monmouth/l/47 (HiNi), A/Brisbane/59/07 (HiN1), A/Baylor/4052/81 (HiN1), A/Albany/4835/48 (HiN1), A/Hong Kong/156/97 (H5N1), A/common magpie/Hong Kong/5052/07 (H5N1), A/chicken/Shanxi/2/06 (H5N1), A/silky chicken/Hong Kong/SF189/01 (H5N1), A/chicken/Henan/16/04 (H5N1), A/Victoria/361/11 (H3N2), B/Massachusetts/2/12 (influenza B), B/Brisbane/60/08 (influenza B) and A/Texas/50/12 (H3N2). In one embodiment, the immunogenic portions comprises at least 10, atleast20, at least30, atleast40, at least50, atleast60, atleast70, atleast 80, atleast90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the regions '0 corresponding to the globular head regions of one or more HA proteins, or variant thereof, listed in Table 1. In one embodiment, the immunogenic portions comprises at least 10, at least 20, at least30, atleast40, atleast50, atleast60, atleast70, atleast 80, atleast90, atleast 100, atleast 110, atleast 120, atleast 130, atleast 140, at least 150, at least 160, atleast 170, atleast 180, at least 190 or at least 200 contiguous amino acid residues from regions corresponding to the globular head regions of one or more HA proteins, or variant thereof, comprising sequences selected from the group consisting of SEQ ID NO:I-SEQ ID NO:31. A particularly useful portion of the globular head region is the receptor-binding domain (RBD). The receptor-binding domain comprises (approximately) amino acid residues 56-264 of influenza A HA protein (H3 numbering system). One embodiment of the present invention is a nanoparticle comprising a heterologous population of fusion proteins, wherein each fusion protein comprises at least one immunogenic portion from the RBD of an influenza HA protein joined to at least 25 contiguous amino acids from a monomeric subunit protein capable of assembling into a nanoparticle (i.e., a self-assembly (SA) protein), wherein the heterologous population of fusion proteins comprises at least two different species of fusion proteins. In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, atleast50, atleast60, atleast70, atleast 80, atleast90, atleast 100, atleast 110, atleast 120, at least 130, atleast 140, at least 150, at least 160, at least 170, atleast 180, at least 190 or atleast 200 contiguous amino acid residues from the receptor-binding domains (RBDs) of one or more influenza virus HA proteins. In one embodiment, the immunogenic portions comprise at least 10, atleast20, at least30, atleast40, atleast50, atleast60, atleast70, atleast 80, atleast90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the RBDs of HA proteins, or variants thereof, from one or more influenza viruses selected from the group consisting of Type A influenza viruses, Type B influenza viruses and Type C influenza viruses. In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the RBDs of HA proteins, or variants thereof, from one or more influenza viruses selected from the group consisting of Group 1 influenza viruses and Group 2 influenza viruses. In one embodiment, the immunogenic portions '0 comprise at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the RBDs of HA proteins, or variants thereof, from one or more viruses selected from the group consisting of an HI influenza virus, an H2 influenza virus, an influenza H3 virus, an influenza H4 virus, an influenza H5 virus, an influenza H6 virus, an H7 influenza virus, an H8 influenza virus, an H9 influenza virus, an H10 influenza virus, an Hi1 influenza virus, an H12 influenza virus, an H13 influenza virus, an H14 influenza virus, an H15 influenza virus, an H16 influenza virus, an H17 influenza virus, an H18 influenza virus and an influenza lineage B virus. In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the RBDs of HA proteins, or variants thereof, from one or more influenza viruses selected from the group consisting of A/New Caledonia/20/1999 (HiN1), A/California/04/2009 (HIN1), A/Singapore/i/1957 (H2N2), A/Hong Kong/1/1968 (H3N2), A/Brisbane/10/2007 (H3N2), A/Indonesia/05/2005 (H5N1), B/Florida/4/2006 (influenza B), A/Perth/16/2009 (H3N2), A/Brisbane/59/2007 (HIN1), B/Brisbane/60/2008 (influenza B), A/Wilson-Smith/33 (HiN1), A/Tientsin/78/77 (HiN1), A/Texas/36/91 (HiN1), A/Singapore/6/86 (HiN1), A/Memphis/39/83 (HiN1), A/Malaysia/54 (HiNi), A/Iowa/43 (HiNi), A/Hong Kong/117/77 (HiNi), A/Fort Monmouth/l/47 (HiNi), A/Brisbane/59/07 (HiN1), A/Baylor/4052/81 (HiN1), A/Albany/4835/48 (HiN1), A/Hong Kong/156/97 (H5N1), A/common magpie/Hong Kong/5052/07 (H5N1), A/chicken/Shanxi/2/06 (H5N1), A/silky chicken/Hong Kong/SF189/01 (H5N1), A/chicken/Henan/16/04 (H5N1), A/Victoria/361/11 (H3N2), B/Massachusetts/2/12 (influenza B), B/Brisbane/60/08 (influenza B) and A/Texas/50/12 (H3N2). In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from the RBDs of one or more HA proteins, or variants thereof, Listed in Table 1. In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, atleast 70, atleast 80, at least 90, atleast 100, atleast 110, atleast 120, atleast 130, atleast '0 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from an amino acid sequence at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% identical to a sequence selected from the group consisting of SEQ ID NO:32-SEQ ID NO:62. In one embodiment, the immunogenic portions comprise at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, atleast 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190 or at least 200 contiguous amino acid residues from one or more amino acid sequences selected from the group consisting of SEQ ID NO:32-SEQ ID NO:62. In one embodiment, the immunogenic portions comprise one or more amino acid sequence selected from the group consisting of SEQ ID NO:32-SEQ ID NO:62.
As described herein, in order to form nanoparticles expressing immunogenic portions of influenza HA proteins on theirs surfaces, each immunogenic portion is joined to a self-assembly (SA) subunit protein, or a functional portion or variant thereof, thereby forming a hemagglutinin self-assembly (HA-SA) fusion protein. Upon expression, the HA-SA fusion proteins assemble into a nanoparticle that displays the immunogenic portion of the HA protein on its surface. Any self-assembly subunit protein, or variant thereof, can be used to produce a fusion protein of the present invention, as long as the resulting fusion protein is capable of self-assembling into a nanoparticle. Examples of self-assembly subunit proteins useful for constructing fusion proteins of the present invention include, but are not limited to, ferritin, encapsulin, sulfur oxygenase reductase, lumazine synthase, dihydrolipoamide acetyltransferase (E2), Chikungunya virus envelope proteins, and fragments and/or variants thereof. In one embodiment, the self-assembly protein is ferritin. Ferritin, which is found in all animals, bacteria and plants, forms a spherical protein complex that acts primarily to control the rate and location of polynuclear Fe(III)203 formation through the transportation of hydrated iron ions and protons to and from a mineralized core. The spherical form of ferritin is made up of monomeric subunit proteins (also referred to as monomeric ferritin subunits), which are polypeptides having a molecule weight of approximately 17-20 kDa. Examples of the sequences of monomeric ferritin subunits are represented by SEQ ID NO:64, SEQ ID NO:67 and SEQ ID NO:69. Each monomeric ferritin subunit has the topology of a helix bundle which includes a '0 four antiparallel helix motif, with a fifth shorter helix (the c-terminal helix) lying roughly perpendicular to the long axis of the 4 helix bundle. According to convention, the helices are labeled 'A, B, C, and D & E 'from the N-terminus respectively. The N-terminal sequence lies adjacent to the capsid three-fold axis and extends to the surface, while the E helices pack together at the four-fold axis with the C-terminus extending into the particle core. The consequence of this packing creates two pores on the capsid surface. While not intended to be bound by theory, it is expected that one or both of these pores represent the point by which the hydrated iron diffuses into and out of the capsid. Following production, these monomeric ferritin subunit proteins self-assemble into the spherical ferritin protein. Thus, the spherical form of ferritin comprises 24 monomeric, ferritin subunit proteins, and has a capsid-like structure having 432 symmetry.
According to the present invention, a monomeric ferritin subunit of the present invention is a full length, single polypeptide of a ferritin protein, or any portion thereof, which is capable of directing self-assembly of monomeric ferritin subunits into the spherical form of the protein. Amino acid sequences from monomeric ferritin subunits of any known ferritin protein can be used to produce fusion proteins of the present invention, so long as the monomeric ferritin subunit is capable of directing self-assembly of the fusion protein into a nanoparticle displaying immunogenic portions from influenza virus HA proteins on its surface. In one embodiment, the monomeric ferritin subunit is selected from the group consisting of a bacterial ferritin protein, a plant ferritin protein, an algal ferritin protein, an insect ferritin protein, a fungal ferritin protein and a mammalian ferritin protein. In one embodiment, the monomeric ferritin subunit is from Helicobacterpylori. In one embodiment, the monomeric ferritin subunit is from E. coli. In one embodiment, the monomeric ferritin subunit is bullfrog ferritin. In one embodiment, the monomeric ferritin subunit is a hybrid ferritin protein made by joining amino acid sequences from more than one ferritin proteins selected from the group consisting of H. pylori ferritin, E. coli ferritin and bullfrog ferritin. Amino acid sequences from representative ferritin proteins of the present invention are disclosed herein as SEQ ID NO:64 (H. pylori ferritin), SEQ ID NO:66 (E. coli ferritin), SEQ ID NO:70 (bullfrog ferritin). Examples of representative hybrid ferritin proteins of the present invention include SEQ ID NO:73 (H. pylori ferritin-bullfrog ferritin fusion) and SEQ ID NO:76 (E. coli ferritin-bullfrog ferritin fusion. In one embodiment, '0 nanoparticles of the present invention contain fusion proteins comprising an amino acid sequence selected from the group consisting of SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:70, SEQ ID NO:73 and SEQ ID NO:76. In one embodiment, the self-assembly protein is encapsulin. According to the present invention, a monomeric encapsulin subunit of the present invention is a full length, single polypeptide of an encapsulin protein, or any portion thereof, which is capable of directing self assembly of monomeric encapsulin subunits into a nanoparticle. Amino acid sequences from monomeric encapsulin subunits of any known encapsulin protein can be used to produce fusion proteins of the present invention, so long as the monomeric encapsulin subunit is capable of directing self-assembly of the fusion protein into a nanoparticle displaying immunogenic portions from influenza virus HA proteins on its surface. The amino acid sequence of a representative encapsulin protein is disclosed herein as SEQ ID NO:79. The spherical form of encapsulin comprises 60 monomeric encapsulin subunit proteins. In one embodiment, the self-assembly protein is artificially designed Salmonella enteritis 03-33 subunit protein. According to the present invention, a monomeric 03-33 subunit of the present invention is a full length, single polypeptide of an 03-33 protein, or any portion thereof, which is capable of directing self-assembly of monomeric 03-33 subunits into a nanoparticle. Amino acid sequences from monomeric 03-33 subunits of any known 03-33 protein can be used to produce fusion proteins of the present invention, so long as the monomeric 03-33 subunit is capable of directing self-assembly of the fusion protein into a nanoparticle displaying immunogenic portions from influenza virus HA proteins on its surface. The amino acid sequence of a representative 03-33 protein is disclosed herein as SEQ ID NO:82. In one embodiment, the self-assembly protein is sulfur oxygenase reductase (SOR). According to the present invention, a monomeric SOR subunit of the present invention is a full length, single polypeptide of an SOR protein, or any portion thereof, which is capable of directing self-assembly of monomeric SOR subunits into a nanoparticle. Amino acid sequences from monomeric SOR subunits of any known SOR protein can be used to produce fusion proteins of the present invention, so long as the monomeric SOR subunit is capable of directing self-assembly of the fusion protein into a nanoparticle displaying immunogenic portions from influenza virus HA proteins on its surface. The amino acid sequence of a representative SOR '0 protein is disclosed herein as SEQ ID NO:85. The spherical form of SOR comprises 24 monomeric SOR subunit proteins. In one embodiment, the self-assembly protein is lumazine synthase (LS). According to the present invention, a monomeric LS subunit of the present invention is a full length, single polypeptide of an LS protein, or any portion thereof, which is capable of directing self-assembly of monomeric LS subunits into a nanoparticle. Amino acid sequences from monomeric LS subunits of any known LS protein can be used to produce fusion proteins of the present invention, so long as the monomeric LS subunit is capable of directing self-assembly of the fusion protein into a nanoparticle displaying immunogenic portions from influenza virus HA proteins on its surface. The amino acid sequence of a representative LS protein is disclosed herein as SEQ ID NO:88. The spherical form of LS comprises a 60 monomeric subunit capsid comprising 12 pentameric units.
In one embodiment, the self-assembly protein is pyruvate dehydrogenase complex (PDC) dihydrolipoamide acetyltransferase (E2p). According to the present invention, a monomeric E2p subunit of the present invention is a full length, single polypeptide of an E2p protein, or any portion thereof, which is capable of directing self-assembly of monomeric E2p subunits into a nanoparticle. Amino acid sequences from monomeric E2p subunits of any known E2p protein can be used to produce fusion proteins of the present invention, so long as the monomeric E2p subunit is capable of directing self-assembly of the fusion protein into a nanoparticle displaying immunogenic portions from influenza virus HA proteins on its surface. The amino acid sequence of a representative E2p protein is disclosed herein as SEQ ID NO:91. In one embodiment, the nanoparticles comprise self-assembly proteins from Chikungunya virus. In particular, the nanoparticles comprises one or more structural proteins (e.g., capsid, El, E2 an E3) from Chikungunya virus (CHKV). Methods of forming nanoparticles from CHKV are disclosed herein and are also taught in U.S. Patent Application No. 13/131,287, which is incorporated herein in its entirety by reference. According to the present invention, CHKV structural proteins are full length, single polypeptides of CHKV envelope proteins, or any portion thereof, which are capable of directing self-assembly of monomeric structural proteins into a nanoparticle. Amino acid sequences of structural proteins from any known CHKV virus can be used to produce fusion proteins of the present invention, so long as the amino acid sequences are capable of directing self-assembly of the fusion protein into '0 a nanoparticle displaying immunogenic portions from an influenza virus HA protein on its surface. It is understood by those skilled in the art that CHKV proteins are expressed as a polyprotein, which is subsequently cleaved into individual proteins. The amino acid sequence of a representative CHKV polyprotein is disclosed herein as SEQ ID NO:94. It should be further understood that the amino acid sequences of immunogenic portions can be inserted into the polyprotein such upon cleavage of the polyprotein and formation of the virus-like particle, the immunogenic portions are properly folded and displayed on the surface of the nanoparticle. HA-SA fusion proteins of the present invention need not comprise the full-length sequence of a monomeric subunit polypeptide of a self-assembly protein. Portions, or regions, of the monomeric SA subunit protein can be utilized so long as the portion comprises an amino acid sequence that directs self-assembly of the HA-SA fusion protein into a nanoparticle. One example of such a portion is located between amino acids 5 and 167 of the Helicobacterpylori ferritin protein (SEQ ID NO:64). More specific regions of the ferritin protein are described in Zhang, Y. Self-Assembly in the Ferritin Nano-Cage Protein Super Family. 2011, Int. J. Mol. Sci., 12, 5406-5421, which is incorporated herein by reference in its entirety. One embodiment of the present invention is a nanoparticle comprising a heterogeneous population of HA-SA fusion proteins, wherein each HA-SA fusion protein comprises at least one immunogenic portion an influenza virus HA protein, joined to at least 25 contiguous amino acids, at least 50 contiguous amino acids, at least 75 contiguous amino acids, at least 100 contiguous amino acids, or at least 150 contiguous amino acids from a protein selected from the group consisting of ferritin, encapsulin, sulfur oxygenase reductase, lumazine synthase and pyruvate dehydrogenase complex (PDC) dihydrolipoamide acetyltransferase (E2), wherein the HA-SA fusion protein is capable of being assembled into a nanoparticle. One embodiment of the present invention is a nanoparticle comprising a heterogeneous population of HA-SA fusion proteins, wherein each HA-SA fusion protein comprises at least one immunogenic portion of an influenza virus HA protein joined to at least 25 contiguous amino acids, at least 50 contiguous amino acids, at least 75 contiguous amino acids, at least 100 contiguous amino acids, or at least 150 contiguous amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:79, SEQ ID NO:82, SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:91 and SEQ ID NO:94, wherein the HA-SA fusion protein is capable of being assembled into a nanoparticle. One '0 embodiment of the present invention is nanoparticle comprising a heterogeneous population of HA-SA fusion proteins, wherein each fusion protein comprises at least one immunogenic portion of an influenza virus HA protein joined to at least 25 contiguous amino acids, at least 50 contiguous amino acids, at least 75 contiguous amino acids, at least 100 contiguous amino acids, or at least 150 contiguous amino acids from a region of a ferritin protein comprising amino acid residues 5-167 of SEQ ID NO:64, wherein the HA-SA fusion protein is capable of being assembled into a nanoparticle. As has been previously discussed, it is well-known in the art that some variations can be made in the amino acid sequence of a protein without affecting the activity of that protein. Such variations include insertion of amino acid residues, deletions of amino acid residues, and substitutions of amino acid residues. Thus, in one embodiment, the sequence of a SA protein subunit is divergent enough from the sequence of a SA protein subunit found in nature, such that when the variant SA protein subunit is introduced into an animal, such as a mouse, it does not result in the production of antibodies that react with the natural SA protein. According to the present invention, such a monomeric subunit is referred to as immunogenically neutral. One embodiment of the present invention is a nanoparticle comprising a heterogeneous population of HA-SA fusion proteins, wherein each fusion protein comprises at least one immunogenic portion from an influenza virus HA protein joined to an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, or at least 97% identical to the amino acid sequence of a monomeric SA protein subunit protein capable of self-assembling into a nanoparticle, wherein the HA-SA fusion protein is capable of self-assembling into nanoparticles. In one embodiment, the HA-SA fusion protein comprises a polypeptide sequence identical in sequence to a monomeric SA protein subunit selected from the group consisting of ferritin, encapsulin, sulfur oxygenase reductase, lumazine synthase, pyruvate dehydrogenase complex (PDC) dihydrolipoamide acetyltransferase (E2) and the structural proteins of CHKV. One embodiment of the present invention is a nanoparticle comprising a heterogeneous population of HA-SA fusion proteins, wherein each fusion protein comprises at least one influenza virus HA protein immunogenic portion of the present invention joined to an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, or at least 97% identical to the amino acid sequence of a monomeric SA protein subunit selected from the group consisting of ferritin, encapsulin, sulfur oxygenase reductase, lumazine synthase, pyruvate dehydrogenase complex (PDC) dihydrolipoamide '0 acetyltransferase (E2) and the envelope proteins of CHKV, wherein the HA-SA fusion protein is capable of self-assembling into nanoparticles. One embodiment of the present invention is a nanoparticle comprising a heterogeneous population of HA-SA fusion proteins, wherein each fusion protein comprises at least one immunogenic portion of an influenza HA protein of the present invention joined to an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, and at least 97% identical to a sequence selected from the group consisting of SEQ ID NO:64, SEQ ID NO:67, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:79, SEQ ID NO:82, SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:91 and SEQ ID NO:94, wherein the HA-SA fusion protein is capable of self-assembling into nanoparticles. In some embodiments of the present invention, the immunogenic portion of an influenza virus HA protein and the amino acid sequence of the SA protein may be joined directly to one another. In other embodiments, it may be necessary to employ linkers (also referred to as a spacer sequences) so that the various domains are in the proper special orientation. The linker sequence is designed to position the immunogenic portion of the influenza virus HA protein in such a way to that it maintains the ability to elicit an immune response to the influenza virus. Linker sequences of the present invention comprise amino acids. Preferable amino acids to use are those having small side chains and/or those which are not charged. Such amino acids are less likely to interfere with proper folding and activity of the fusion protein. Accordingly, preferred amino acids to use in linker sequences, either alone or in combination are serine, glycine and alanine. Examples of such linker sequences include, but are not limited to, SG, SGG, GSG, GG and GGSGG. Amino acids can be added, subtracted or rearranged as needed. Those skilled in the art are capable of determining appropriate linker sequences for proteins of the present invention. In addition to linker sequences, fusion proteins of the present invention can also comprise other heterologous amino acid sequences. For example, fusion proteins may comprise signal sequences that direct the fusion protein into the proper cellular pathway. For example, a signal sequence may direct the protein into the ER-golgi complex so that it is properly glycosylated and secreted. Any signal sequence can be used as long as it directs the fusion protein in the desired manner. Examples of signal sequences useful for preparing fusion proteins of the present invention include, but are not limited to, the signal sequence from bovine prolactin, the human CD5 signal sequence and the CHIKV signal sequence. Fusion proteins of the present invention can also contain cleavage sequences. For example, in embodiments in which more than one immunogenic portion from influenza HA proteins are linked together in the fusion protein, enzyme cleavage sites can be included between segments of the fusion protein (e.g., immunogenic portions, SA proteins, linker sequences, etc.) such that upon expression of the protein, the various domains are cleaved from one another. Any cleavage sequence can be used to prepare fusion proteins of the present invention. Examples of such cleavage sequences are furin and 2A cleavage sequences. An exemplary embodiment is illustrated in Figure 2. In some embodiments, it may be useful to engineer mutations into the amino acid sequences of fusion proteins of the present invention. For example, it may be useful to alter sites such as enzyme recognition sites or glycosylation sites in the monomeric SA protein, the linker sequence or the immunogenic portions of the influenza HA proteins., in order to give the fusion protein beneficial properties (e.g., stability, solubility, half-life, mask portions of the protein from immune surveillance, avoid steric hinderance, etc). For example, it is known that the monomeric subunit of ferritin is not glycosylated naturally. However, it can be glycosylated if it is expressed as a secreted protein in mammalian or yeast cells. Thus, in one embodiment, potential N-linked glycosylation sites in the amino acid sequences from the monomeric ferritin subunit are mutated so that the mutated ferritin subunit sequences are no longer glycosylated at the mutated site. Examples of useful sites at which to introduce mutations include, but are not limited to, amino acid residues 98 and 264 of influenza virus HA proteins. One embodiment of the present invention is a fusion protein encoded by a nucleic acid molecule of the present invention. One embodiment of the present invention is a fusion protein encoded by a nucleic acid molecule comprising a nucleic acid sequence at least 80%, at least 85%, at least 90%, at least 95% at least 97%, or which is, identical to a sequence selected from the group consisting of SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:126, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171, SEQ ID NO:174, SEQ ID NO:177, SEQ ID NO:180, SEQ ID NO:183, SEQ ID NO:186 and SEQ ID NO:189. One embodiment of the present invention is a '0 fusion protein encoded by a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:126, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171, SEQ ID NO:174, SEQ ID NO:177, SEQ ID NO:180, SEQ ID NO:183, SEQ ID NO:186 and SEQ ID NO:189. One embodiment of the present invention is a fusion protein encoded by a nucleic acid molecule consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:126, SEQ ID NO:129, SEQ ID
NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171, SEQ ID NO:174, SEQ ID NO:177, SEQ ID NO:180, SEQ ID NO:183, SEQ ID NO:186 and SEQ ID NO:189. One embodiment of the present invention is a fusion protein comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95% at least 97%, or which is, identical to an amino acid sequence selected form the group consisting of SEQ ID NO:97, SEQ ID NO:100, SEQ ID NO:103, SEQ ID NO:106, SEQ ID NO:109, SEQ ID NO:112, SEQ ID NO:115, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:124, SEQ ID NO:127, SEQ ID NO:130, SEQ ID NO:133, SEQ ID NO:136, SEQ ID NO:139, SEQ ID NO:142, SEQ ID NO:145, SEQ ID NO:148, SEQ ID NO:151, SEQ ID NO:154, SEQ ID NO:157, SEQ ID NO:160, SEQ ID NO:163, SEQ ID NO:166, SEQ ID NO:169, SEQ ID NO:172, SEQ ID NO:175, SEQ ID NO:178, SEQ ID NO:181, SEQ ID NO:184, SEQ ID NO:187 and SEQ ID NO:190. One embodiment of the present invention is a fusion protein consisting of an amino acid sequence selected form the group consisting of SEQ ID NO:97, SEQ ID NO:100, SEQ ID NO:103, SEQ ID NO:106, SEQ ID NO:109, SEQ ID NO:112, SEQ ID NO:115, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:124, SEQ ID NO:127, SEQ ID NO:130, SEQ ID NO:133, SEQ ID NO:136, SEQ ID NO:139, SEQ ID NO:142, SEQ ID NO:145, SEQ ID NO:148, SEQ ID NO:151, SEQ ID NO:154, SEQ ID NO:157, SEQ ID NO:160, SEQ ID '0 NO:163, SEQ ID NO:166, SEQ ID NO:169, SEQ ID NO:172, SEQ ID NO:175, SEQ ID NO:178, SEQ ID NO:181, SEQ ID NO:184, SEQ ID NO:187 and SEQ ID NO:190. Fusion proteins of the present invention are encoded by nucleic acid molecules of the present invention. In addition, they are expressed by nucleic acid constructs of the present invention. As used herein a nucleic acid construct is a recombinant expression vector, i.e., a vector linked to a nucleic acid molecule encoding a protein such that the nucleic acid molecule can effect expression of the protein when the nucleic acid construct is administered to, for example, a subject or an organ, tissue or cell. The vector also enables transport of the nucleic acid molecule to a cell within an environment, such as, but not limited to, an organism, tissue, or cell culture. A nucleic acid construct of the present disclosure is produced by human intervention. The nucleic acid construct can be DNA, RNA or variants thereof. The vector can be a DNA plasmid, an mRNA, a viral vector, or other vector. In one embodiment, a vector can be a cytomegalovirus (CMV), retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, poliovirus, sindbis virus, or any other DNA or RNA virus vector. In one embodiment, a vector can be a pseudotyped lentiviral or retroviral vector. In one embodiment, a vector can be a DNA plasmid. In one embodiment, a vector can be a DNA plasmid comprising viral components and plasmid components to enable nucleic acid molecule delivery and expression. Methods for the construction of nucleic acid constructs of the present disclosure are well known. See, for example, Molecular Cloning: a LaboratoryManual,3 rd edition, Sambrook et al. 2001 Cold Spring Harbor Laboratory Press, and Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons, 1994. In one embodiment, the vector is a DNA plasmid, such as a CMV/R plasmid such as CMV/R or CMV/R 8KB (also referred to herein as CMV/R 8Kb). Examples of CMV/R and CMV/R 8 Kb are provided herein. CMV/R is also described in US 7,094,598 B2, issued August 22, 2006. As used herein, a nucleic acid molecule comprises a nucleic acid sequence that encodes an HA-SA fusion protein of the present invention. A nucleic acid molecule can be produced recombinantly, synthetically, or by a combination of recombinant and synthetic procedures. A nucleic acid molecule of the disclosure can have a wild-type nucleic acid sequence or a codon modified nucleic acid sequence to, for example, incorporate codons better recognized by the human translation system. In one embodiment, a nucleic acid molecule can be genetically engineered to introduce, or eliminate, codons encoding different amino acids, such as to '0 introduce codons that encode an N-linked glycosylation site. Methods to produce nucleic acid molecules of the disclosure are known in the art, particularly once the nucleic acid sequence is know. It is to be appreciated that a nucleic acid construct can comprise one nucleic acid molecule or more than one nucleic acid molecule. It is also to be appreciated that a nucleic acid molecule can encode one protein or more than one protein. One embodiment of the present invention is a nucleic acid molecule comprising a nucleic acid sequence encoding a fusion protein of the present invention. One embodiment of the present invention is a nucleic acid molecule comprising a nucleic acid sequence encoding a fusion protein that comprises a monomeric self-assembly subunit protein joined to one or more immunogenic portions of one or more influenza hemagglutinin proteins. One embodiment of the present invention is a nucleic acid molecule comprising a nucleic acid sequence encoding a fusion protein comprising one or more amino acid sequence at least 80%, at least 85%, at least
90%, at least 95% at least 97%, or which are, identical to one or more immunogenic portions from one or more influenza hemagglutinin proteins of the present invention, wherein the fusion protein is capable of forming a nanoparticle displaying the immunogenic portions on its surface. In a further embodiment, a nucleic acid molecule of the present invention comprises a nucleic acid sequence encoding a fusion protein comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95% at least 97%, or which is, identical to the amino acid sequence of a monomeric self-assembly subunit protein of the present invention, wherein the fusion protein is capable of forming a nanoparticle displaying the immunogenic portions on its surface. In one embodiment, a nucleic acid molecule of the present invention comprises a nucleic acid sequence encoding a fusion protein comprising i) one or more amino acid sequence at least 80%, at least 85%, at least 90%, at least 95% at least 97%, or which are, identical to one or more immunogenic portions from one or more influenza hemagglutinin proteins of the present invention; and, ii) an amino acid sequence at least 80%, at least 8 5 %, at least 90%, at least 95
% at least 97%, or which is, identical to the amino acid sequence of a monomeric self-assembly subunit protein of the present invention, wherein the fusion protein is capable of forming a nanoparticle displaying the immunogenic portions on its surface. One embodiment of the present invention is a nucleic acid molecule comprising a nucleic acid sequence encoding a fusion protein comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95% at least 97%, or which is, identical to an amino acid sequence selected form the group '0 consisting of SEQ ID NO:97, SEQ ID NO:100, SEQ ID NO:103, SEQ ID NO:106, SEQ ID NO:109, SEQ ID NO:112, SEQ ID NO:115, SEQ ID NO:118, SEQ ID NO:121, SEQ ID NO:124, SEQ ID NO:127, SEQ ID NO:130, SEQ ID NO:133, SEQ ID NO:136, SEQ ID NO:139, SEQ ID NO:142, SEQ ID NO:145, SEQ ID NO:148, SEQ ID NO:151, SEQ ID NO:154, SEQ ID NO:157, SEQ ID NO:160, SEQ ID NO:163, SEQ ID NO:166, SEQ ID NO:169, SEQ ID NO:172, SEQ ID NO:175, SEQ ID NO:178, SEQ ID NO:181, SEQ ID NO:184, SEQ ID NO:187 and SEQ ID NO:190. One embodiment of the present invention is a nucleic acid molecule comprising a nucleic acid sequence encoding a fusion protein comprising an amino acid sequence selected form the group consisting of SEQ ID NO:97, SEQ ID NO:100, SEQ ID NO:103, SEQ ID NO:106, SEQ ID NO:109, SEQ ID NO:112, SEQ ID NO:115, SEQ IDNO:118,SEQIDNO:121,SEQIDNO:124,SEQIDNO:127,SEQIDNO:130,SEQID NO:133, SEQ ID NO:136, SEQ ID NO:139, SEQ ID NO:142, SEQ ID NO:145, SEQ ID
NO:148, SEQ ID NO:151, SEQ ID NO:154, SEQ ID NO:157, SEQ ID NO:160, SEQ ID NO:163, SEQ ID NO:166, SEQ ID NO:169, SEQ ID NO:172, SEQ ID NO:175, SEQ ID NO:178, SEQ ID NO:181, SEQ ID NO:184, SEQ ID NO:187 and SEQ ID NO:190. One embodiment of the present invention is a nucleic acid molecule comprising a nucleic acid sequence at least 80%, at least 85%, at least 90%, at least 95% at least 97%, or which is, identical to a sequence selected form the group consisting of SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:188, SEQ ID NO:189 and SEQ ID NO:191. One embodiment of the present invention is a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:179, SEQ ID NO:180, SEQ ID
NO:182, SEQ ID NO:183, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:188, SEQ ID NO:189 and SEQ ID NO:191. One embodiment of the present invention is a nucleic acid molecule consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:188, SEQ ID NO:189 and SEQ ID NO:191. As has been discussed, nanoparticles of the present invention comprise populations of fusion proteins which are heterogeneous due to at least two fusion proteins in the population differing in their amino acid sequences by at least one amino acid. It will be appreciated by '0 those skilled in the art that, as described hereto, a heterogeneous population of fusion proteins can be due to the aforementioned amino acid difference being at any location in the fusion protein, including in the SA portion of the protein. However, preferred nanoparticles of the present invention are those in which a single nanoparticle is capable of eliciting an immune response to more than one Type, sub-type or strain of influenza virus. Consequently, preferred nanoparticles are those comprising a heterogeneous population of fusion proteins, wherein at least two fusion proteins in the heterogeneous population differ in the sequences of their immunogenic portions by at least one amino acid. It should be understood that fusion proteins of preferred nanoparticles are not excluded from having sequences differences in regions other than the immunogenic portion. However, in order to elicit an immune response against more than one Type, Group, sub-type or strain of influenza virus, preferred nanoparticles comprise at least two fusion proteins that differ by at least one amino acid residue in the their immunogenic portions.
It will be understood by those skilled in the art that differences in the amino acid sequences of the immunogenic portion of two fusion proteins may or may not cause the two different immunogenic portions (i.e., the two species of immunogenic portions) to be recognized by two different receptors (e.g., B-cell, T-cell, etc). Such differences, or lack thereof, in recognition depend on such things as, for example, the differences in properties between the corresponding amino acid residues in the immunogenic portions and whether or not the locations at which the sequences differ (i.e., the amino acid residue) are part of the recognized epitope. In preferred embodiments, the heterogeneous population comprises at least two species of fusion proteins, wherein the immunogenic portions of each of the species is recognized by the same B-cell receptor, T-cell receptor and/or antibody. Thus, in one embodiment, a nanoparticle of the present invention elicits a cross-reactive immune response (an immune response against more than one Type, subtype or strain of influenza virus). It should be understood that the number of immunogenic regions displayed by nanoparticles of the present invention is only limited by the number of fusion proteins that make up the nanoparticle, which itself is determined by the SA protein used to construct the fusion proteins. For example, ferritin forms a nanoparticle consisting of 24 monomeric, ferritin subunit proteins. Thus, ferritin-based nanoparticle of the present invention can comprise a maximum of 24 fusion proteins and thus, can display a maximum of 24 different immunogenic portions. Similarly, encapsulin proteins from Thermotoga maritima form nanoparticles having 60 '0 subunits. Thus, encapsulin-based nanoparticle of the present invention can display a maximum of 60 different immunogenic portions. Likewise, structural proteins from CHIKV form virus like particles having 240 envelope E2 subunits. Thus CHIKV-based virus-like particle of the present invention can display a maximum of 240 different immunogenic portions. Those skilled in the art will understand that such calculations assume each fusion protein comprises a single immunogenic portion. Nanoparticles displaying higher numbers of immunogenic portions could of course be constructed using fusion proteins comprising two or more immunogenic portions. An example of a fusion protein comprising multiple epitopes is illustrated in Figure 2. In one embodiment, the nanoparticles comprises a heterogeneous population of fusion proteins, wherein each fusion protein comprises a single immunogenic portion of an influenza HA protein. In one embodiment, the nanoparticles comprises a heterogeneous population of fusion proteins, wherein each fusion protein comprises multiple immunogenic portions from one or more influenza HA proteins. In one embodiment, the nanoparticles comprises a heterogeneous population of fusion proteins, wherein each fusion protein comprises at least 2, at least 3, at least 4 or at least 5 immunogenic portions from one or more influenza HA proteins. In one embodiment, a nanoparticle of the present invention comprises between 2 and 240 species of fusion proteins, wherein each species differs from every other species, at least in part, by at least one amino acid in change in the sequence of its immunogenic portion. In certain embodiments, a nanoparticle of the present invention comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, atleast 15, at least 16, at least 17, atleast 18, at least 19, at least20, at least21, at least 22, atleast23, at least24, atleast25, at least26, atleast27, atleast28, atleast29, atleast 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least3, at least 39, atleast40, at least41, atleast42, at least43, atleast44, at least45, atleast46, atleast47, at least48, atleast49, at least 50, at least 51, atleast 52, at least 53, at least 54, at least 55, at least 56, atleast57, at least58, atleast59, at least 60, atleast70, at least 80, atleast 90, atleast 100, atleast 110, atleast 120, atleast 130, at least 140, atleast 150, at least 160, at least 170, atleast 180, at least 190, at least 200, at least 210, at least 220, at least 230 or at least 240 species of fusion proteins, wherein the species differ from one another, at least in part, by at least one amino acid in their immunogenic portions. In certain embodiments, a nanoparticle of the present invention display at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least '0 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, atleast 19, at least20, at least21, atleast22, at least23, at least24, at least25, at least 26, atleast27, at least28, atleast29, atleast30, atleast31, atleast32, atleast33, atleast34, at least 35, at least 36, at least 37, at least3, at least 39, at least 40, at least 41, at least 42, at least 43, atleast44, at least45, atleast46, at least47, atleast48, at least49, atleast50, atleast51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59 or at least 60 unique immunogenic portions. One embodiment of the present invention is a method of producing nanoparticles of the present invention, the method comprising introducing one or more nucleic acid molecules encoding fusion proteins of the present invention into a cell, and incubating the cell under conditions suitable for expressing the encoded proteins and forming nanoparticles. In a further embodiment, the nanoparticles are isolated from the cell into which the nucleic acid molecule was introduced. Methods of isolating nanoparticles are known to those skilled in the art and are also described in U.S. Patent Application No. 13/131,287 and International Application No. PCT/US14/60142, both of which are incorporated herein by reference in their entirety. It should be realized by those skilled in the art nanoparticles displaying a heterogeneous population of immunogenic portions on its surface can be produced by either i) introducing more than one nucleic acid molecule into the cell, wherein each nucleic acid molecule encodes a different species of fusion protein; and/or ii) introducing one or more nucleic acid molecule into a cell, wherein at least one nucleic acid molecule encode at least one of the one or more nucleic acid molecules encode a species of fusion protein that differs from a fusion protein encoded by a nucleic acid molecule introduced into the cell. Thus, for example, a nanoparticle comprising a heterogeneous population of fusion proteins can be produced by introducing into a cell a nucleic acid molecule encoding two different species of fusion proteins. Nanoparticles of the present invention can also be produced by combining expressed and isolated recombinant proteins. Thus, one embodiment of the present invention is a method of producing nanoparticles of the present invention, the method comprising introducing into a cell a nucleic acid molecule encoding a fusion protein of the present invention, incubating the cell under conditions suitable for expressing the protein encoded by the nucleic acid molecule, and isolating the expressed protein. The isolated proteins are then disassembled and combined with one or more heterogeneous species of isolated, disassembled fusion protein (i.e., fusion proteins '0 having a different sequence, especially in their immunogenic portion) such that the mixture of heterogeneous species of fusion proteins reassembles in a nanoparticle comprising a heterogeneous population of fusion proteins, wherein each nanoparticle comprises at least two different species of fusion proteins. Because nanoparticles of the present invention elicit an immune response to an infectious agent, such as influenza virus, they can be used as vaccines to protect individuals against infection by one or more Types, sub-types, strains and/or species of infectious agent (e.g., influenza virus). Thus, one embodiment of the present invention is a vaccine comprising a nanoparticle of the present invention. Vaccines of the present invention can also contain other components such as adjuvants, buffers and the like. Although any adjuvant can be used, preferred embodiments can contain: chemical adjuvants such as aluminum phosphate, benzyalkonium chloride, ubenimex, and QS21; genetic adjuvants such as the IL-2 gene or fragments thereof, the granulocyte macrophage colony-stimulating factor (GM-CSF) gene or fragments thereof, the IL-18 gene or fragments thereof, the chemokine (C-C motif) ligand 21 (CCL21) gene or fragments thereof, the IL-6 gene or fragments thereof, CpG, LPS, TLR agonists, and other immune stimulatory genes; protein adjuvants such IL-2 or fragments thereof, the granulocyte macrophage colony-stimulating factor (GM-CSF) or fragments thereof, IL-18 or fragments thereof, the chemokine (C-C motif) ligand 21 (CCL21) or fragments thereof, IL-6 or fragments thereof, CpG, LPS, TLR agonists and other immune stimulatory cytokines or fragments thereof; lipid adjuvants such as cationic liposomes, N3 (cationic lipid), monophosphoryl lipid A (MPL1); other adjuvants including cholera toxin, enterotoxin, Fms-like tyrosine kinase-3 ligand (Flt-3L), bupivacaine, marcaine, and levamisole. One embodiment of the present invention is a method to vaccinate an individual against an infectious agent, the method comprising administering to the individual a nanoparticle of the present invention. One embodiment of the present invention is a method to vaccinate an individual against influenza virus, the method comprising administering to the individual a nanoparticle vaccine of the present invention. In one embodiment, the nanoparticle comprises self-assembling fusion proteins of the present invention, and the nanoparticle displays on its surface a heterogeneous population of immunogenic portions from HA proteins from one or more types, subtypes or strains of influenza virus. One embodiment of the present invention is a method to vaccinate an individual against '0 infection with influenza virus, the method comprising: a) obtaining a nanoparticle of the present invention; and, b) administering the nanoparticle to an individual such that an immune response against an influenza virus is produced. As used herein, an immune response to a vaccine, or nanoparticle, of the present invention is the development in a subject of a humoral and/or a cellular immune response to a hemagglutinin protein present in the vaccine. For purposes of the present invention, a "humoral immune response" refers to an immune response mediated by antibody molecules, including secretory IgA or IgG molecules, while a "cellular immune response" is one mediated by T-lymphocytes and/or other white blood cells. One important aspect of cellular immunity involves an antigen-specific response by cytolytic T-cells ("CTL"s). CTLs have specificity for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the surfaces of cells.
CTLs help induce and promote the destruction of intracellular microbes, or the lysis of cells infected with such microbes. Another aspect of cellular immunity involves an antigen-specific response by helper T-cells. Helper T-cells act to help stimulate the function, and focus the activity of, nonspecific effector cells against cells displaying peptide antigens in association with MHC molecules on their surface. A cellular immune response also refers to the production of cytokines, chemokines and other such molecules produced by activated T-cells and/or other white blood cells, including those derived from CD4+ and CD8+T-cells. Thus, an immunological response may be one that stimulates CTLs, and/or the production or activation of helper T-cells. The production of chemokines and/or cytokines may also be stimulated. The vaccine may also elicit an antibody-mediated immune response. Hence, an immunological response may include one or more of the following effects: the production of antibodies (e.g., IgA or IgG) by B-cells; and/or the activation of suppressor, cytotoxic, or helper T-cells and/or T-cells directed specifically to a protein (e.g., hemagglutinin) present in the vaccine. These responses may serve to neutralize infectivity, and/or mediate antibody complement, or antibody dependent cell cytotoxicity (ADCC) to provide protection to an immunized individual. Such responses can be determined using standard immunoassays and neutralization assays, well known in the art. As used herein, neutralizing antibodies are antibodies that prevent in infectious agent from replicating and spreading within a host. With regard to influenza virus, neutralizing '0 antibodies prevent influenza virus from completing one round of replication. As defined herein, one round of replication refers the life cycle of the virus, starting with attachment of the virus to a host cell and ending with budding of newly formed virus from the host cell. This life cycle includes, but is not limited to, the steps of attaching to a cell, entering a cell, cleavage and rearrangement of the HA protein, fusion of the viral membrane with the endosomal membrane, release of viral ribonucleoproteins into the cytoplasm, formation of new viral particles and budding of viral particles from the host cell membrane. In one embodiment, a vaccine or nanoparticle of the present invention elicits broadly neutralizing antibodies. As used herein, broadly neutralizing antibodies are antibodies that neutralize more than one genera, type, subtype, species and/or strain of infectious agent within a taxonomic family. With specific regard to influenza viruses used herein, broadly neutralizing antibodies are antibodies that neutralize more than one type, subtype and/or strain of influenza virus. For example, broadly neutralizing antibodies elicited against an HA protein from a Type A influenza virus may neutralize a Type B or Type C virus. As a further example, broadly neutralizing antibodies elicited against an HA protein from Group 1 influenza virus may neutralize a Group 2 virus. As an additional example, broadly neutralizing antibodies elicited against an HA protein from one sub-type or strain of virus, may neutralize another sub-type or strain of virus. For example, broadly neutralizing antibodies elicited against an HA protein from an Hi influenza virus may neutralize viruses from one or more sub-types selected from the group consisting of H2, H3, H4, H5, H6, H7, H8, H8, H10, H11, H12, H13, H14, H15, H16, H17 or H18. The terms individual, subject, and patient are well-recognized in the art, and are herein used interchangeably to refer to any human or other animal susceptible to influenza infection. Examples include, but are not limited to, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, seals, goats and horses; domestic mammals such as seals, dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The terms individual, subject, and patient by themselves, do not denote a particular age, sex, race, and the like. Thus, individuals of any age, whether male or female, are intended to be covered by the present disclosure and include, but are not limited to the elderly, adults, children, '0 babies, infants, and toddlers. Likewise, the methods of the present invention can be applied to any race, including, for example, Caucasian (white), African-American (black), Native American, Native Hawaiian, Hispanic, Latino, Asian, and European. An infected subject is a subject that is known to have influenza virus in their body. Methods of the present invention can be used to vaccinate any individual. Such individual can, but need not, be suspected of having been exposed to an infectious agent, such as influenza virus. Similarly, methods of the present invention can be used to vaccinate an individual known to have been exposed to and infectious agent, such as influenza virus, or a person suspected of, or known to have, having been exposed to an infectious agent, such as influenza virus. As such, methods of the present invention can be used to contain a known, or potential, out break of an infectious agent, such as influenza (e.g., epidemic, pandemic).
One embodiment of the present invention is a method to vaccinate an individual against influenza virus, the method comprising administering a vaccine of the embodiments to an individual in need of such a vaccine, such that an immune response against influenza virus is produced in the individual, wherein the vaccine comprises a nanoparticle comprising self assembling fusion proteins, wherein the nanoparticle displays on its surface a heterogeneous population of immunogenic portions from HA proteins from one or more Type, Group, sub-type or strain of influenza virus. In one embodiment, the immunogenic portions are from the globular head regions of HA proteins from one or more Type, Group, sub-type or strain of influenza virus. In one embodiment, the immunogenic portions are from the RBDs of HA proteins from one or more Type, group, sub-type or strain of influenza virus. Another embodiment of the present invention is a method to vaccinate an individual against infection with influenza virus, the method comprising: a) obtaining a vaccine comprising at least one nanoparticle comprising HA-SA fusion proteins, wherein the fusion proteins comprise an SA protein joined to an immunogenic portion of an influenza HA protein, and wherein the nanoparticle displays on its surface a heterogeneous population of immunogenic portions from HA proteins from one or more Type, Group, sub-type or strain of influenza virus; and, b) administering the vaccine to an individual such that an immune response against an influenza virus is produced. In one embodiment, the immunogenic portions are from the '0 globular head regions of HA proteins from one or more Types, sub-types or strains of influenza virus. In one embodiment, the immunogenic portions are from the RBDs of HA proteins from one or more Types, sub-types or strains of influenza virus. Vaccines of the present invention can be used to vaccinate individuals using a prime/boost protocol. Such a protocol is described in U.S. Patent Publication No. 20110177122, which is incorporated herein by reference in its entirety. In such a protocol, a first vaccine composition may be administered to the individual (prime) and then after a period of time, a second vaccine composition may be administered to the individual (boost). Administration of the boosting composition is generally weeks or months after administration of the priming composition, preferably about 2-3 weeks or 4 weeks, or 8 weeks, or 16 weeks, or 20 weeks, or 24 weeks, or 28 weeks, or 32 weeks. In one embodiment, the boosting composition is formulated for administration about 1week, or 2 weeks, or 3 weeks, or 4 weeks, or 5 weeks, or 6 weeks, or
7 weeks, or 8 weeks, or 9 weeks, or 16 weeks, or 20 weeks, or 24 weeks, or 28 weeks, or 32 weeks after administration of the priming composition. As used herein, a vaccinated subject is a subject that has been administered a vaccine that is intended to provide a protective effect against an influenza virus. The first and second vaccine compositions can be, but need not be, the same composition. Thus, in one embodiment of the present invention, the step of administering the vaccine comprises administering a first vaccine composition, and then at a later time, administering a second vaccine composition. In one embodiment, the first vaccine composition comprises a nanoparticle of the present invention. In one embodiment, the individual has been exposed to influenza virus. As used herein, the terms exposed, exposure, and the like, indicate the subject has come in contact with a person of animal that is known to be infected with an influenza virus. Vaccines of the present invention may be administered using techniques well known to those in the art. Techniques for formulation and administration may be found, for example, in "Remington's Pharmaceutical Sciences", 1 8 th ed., 1990, Mack Publishing Co., Easton, PA. Vaccines may be administered by means including, but not limited to, traditional syringes, needleless injection devices, or microprojectile bombardment gene guns. Suitable routes of administration include, but are not limited to, parenteral delivery, such as intramuscular, intradermal, subcutaneous, intramedullary injections, as well as, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, '0 or intraocular injections, just to name a few. For injection, the compounds of one embodiment of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. In one embodiment, vaccines, or nanoparticles, of the present invention can be used to protect an individual against infection by heterologous influenza virus. That is, a vaccine made using hemagglutinin protein from one strain of influenza virus is capable of protecting an individual against infection by different strains of influenza. For example, a vaccine made using hemagglutinin protein from influenza A/New Caledonia/20/1999 (HiNi), A/California/04/2009 (HiN1), A/Singapore/i/1957 (H2N2), A/Hong Kong/i/1968 (H3N2), A/Brisbane/10/2007 (H3N2), A/Indonesia/05/2005 (H5N1), B/Florida/4/2006 (influenza B), A/Perth/16/2009 (H3N2), A/Brisbane/59/2007 (HiN1), B/Brisbane/60/2008 (influenza B), A/Wilson-Smith/33 (HiN1), A/Tientsin/78/77 (HiN1), A/Texas/36/91 (HiN1), A/Singapore/6/86 (HiN1),
A/Memphis/39/83 (HINI), A/Malaysia/54 (HINI), A/Iowa/43 (HINI), A/Hong Kong/117/77 (HINI), A/Fort Monmouth/l/47 (HINI), A/Brisbane/59/07 (HINI), A/Baylor/4052/81 (HINI), A/Albany/4835/48 (HiN1), A/Hong Kong/156/97 (H5N1), A/common magpie/Hong Kong/5052/07 (H5N1), A/chicken/Shanxi/2/06 (H5N1), A/silky chicken/Hong Kong/SF189/01 (H5N1), A/chicken/Henan/16/04 (H5N1), A/Victoria/361/11 (H3N2), B/Massachusetts/2/12 (influenza B), B/Brisbane/60/08 (influenza B) and A/Texas/50/12 (H3N2). In one embodiment, vaccines, or nanoparticles, of the present invention can be used to protect an individual against infection by an antigenically divergent influenza virus. In this regard, the term antigenically divergent refers to the tendency of a strain of influenza virus to mutate over time, thereby changing the amino acids that are displayed to the immune system. Such mutation over time is also referred to as antigenic drift. Thus, for example, a vaccine made using hemagglutinin protein from an A/New Caledonia/20/1999 (HiNi) strain of influenza virus is capable of protecting an individual against infection by earlier, antigenically divergent New Caledonia strains of influenza, and by evolving (or diverging) influenza strains of the future. One embodiment of the present invention is a kit for practicing methods of the present invention. Kits can include nanoparticles or vaccines of the present invention as well components for making such nanoparticles and vaccines. As such, kits can include, for example, primers, nucleic acid molecules, expression vectors, DNA constructs encoding proteins of the present invention, cells, buffers, reagents, syringes, and directions for using any of said '0 components. It should be appreciated that a kit may comprise more than one container comprising any of the aforementioned, or related, components. For example, certain parts of the kit may require refrigeration, whereas other parts can be stored at room temperature. Thus, as used herein, a kit comprises components sold in separate containers by one or more entity, with the intention that the components contained therein be used together. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub combination. All combinations of the embodiments are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein. The inventors have discovered that specific fusion proteins comprising portions of hemagglutinin protein are useful for eliciting a broad immune response against influenza viruses. Each of these embodiments will now be disclosed in detail below.
'0 Example 1. Production of heterogeneous nanoparticles A. Gene synthesis and vector construction All genes used in the study were human codon optimized. The gene encoding Helicobacter pylori-bullfrog hybrid ferritin was constructed by fusing residues 2-9 of bullfrog (Rana catesbeiana) ferritin lower subunit (UniProt: P07797 with a point mutation at residue 8 (N8Q) to abolish a potential N-glycosylation site) to H. pylori nonheme ferritin (UniProt: Q9ZLIl, residues 3-167) with mutations at residue 7 (17E) and residue 19 (N19Q) to make a salt bridge with 6R of bullfrog ferritin and abolish a potential N-glycosylation site, respectively. In some cases, there were extra GS residues at the carboxyl terminus of H. pylori ferritin. The secreted encapsulin gene was constructed by fusing a human CD5 signal to Termotoga maritima encapsulin (UniProt: Q9WZP2, residues 1-264). The genes encoding HA RBD (residues 56-264, H3 numbering system) were synthesized or amplified from appropriate plasmids. In some cases, the Y98F mutation was introduced to abolish sialic acid binding property of HA, and the F/K264A mutation to avoid potential steric crash at the junction between HA RBD and nanoparticle scaffolds. These fragments were fused to downstream of a modified bovine prolactin signal sequence (bPRL: MDSKGSSQKG SRLLLLLVVS NLLLPQGVLA) and upstream of the hybrid ferritin with a SG linker to give rise to the HA RBD-ferritin genes. To construct the HA RBD-encapsulin genes, gp350 fragments were fused to downstream of encapsulin with a SG linker. To construct HA RBD Chikungunya virus-like particle (CHIKVLP), the HA RBD gene fragments (residues 59-264, H3 numbering system) were amplified and inserted in the furin cleavage loop between envelope E3 and E2. To accommodate HA RBD insertion and furin cleavage, there were 3 amino acid deletions in E3 (E3 residues 58-60, SPH) and 4 amino acid deletions in E2 (E2 residues 1-4, STKD). All genes were then cloned into the CMV/R or CMV/R 8Kb mammalian expression vector for protein production. B. Biosynthesis of recombinant proteins and purification The expression vectors were transiently transfected into FreeStyle 293F or Expi293F cells (Life Technologies) using 293fectin or ExpiFectamine 293 transfection reagents, respectively (Life Technologies). For co-transfection, equimolar amount of 2-8 different plasmids were mixed (a total DNA amount was constant for all transfections). Four days after transfection, culture supernatants were harvested and cleared. The HA RBD-ferritin and HA RBD-encapsulin '0 nanoparticles were purified by ion exchange chromatography using Q Sepharose HP (GE Healthcare) followed by size exclusion chromatography with a Superose 6 10/300 GL column (GE Healthcare) in PBS. The HA RBD-CHIKVLP were purified by ultracentrifugation using Opriprep (Sigma-Aldrich). Briefly, the cleared culture supernatants were overlaid on 1 ml of Optiprep and spun at 50,000 rcf in an SW 32 Ti rotor for 90 min. After the spin, bottom 2 ml was collected, mixed thoroughly to make 1:1 Optiprep/concentrated supernatant mixture, and spun again at 360,000 rcf in an NVT 100 rotor for 3 hours. The band corresponding HA RBD CHIKVLP was collected and further purified by a Sephacryl S-500 16/60 HR column (GE Healthcare) in PBS. C. Electron microscopy (EM) of purified nanoparticles The nanoparticles purified in part (B) were analyzed by negative stain EM. Briefly, samples of about 50 pg ml-1 were adsorbed to freshly glow-discharged carbon-coated grids, rinsed with
PBS, and stained with 0.75% uranyl formate solution. Images were recorded on an FEI T20 microscope with an Eagle CCD camera. The results of these analyses are shown in Figures 3 and 4.
Example 2. Immunoprecipitation analysis of purified nanoparticles expressing influenza HA protein RBDs HA RBD-nanoparticles expressing RBDs from NC99, CA09 or both (CoAsmbl 2) were prepared and purified as described in Example 1. Four micrograms of purified RBD nanoparticles were incubated with 4 pg of either anti-NC99 (3u-u), anti-pandemic HIN HA (2D1) or anti-HA stem (C179) monoclonal antibodies for 30 min at room temperature. Immune complexes were then captured using protein G-conjugated magnetic beads, and the complexes washed thoroughly with PBS containing 0.01% Tween 20. The washed pellets were resuspended in 20 pl of Laemmli buffer without reducing agent and analyzed on SDS-PAGE. Five micrograms of each protein were loaded. NC99, A/New Caledonia/20/1999; CA09, A/Califomia/04/2009; WS33, A/Wilson-Smith/1933; AB48, A/Albany/4835/1948; BR07, A/Brisbane/59/2007; IA43, A/Iowa/1943; HK77, A/Hong Kong/117/1977; FM47, A/Fort Monmouth/l/1947. The results of these analyses are shown in Figures 5 and 6
Example 3. Immunization of mice using purified nanoparticles. The ability of compositions comprising purified monovalent, admixed, or heterogeneous nanoparticles to elicit a neutralizing immune response was tested in mice. Six to eight week old BALB/c mice were divided into 9 groups (N = 5). To each group was administered a composition comprising 2 pg of either a) a monovalent (i.e., expresses single HA RBD) nanoparticle, b) a mixture of various monovalent nanoparticle, or c) the indicated, co-assembled nanoparticles, in the presence of Sigma Adjuvant System (SAS) at weeks 0 and 3. The immunogens administered and the dosing schedule is shown below in Table 3.
Table 3.
Group1 HA RBD 2 Dose 3 Adjuvant 4 Immunization
Mono (NC99) NC99 2 pg SAS Week 0, 3 (20)
Mono (CA09) CA09 2 pg SAS Week 0, 3 (20)
Admixed 2 NC99/CA09 2 pg total SAS Week 0, 3 (20)
Admixed 4 2 + WS33/AB48 2 pg total SAS Week 0, 3 (20)
Admixed 6 4 + BR07/IA43 2 pg total SAS Week 0, 3 (20)
CoAsmbl2 NC99/CA09 2 pg SAS Week 0, 3 (20)
CoAsmbl4 2 + WS33/AB48 2 pg SAS Week 0, 3 (20)
CoAsmbl6 4 + BR07/1A43 2 pg SAS Week 0, 3 (20)
CoAsmbl8 6 + HK77/FM47 2 pg SAS Week 0, 3 (20) 'Balb/c mice (N= 5) 2 A/New Caledonia/20/99 (NC99); A/Califomia/04/09 (CA09); A/Wilson-Smith/33 (WS33); A/Albany/4835/48 (AB48); A/Brisbane/59/07 (BRO7); A/Iowa/43 (IA43); A/Hong Kong/117/77 (HK77); A/Fort Monmouth/1/47 (FM47) 3 Total protein amount per dose 4 Sigma Adjuvant System (SAS)
Serum samples were collected prior to the first immunization and at two and three weeks after the second immunization for serological analyses. More specifically the immune sera were tested for their ability to inhibit hemagglutination mediated by NC99 virus and neutralize NC99 pseudotyped lentivirus The results of these analyses are shown in Figures 7 and 8.
Example 4. Analysis of breadth of immune response using monovalent nanoparticles, Admixed monovalent nanoparticles or multivalent, co-assembled nanoparticles. Mice (N=5) were immunized with either monovalent nanoparticles against NC99 or CA09, admixed nanoparticles (Admix 4), or multivalent nanoparticles (CoAsmbl 4 or CoAsmbl 8) (N = 5) at week 0 and again at week 3. At 2-3 weeks following the second immunization, sera was collected from each mouse and the sera analyzed by HAI assays using a panel of 18 H1N1 viruses. The resulting titers are shown as a heatmap in Figure 9.
The results of this analysis demonstrate that immunization with multivalent co-assembled particles produces a broader immune response (i.e., an immune response against a wider range of influenza viruses) than does immunization with either monovalent nanoparticles or admixed monovalent nanoparticles.
Example 5. Detection of HA-specific, cross-reactive B-cells in peripheral cells in HA RBD nanoparticle immunized mice Mice (N=5) were immunized with either monovalent nanoparticles against NC99 or CA09, admixed nanoparticles (Admix 2, Admix 4, or Admix 6), or multivalent nanoparticles (CoAsmbl 2, CoAsmbl 4, CoAsmbl 6 or CoAsmbl 8) at week 0, 3 and 20. At 10 days following the third immunization, peripheral blood was collected from each mouse and the white blood cells were isolated and analyzed by flow cytometer using NC99 and CA09 HA probes. Live, non-T, non-mactophage, IgD negative, singlet memory B cells were gated and the cell population (percentage of memory B cells) positive to both NC99 and CA09 HA was quantitated. The gating strategy and the resulting frequency of HA double positive cells across different immunization groups are shown in Figures 10 and 11. The results of this analysis demonstrate that immunization with multivalent co-assembled particles induces an increased frequency of cross-reactive HA-specific memory B cells in immunized animals (i.e., B cells specific for both NC99 and CA09 HA) than does immunization '0 with either monovalent nanoparticles or admixed monovalent nanoparticles.
Example 6. Correlation of NC99/CA09 cross-reactive B-cell frequency and antigenic heterogeneity of co-assembled RDP-nanoparticle Relationship between frequency of HA double positive cells in immunized animals and antigen valence of co-assembled immunogens was examined by Pearson product moment correlation analysis. This relationship is illustrated by the graph in Figure 12. The result of this analysis show that the degree of heterogeneity on the co-assembled immunogens positively correlates with frequency of cross-reactive HA-specific memory B cells in immunized animal.
Example 7. Neutralization breadth elicited by vaccination with co-assembled HA RBD nanoparticles
Mice were vaccinated with co-assembled nanoparticles, according to the schedule shown above in Table 3. Ten days after the final immunization, sera were collected and tested for its ability to neutralize pseudotyped lentiviruses expressing HA and NA from various HINI virus strains. The serum neutralization titers obtained from these assays are shown below in Table 4.
Table 4. Serum neutralization titers from mice immunized with co-assembled nanoparticles
IC 5 o (serum dilution) HINI pseudovirus #8441 #8442 #8443 #8444 #8445
A/Califomia/4/09 NT NT NT NT NT
A/New Jersey/76 2528 947 27580 11222 7463
A/South Carolina/1/18 1146 242 1354 11129 217
A/Wilson-Smith/33 NT NT NT NT NT
A/Puerto Rico/8/34 5439 <40 3440 9822 2817
A/Iowa/43 3062 1709 12821 12095 2466
A/Fort Monmouth/l/47 31302 85350 77846 126781 719
A/Malaysia/54 NT NT NT NT NT
A/Albany/4835/48 NT NT NT NT NT
A/Hong Kong/117/77 2636 7525 16876 37845 1724
A/Singapore/6/86 8888 4064 9822 3469 24751
A/New York/146/00 13366 7780 6866 3113 15399
A/New York/653/96 17302 158 9190 5349 22212
A/Beijing/262/95 5960 <40 1905 9422 96
A/New Caledonia/20/99 5217 15788 18649 42171 46992
A/New York/8/06 1695 423 947 620 2317
A/Solomon Islands/3/06 1072 604 226 1072 1858
A/Brisbane/59/07 NT NT NT NT NT
NT, not tested.
Example 8. Neutralization breadth of an isolated, anti-HA monoclonal antibody
B cells obtained from mouse #8441 in Example 7 were sorted using fluorescently labeled HA probe as bait. Genes encoding variable regions of the antibody heavy and light chains were then amplified from single B cells, sequenced, and cloned into appropriate backbone vectors (mouse IgG2a heavy and kappa light chain backbone) to express the encoded proteins as an antibody. Reconstructed antibody vectors were used for transient transfection in 293-Freestyle expression system (Life technologies) and the IgG was purified by affinity column purification using protein A resin. The resulting antibody was referred to as 441D6. Neutralization IC5 o titers of 441D6 were determined by lentivirus pseudotype neutralization assays in which pseudoviruses express HA and NA from various HINI viral strains. Monoclonal antibodies CH65 (anti-receptor binding site of HA) and FI6v3 (anti-HA stem region) were used as controls. NT=not tested. The neutralization titers obtained from these assays are shown below in Table 5.
Table 5. Neutralization titers of monoclonal antibody 441D6
IC5 o (pg/ml) HINI pseudovirus CH65 441D6 FI6v3
A/Califomia/4/09 6.25 0.16 0.13
A/New Jersey/76 >25 0.03 0.36
A/South Carolina/1/18 0.57 0.04 4.40
A/Wilson-Smith/33 NT NT NT
A/Puerto Rico/8/34 0.44 0.08 0.97
A/Iowa/43 >50 11.08 3.40
A/Fort Monmouth/l/47 5.86 0.02 22.17
A/Malaysia/54 NT NT NT
A/Albany/4835/48 NT NT NT
A/Hong Kong/117/77 0.97 0.04 0.09
A/Singapore/6/86 <0.005 0.01 0.01
A/New York/146/00 0.03 0.01 0.08
A/New York/653/96 <0.005 0.02 0.15
A/Beijing/262/95 0.01 0.07 1.01
A/New Caledonia/20/99 0.01 0.04 0.09
A/New York/8/06 0.02 0.14 >25
A/Solomon Islands/3/06 1.30 0.29 0.94
A/Brisbane/59/07 NT NT NT
NT, not tested.
The results demonstrate the ability of the monoclonal antibody 441D6 to neutralize broader range of HIN viruses than CH65 and more potently neutralize viruses than FI6v3, documenting a novel broad and potent neutralizing monoclonal antibody 441D6 against HIN1 viruses.
To better understand the interaction of monoclonal antibody 441D6 with influenza HA protein, a three-dimensional reconstruction model of an HA trimer complexed with Fab 441D6 was produced. Briefly, HA trimer (A/New York/653/1996 (HINI)) was incubated with 1.5 times excess amount of Fab 441D6 and the complex purified by size exclusion column chromatography. The purified HA-Fab complex was then used in negative stain electron microscopy experiments. Approximately 9,000 particles were used for three dimensional reconstruction and the calculated resolution of the final model was -18.5 A. HA and Fab models were docked in the EM density (bottom). The resulting three-dimensional model is shown in Figure 13.
Claims (6)
1. A nanoparticle, comprising: at least four species of immunogenic portions of influenza virus hemagglutinin (HA) proteins from at least four different strains of influenza virus; wherein each species of the immunogenic portions of the HA proteins comprises an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 32-62; wherein each species of the immunogenic portions of the HA proteins is joined to subunits of the nanoparticle; and wherein the nanoparticle displays on its surface each species of the immunogenic portions of the HA proteins.
2. The nanoparticle of claim 1, wherein the subunits of the nanoparticle are selected from the group consisting of a monomeric ferritin subunit protein, a monomeric encapsulin protein, a monomeric 03-33 protein, a monomeric SOR protein, a monomeric LS protein, and a monomeric PDC protein.
3. A kit comprising the nanoparticle of claim 1 or claim 2.
4. A method of eliciting in an individual, an immune response against influenza virus, comprising administering to the individual the nanoparticle of claim 1 or claim 2.
5. The method of claim 4, wherein the immune response is a broadly neutralizing immune response.
6. A method of vaccinating an individual against influenza virus, comprising administering to the individual the nanoparticle of claim 1 or claim 2.
<?xml version="1.0" encoding="UTF‐8"?> Nov 2022
<!DOCTYPE ST26SequenceListing PUBLIC "‐//WIPO//DTD Sequence Listing 1.3//EN" "ST26SequenceListing_V1_3.dtd"> <ST26SequenceListing dtdVersion="V1_3" fileName="4239‐104866‐16 Sequence Listing.xml" softwareName="WIPO Sequence" softwareVersion="2.2.0" productionDate="2022‐10‐31"> <ApplicantFileReference>4239‐104866‐16</ApplicantFileReference> <EarliestPriorityApplicationIdentification> <IPOfficeCode>US</IPOfficeCode> <ApplicationNumberText>62/098,755</ApplicationNumberText> <FilingDate>2014‐12‐31</FilingDate> 2022279441
</EarliestPriorityApplicationIdentification> <ApplicantName languageCode="en">The USA, as represented by the Secretary, Dept. of Health and Human Services</ApplicantName> <InventionTitle languageCode="en">NOVEL MULTIVALENT NANOPARTICLE‐BASED VACCINES</InventionTitle> <SequenceTotalQuantity>191</SequenceTotalQuantity> <SequenceData sequenceIDNumber="1"> <INSDSeq> <INSDSeq_length>517</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..517</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q1">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MKAKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCLL KGIAPLQLGNCSVAGWILGNPECELLISKESWSYIVETPNPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSW PNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPNLSKSYVNNKEKEVLVLWGVHHPPNIGNQRALYHTENAYVSVVS SHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNAPMDECDAKCQTP QGAINSSLPFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGY AADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDS NVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence > </INSDSeq>
</SequenceData> Nov 2022
<SequenceData sequenceIDNumber="2"> <INSDSeq> <INSDSeq_length>518</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> 2022279441
<INSDFeature_location>1..518</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q2">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKL RGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSW PNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADTYVFVG SSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQT PKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSG YAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHD SNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEID</INSDSeq_sequenc e> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="3"> <INSDSeq> <INSDSeq_length>514</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..514</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q3">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> 2022279441
</INSDSeq_feature‐table>
<INSDSeq_sequence>MAIIYLILLFTAVRGDQICIGYHANNSTEKVDTILERNVTVTHAKDILEKTHNGKLCKLNG IPPLELGDCSIAGWLLGNPECDRLLSVPEWSYIMEKENPRDGLCYPGSFNDYEELKHLLSSVKHFEKVKILPKDRWTQH TTTGGSRACAVSGNPSFFRNMVWLTKKGSNYPVAKGSYNNTSGEQMLIIWGVHHPNDETEQRTLYQNVGTYVSVGTSTL NKRSTPDIATRPKVNGQGGRMEFSWTLLDMWDTINFESTGNLIAPEYGFKISKRGSSGIMKTEGTLENCETKCQTPLGA INTTLPFHNVHPLTIGECPKYVKSEKLVLATGLRNVPQIESRGLFGAIAGFIEGGWQGMVDGWYGYHHSNDQGSGYAAD KESTQKAFDGITNKVNSVIEKMNTQFEAVGKEFSNLERRLENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVK NLYDKVRMQLRDNVKELGNGCFEFYHKCDDECMNSVKNGTYDYPKYEEESKLNRNEIK</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="4"> <INSDSeq> <INSDSeq_length>519</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..519</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q4">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQS SSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEG FTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVLNVTMPNNDNFDKLYIWGVHHPSTNQEQTSLYVQASGRVT VSTRRSQQTIIPNIESRPWVRGLSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECI
TPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGT Nov 2022
GQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLT DSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIK</INSDSeq_sequen ce> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="5"> <INSDSeq> <INSDSeq_length>519</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> 2022279441
<INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..519</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q5">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MKTIIALSYILCLVFTQKLPGNDNSTATLCLGHHAVPNGTIVKTITNDQIEVTNATELVQS SSTGEICDSPHQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNES FNWTGVTQNGTSSACIRRSNNSFFSRLNWLTHLKFKYPALNVTMPNNEKFDKLYIWGVHHPGTDNDQIFPYAQASGRIT VSTKRSQQTVIPNIGSRPRVRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECI TPNGSIPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGI GQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLT DSEMNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIK</INSDSeq_sequen ce> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="6"> <INSDSeq> <INSDSeq_length>520</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..520</INSDFeature_location> Nov 2022
<INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q6">
<INSDQualifier_name>organism</INSDQualifier_name> 2022279441
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCDLD GVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPTNDLCYPGSFNDYEELKHLLSRINHFEKIQIIPKSSWSD HEASSGVSSACPYLGSPSFFRNVVWLIKKNSTYPTIKKSYNNTNQEDLLVLWGIHHPNDAAEQTRLYQNPTTYISIGTS TLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPM GAINSSMPFHNIHPLTIGECPKYVKSNRLVLATGLRNSPQRESRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQG SGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDF HDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESIRNGTYNYPQYSEEARLKREEIS</INSDSeq_seque nce> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="7"> <INSDSeq> <INSDSeq_length>534</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..534</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q7">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature>
</INSDSeq_feature‐table> Nov 2022
<INSDSeq_sequence>MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTPTKSYFANLKG TRTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILHEVKPVTSGCFPIMHDRTKIRQLPNLLRGYENIRLSTQNVI DAEKAPGGPYRLGTSGSCPNATSKSGFFATMAWAVPKDNNKNATNPLTVEVPYICTEGEDQITVWGFHSDDKTQMKNLY GDSNPQKFTSSANGVTTHYVSQIGSFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRSKVIK GSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEG MIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQ IELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNIT< /INSDSeq_sequence> </INSDSeq> 2022279441
</SequenceData> <SequenceData sequenceIDNumber="8"> <INSDSeq> <INSDSeq_length>519</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..519</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q8">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTITNDQIEVTNATELVQS SSTGEICDSPHQILDGKNCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNES FNWTGVTQNGTSSACIRRSKNSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPGTDKDQIFLYAQASGRIT VSTKRSQQTVSPNIGSRPRVRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECI TPNGSIPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGR GQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLT DSEMNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIK</INSDSeq_sequen ce> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="9"> <INSDSeq> <INSDSeq_length>517</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division> Nov 2022
<INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..517</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name> 2022279441
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q9">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCLL KGIAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELREQLSSVSSFERFEIFPKESSW PNHTVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGIQKALYHTENAYVSVVS SHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTP QGAINSSLPFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGY AADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFIDIWTYNAELLVLLENERTLDFHDS NVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence > </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="10"> <INSDSeq> <INSDSeq_length>535</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..535</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q10">
<INSDQualifier_name>organism</INSDQualifier_name> Nov 2022
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTPTKSHFANLKG TETRGKLCPKCLNCTDLDVALGRPKCTGKIPSARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHNVI NAENAPGGPYKIGTSGSCPNITNGNGFFATMAWAVPKNDKNKTATNPLTIEVPYICTEGEDQITVWGFHSDNETQMAKL 2022279441
YGDSKPQKFTSSANGVTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGRSKVI KGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWE GMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISS QIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFDAGEFSLPTFDSLNIT </INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="11"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q11">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTLLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLGKCNIAGWL LGNPECDSLLPAKSWSYIVETPNSENGACYPGDFIDYEELKEQLSSVSSLERFEIFPKESSWPNHNTLKGVTAACSHRG KSSFYRNLLWLTKTGDSYPKLNNSYVNNKGKEVLVLWGVHHPSSSNEQQSLYHNVNAYVSVVSSNYNRRFTPEIAARPK VRDQPGRMNYYWTLLEPGDTIIFEATGNLIAPWYAFALSRGFGSGIITSNASMHECNTKSQTPQGAINSSLPFQNIHPV PIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITN KVNSIIEKMNTQFTAVSKEFNNLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNN AKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq>
</SequenceData> Nov 2022
<SequenceData sequenceIDNumber="12"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> 2022279441
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q12">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCSIAGWI LGNPECESLFSKKSWSYIAETPNSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKERSWPKHNVTRGVTASCSHKG KSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTIYRKENAYVSVVSSNYNRRFTPEIAERPK VRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWHAFALSRGFGSGIITSNASMDECDTKCQTPQGAINSSLPFQNIHPV TIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITN KVNSVIEKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNN AKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="13"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> Nov 2022
</INSDQualifier> <INSDQualifier id="q13">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table> 2022279441
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGNCSVAGWI LGNPKCESLFSKESWSYIAETPNPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVTTSCSHNG KSSFYRNLLWLTEKNGLYPNLSKSYVNNKEKEVLVLWGVHHPSNIRDQRAIYHTENAYVSVVSSHYSRRFTPEIAKRPK VRGQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCQTPQGAINSSLPFQNVHPV TIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITN KVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENGRTLDFHDSNVKNLYEKVKSQLKNN AKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNRGKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="14"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q14">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGNCSIAGWI LGNPECESLFSKKSWSYIAETPNSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVTASCSHKG RSSFYRNLLWLTKKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIGDQRAIYHTENAYVSVVSSHYNRRFTPEIAKRPK VRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCQTPQGAINSSLPFQNVHPV TIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITN
KVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNN Nov 2022
AKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="15"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature> 2022279441
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q15">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDNHNGKLCKLKGIAPLQLGKCSIAGWI LGNPECESLFSKKSWSYIAETPNSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPKHNVTKGVTASCSHKG KSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTIYRKENAYVSVVSSHYNRRFTPEIAKRPK VRNQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCQTPQGAINSSLPFQNVHPV TIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITN KVNSIIEKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNN AKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="16"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q16">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> 2022279441
</INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWI LGNPECESLLSNRSWSYIAETPNSENGICYPGDFADYEELREQLSSVSSFERFEIFPKESSWPKHNITRGVTVACSHAK KSSFYKNLLWLTEANGLYPSLSKSYVNDREKEVLVLWGVHHPSNIEDQRTLYRKENAYVSVVSSNYNRRFTPEIAERPK VRGQPGRMNYYWTLLEPGDKIIFEANGNLIAPWYAFALSRGPGSGIITSNASMDECDTKCQTPQGAINSSLPFQNIHPV TIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITN KVNSVIEKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKNQLRNN AKEIGNGCFEFYHKCDNECMESVKNGTYDYPKYSEESKLNRAKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="17"> <INSDSeq> <INSDSeq_length>500</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..500</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q17">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWI LGNPECESLLSERSWSYIVETPNSENGTCYPGDFIDYEELREQLSSVSSFERFEIFSKESSWPKHTTGGVTAACSHAGK
SSFYRNLLWLTEKDGSYPNLNNSYVNKKGKEVLVLWGVHHPSNIKDQQTLYQKENAYVSVVSSNYNRRFTPEIAERPKV Nov 2022
RGQAGRINYYWTLLKPGDTIMFEANGNLIAPWYAFALSRGFGSGIITSNASMHECDTKCQTPQGAINSSLPFQNIHPVT IGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK VNSVIEKMNTQFTAVGKEFNNLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKNQLRNNA KEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="18"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> 2022279441
<INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q18">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCSIAGWI LGNPECESLFSKKSWSYIAETPNSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKERSWPKHNVTRGVTASCSHKG KSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTIYRKENAYVSVVSSNYNRRFTPEIAERPK VRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDTKCQTPQGAINSSLPFQNVHPV TIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITN KVNSVIEKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNN AKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="19"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> Nov 2022
<INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q19">
<INSDQualifier_name>organism</INSDQualifier_name> 2022279441
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWI LGNPECESLLSKRSWSYIAETPNSENGACYPGDFADYEELREQLSSVSSFERFEIFPKERSWPKHNITRGVTAACSHAG KSSFYKNLLWLTETDGSYPKLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTLYRKENAYVSVVSSNYNRRFTPEIAERPK VRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRDFGSGIITSNASMDECDTKCQTPQGAINSSLPFQNIHPV TIGECPKYVKSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINWITN KVNSVIEKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKNQLRNN AKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="20"> <INSDSeq> <INSDSeq_length>500</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..500</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q20">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCLLKGIAPLQLGNCSVAGWI LGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGE SSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGNQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKV RDQEGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSLPFQNVHPVT IGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNK VNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFIDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNA KEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="21"> 2022279441
<INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q21">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCSIAGWI LGNPECESLFSKKSWSYIAETPNSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPKHNVTRGVTASCSHKG KCSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTIYRKENAYVSVVSSHYNRRFTPEIAKRPK VRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCQTPQGAINSSLPFQNVHPV TIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITN KVNSVIEKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNN AKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="22"> <INSDSeq> <INSDSeq_length>501</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..501</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> 2022279441
<INSDQualifier id="q22">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWI LGNPECESLFSKKSWSYIAETPNSENGTCYPGYFADYEELREQLSSVSSFERFEIFPKERSWPKHNITRGVTAACSHKG KSSFYRNLLWLTEKNGSYPNLNKSYVNNKEKEVLVLWGVHHPSNIEDQKTLYRKENAYVSVVSSNYNRRFTPEIAERPK VRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWHAFALSRGFGSGIITSNASMDECDTKCQTPQGAINSSLPFQNIHPV TIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITN KVNSVIEKMNTQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNN AKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKID</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="23"> <INSDSeq> <INSDSeq_length>504</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..504</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q23">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier>
</INSDFeature_quals> Nov 2022
</INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DQICIGYHANNSTEQVDTIMEKNVTVTHAQDILERTHNGKLCDLNGVKPLILRDCSVAGWL LGNPMCDEFINVPEWSYIVEKASPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSNHDASSGVSSACPYLGR SSFFRNVVWLIKKNSAYPTIKRSYNNTNQEDLLVLWGVHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPEIATRPKV NGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSTIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLT IGECPKYVKSNRLVLATGLRNTPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSCYSADKESTQKAIDG VTNKVNSIINKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQL RDNAKELGNGCFEFYHKCDNECMESVKNGTYDYPQYSEEARLNREEIS</INSDSeq_sequence> 2022279441
</INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="24"> <INSDSeq> <INSDSeq_length>503</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..503</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q24">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DHICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCDLNGVKPLILKDCSVAGWL LGNPMCDEFINVPEWSYIVEKANPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKDSWSDHEASLGVSSACPYQGN SSFFRNVVWLIKKGNAYPTIKKSYNNTNQEDLLVLWGIHHPNDEAEQTRLYQNPTTYISIGTSTLNQRLVPKIATRSKV NGQSGRIDFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSTIMKSEVEYGNCNTRCQTPMGAINSSMPFHNIHPLT IGECPKYVKSNKLVLATGLRNSPQRERRRKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGV TNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLR DNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEIS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="25"> <INSDSeq> <INSDSeq_length>503</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division> Nov 2022
<INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..503</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name> 2022279441
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q25">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DQICVGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCNLDGVKPLILKDCSVAGWL LGNPMCDEFLNVSEWSYIVEKASPANGLCYPGDFNDYEELKHLLSRINHFEKIKIIPKSSWSNHEASGVSSACSYLGKP SFFRNLVWLIKKNNTYPPIKVNYTNTNQEDLLVLWGIHHPNDETEQVKIYQNPTTYISVGTSTLNQRLVPKIATRSKVN GQSGRMEFFWTILKPNDAINFDSNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTI GECPKYVKSNRLVLATGLRNAPQREGGRRKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGI TNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYEKVRLQLR DNAKELGNGCFEFYHKCDNECMESVKNGTYDYPQYSEEARLNREEIS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="26"> <INSDSeq> <INSDSeq_length>504</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..504</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q26">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCDLDGVKPLILRDCSVAGWL LGNPMCDEFINVPEWSYIVEKASPANDLCYPGDFNDYEELKHLLSRINHFEKIQIIPKSSWSNHEASSGVSSACPYLGK SSFFRNVVWLIKKNSTYPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPKIATRSKV NGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLT 2022279441
IGECPKYVKSNRLVLATGLRNTPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDG VTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQL RDNAKELGNGCFEFYHKCDNECMESVKNGTYDYPQYSEEARLNREEIS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="27"> <INSDSeq> <INSDSeq_length>504</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..504</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q27">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DQICIGYHANNSTEQVDTIMEKNVAVTHAQDILEKTHNGKLCDLDGVKPLILRDCSVAGWL LGNPMCDEFINVPEWSYIVEKASPANGLCYPGDFNDYEELKHLLSRINHFEKIQIIPKSSWSNHEASSGVSSACPYQGK SSFFRNVVWLIKKNSTYPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTRLYQNPTTYISVGTSTLNQRLVPKIATRSKV NGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLT IGECPKYVKSNRLVLATGLRNSPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDG VTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQL RDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEIS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="28">
<INSDSeq> Nov 2022
<INSDSeq_length>503</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..503</INSDFeature_location> <INSDFeature_quals> 2022279441
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q28">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>QKLPGNDNSTATLCLGHHAVPNGTIVKTITNDQIEVTNATELVQNSSIGEICDSPHQILDG ENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVTQNGTSSACI RRSNNSFFSRLNWLTQLNFKYPALNVTMPNNEQFDKLYIWGVHHPVTDKDQIFLYAQSSGRITVSTKRSQQAVIPNIGY RPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECITPNGSIPNDKPFQNVN RITYGACPRYVKQSTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGRGQAADLKSTQAAIDQI NGKLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTKKQLR ENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIK</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="29"> <INSDSeq> <INSDSeq_length>532</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..532</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier>
<INSDQualifier id="q29"> Nov 2022
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTPTKSYFANLKGTKTRGKLCPDCLNCT 2022279441
DLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLANLLRGYENIRLSTQNVIDAEKAPGGPYRLGTS GSCPNATSKSGFFATMAWAVPKDNNKNATNPLTVEVPYICAEGEDQITVWGFHSDDKTQMKNLYGDSNPQKFTSSANGV TTHYVSQIGGFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEK YGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHG VAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINS EDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHT</I NSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="30"> <INSDSeq> <INSDSeq_length>533</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..533</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q30">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTPTKSHFANLKGTETRGKLCPKCLNCT DLDVALGRPKCTGKIPSARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHNVINAENAPGGPYKIGTS GSCPNITNGNGFFATMAWAVPKNDKNKTATNPLTIEVPYICTEGEDQITVWGFHSDNETQMAKLYGDSKPQKFTSSANG VTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHE KYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAH GVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIIN
SEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHT</ Nov 2022
INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="31"> <INSDSeq> <INSDSeq_length>503</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature> 2022279441
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..503</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q31">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>QKLPGNDNSTATLCLGHHAVPNGTIVKTITNDRIEVTNATELVQNSSIGEICDSPHQILDG ENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWNGVTQNGTSSACI RRSNNSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPVTDKDQIFLYAQPSGRITVSTKRSQQAVIPNIGF RPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCKSECITPNGSIPNDKPFQNVN RITYGACPRYVKQSTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGRGQAADLKSTQAAIDQI NGKLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTKKQLR ENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIK</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="32"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q32">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> 2022279441
</INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGNCSVAGWILGNPECELLISKESWSYIVETPNPENGTCYPGYFADYEELREQLSS VSSFERFEIFPKESSWPNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPNLSKSYVNNKEKEVLVLWGVHHPPNIGN QRALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRG</INSD Seq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="33"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q33">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGNCSVAGWILGNPECELLISKESWSYIVETPNPENGTCFPGYFADYEELREQLSS VSSFERFEIFPKESSWPNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPNLSKSYVNNKEKEVLVLWGVHHPPNIGN QRALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRG</INSD Seq_sequence> </INSDSeq>
</SequenceData> Nov 2022
<SequenceData sequenceIDNumber="34"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> 2022279441
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q34">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>VAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSS VSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSA DQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERN</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="35"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q35">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>VAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCFPGDFIDYEELREQLSS VSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSA 2022279441
DQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERN</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="36"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q36">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IPPLELGDCSIAGWLLGNPECDRLLSVPEWSYIMEKENPRDGLCYPGSFNDYEELKHLLSS VKHFEKVKILPKDRWTQHTTTGGSRACAVSGNPSFFRNMVWLTKKGSNYPVAKGSYNNTSGEQMLIIWGVHHPNDETEQ RTLYQNVGTYVSVGTSTLNKRSTPDIATRPKVNGQGGRMEFSWTLLDMWDTINFESTGNLIAPEYGFKISKRG</INSD Seq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="37"> <INSDSeq> <INSDSeq_length>209</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature‐table> Nov 2022
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..209</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name> 2022279441
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q37">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>HRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERSKAFSNCYPYDVPDYASLRSLVASSG TLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVLNVTMPNNDNFDKLYIWGVHHPSTNQEQTSLY VQASGRVTVSTRRSQQTIIPNIESRPWVRGLSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMRTGK</INSDSeq_ sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="38"> <INSDSeq> <INSDSeq_length>209</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..209</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q38">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals>
</INSDFeature> Nov 2022
</INSDSeq_feature‐table>
<INSDSeq_sequence>HQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSG TLEFNNESFNWTGVTQNGTSSACIRRSNNSFFSRLNWLTHLKFKYPALNVTMPNNEKFDKLYIWGVHHPGTDNDQIFPY AQASGRITVSTKRSQQTVIPNIGSRPRVRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGK</INSDSeq_ sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="39"> <INSDSeq> 2022279441
<INSDSeq_length>232</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..232</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q39">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>RTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILHEVKPVTSGCFPIMHDRTKIRQLP NLLRGYENIRLSTQNVIDAEKAPGGPYRLGTSGSCPNATSKSGFFATMAWAVPKDNNKNATNPLTVEVPYICTEGEDQI TVWGFHSDDKTQMKNLYGDSNPQKFTSSANGVTTHYVSQIGSFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGV LLPQKVWCASGRS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="40"> <INSDSeq> <INSDSeq_length>209</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..209</INSDFeature_location>
<INSDFeature_quals> Nov 2022
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q40">
<INSDQualifier_name>organism</INSDQualifier_name> 2022279441
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>HQILDGKNCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSG TLEFNNESFNWTGVTQNGTSSACIRRSKNSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPGTDKDQIFLY AQASGRITVSTKRSQQTVSPNIGSRPRVRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGK</INSDSeq_ sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="41"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q41">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCNIAGWLLGNPECDSLLPAKSWSYIVETPNSENGACFPGDFIDYEELKEQLSS VSSLERFEIFPKESSWPNHNTLKGVTAACSHRGKSSFYRNLLWLTKTGDSYPKLNNSYVNNKGKEVLVLWGVHHPSSSN EQQSLYHNVNAYVSVVSSNYNRRFTPEIAARPKVRDQPGRMNYYWTLLEPGDTIIFEATGNLIAPWYAFALSRG</INS
DSeq_sequence> Nov 2022
</INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="42"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature> 2022279441
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q42">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCSIAGWILGNPECESLFSKKSWSYIAETPNSENGTCFPGYFADYEELREQLSS VSSFERFEIFPKERSWPKHNVTRGVTASCSHKGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIE DQKTIYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWHAFALSRG</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="43"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier> Nov 2022
<INSDQualifier id="q43">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table> 2022279441
<INSDSeq_sequence>IAPLQLGNCSVAGWILGNPKCESLFSKESWSYIAETPNPENGTCFPGYFADYEELREQLSS VSSFERFEIFPKESSWPNHTVTKGVTTSCSHNGKSSFYRNLLWLTEKNGLYPNLSKSYVNNKEKEVLVLWGVHHPSNIR DQRAIYHTENAYVSVVSSHYSRRFTPEIAKRPKVRGQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRG</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="44"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q44">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGNCSIAGWILGNPECESLFSKKSWSYIAETPNSENGTCFPGYFADYEELREQLSS VSSFERFEIFPKESSWPNHTVTKGVTASCSHKGRSSFYRNLLWLTKKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIG DQRAIYHTENAYVSVVSSHYNRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRG</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="45"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length>
<INSDSeq_moltype>AA</INSDSeq_moltype> Nov 2022
<INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier> 2022279441
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q45">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCSIAGWILGNPECESLFSKKSWSYIAETPNSENGTCFPGYFADYEELREQLSS VSSFERFEIFPKESSWPKHNVTKGVTASCSHKGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIE DQKTIYRKENAYVSVVSSHYNRRFTPEIAKRPKVRNQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRG</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="46"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q46">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value>
</INSDQualifier> Nov 2022
</INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCNIAGWILGNPECESLLSNRSWSYIAETPNSENGICFPGDFADYEELREQLSS VSSFERFEIFPKESSWPKHNITRGVTVACSHAKKSSFYKNLLWLTEANGLYPSLSKSYVNDREKEVLVLWGVHHPSNIE DQRTLYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQPGRMNYYWTLLEPGDKIIFEANGNLIAPWYAFALSRG</INS DSeq_sequence> </INSDSeq> </SequenceData> 2022279441
<SequenceData sequenceIDNumber="47"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q47">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCNIAGWILGNPECESLLSERSWSYIVETPNSENGTCFPGDFIDYEELREQLSS VSSFERFEIFSKESSWPKHTTGGVTAACSHAGKSSFYRNLLWLTEKDGSYPNLNNSYVNKKGKEVLVLWGVHHPSNIKD QQTLYQKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLKPGDTIMFEANGNLIAPWYAFALSRG</INSD Seq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="48"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q48"> 2022279441
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCSIAGWILGNPECESLFSKKSWSYIAETPNSENGTCFPGYFADYEELREQLSS VSSFERFEIFPKERSWPKHNVTRGVTASCSHKGKSSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIE DQKTIYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRG</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="49"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q49">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCNIAGWILGNPECESLLSKRSWSYIAETPNSENGACFPGDFADYEELREQLSS
VSSFERFEIFPKERSWPKHNITRGVTAACSHAGKSSFYKNLLWLTETDGSYPKLSKSYVNNKEKEVLVLWGVHHPSNIE Nov 2022
DQKTLYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRD</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="50"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> 2022279441
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q50">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCFPGHFADYEELREQLSS VSSFERFEIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGI QKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRG</INSD Seq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="51"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q51">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> 2022279441
</INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCSIAGWILGNPECESLFSKKSWSYIAETPNSENGTCFPGYFADYEELREQLSS VSSFERFEIFPKESSWPKHNVTRGVTASCSHKGKCSFYRNLLWLTEKNGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIE DQKTIYRKENAYVSVVSSHYNRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRG</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="52"> <INSDSeq> <INSDSeq_length>214</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..214</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q52">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>IAPLQLGKCNIAGWILGNPECESLFSKKSWSYIAETPNSENGTCFPGYFADYEELREQLSS VSSFERFEIFPKERSWPKHNITRGVTAACSHKGKSSFYRNLLWLTEKNGSYPNLNKSYVNNKEKEVLVLWGVHHPSNIE DQKTLYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWHAFALSRG</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="53">
<INSDSeq> Nov 2022
<INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> 2022279441
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q53">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>VKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPTNDLCFPGSFNDYEELKHLLSR INHFEKIQIIPKSSWSDHEASSGVSSACPYLGSPSFFRNVVWLIKKNSTYPTIKKSYNNTNQEDLLVLWGIHHPNDAAE QTRLYQNPTTYISIGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKK</INSD Seq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="54"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q54">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>VKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKASPANDLCFPGNFNDYEELKHLLSR INHFEKIQIIPKSSWSNHDASSGVSSACPYLGRSSFFRNVVWLIKKNSAYPTIKRSYNNTNQEDLLVLWGVHHPNDAAE QTKLYQNPTTYISVGTSTLNQRLVPEIATRPKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKK</INSD Seq_sequence> 2022279441
</INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="55"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q55">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>VKPLILKDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPANDLCFPGNFNDYEELKHLLSR INHFEKIQIIPKDSWSDHEASLGVSSACPYQGNSSFFRNVVWLIKKGNAYPTIKKSYNNTNQEDLLVLWGIHHPNDEAE QTRLYQNPTTYISIGTSTLNQRLVPKIATRSKVNGQSGRIDFFWTILKPNDAINFESNGNFIAPEYAYKIVKK</INSD Seq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="56"> <INSDSeq> <INSDSeq_length>212</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..212</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> 2022279441
<INSDQualifier id="q56">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>VKPLILKDCSVAGWLLGNPMCDEFLNVSEWSYIVEKASPANGLCFPGDFNDYEELKHLLSR INHFEKIKIIPKSSWSNHEASGVSSACSYLGKPSFFRNLVWLIKKNNTYPPIKVNYTNTNQEDLLVLWGIHHPNDETEQ VKIYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFDSNGNFIAPEYAYKIVKK</INSDS eq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="57"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q57">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>VKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKASPANDLCFPGDFNDYEELKHLLSR INHFEKIQIIPKSSWSNHEASSGVSSACPYLGKSSFFRNVVWLIKKNSTYPTIKRSYNNTNQEDLLVLWGIHHPNDAAE QTKLYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKK</INSD Seq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="58"> <INSDSeq> <INSDSeq_length>213</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> 2022279441
<INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..213</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q58">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>VKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKASPANGLCFPGDFNDYEELKHLLSR INHFEKIQIIPKSSWSNHEASSGVSSACPYQGKSSFFRNVVWLIKKNSTYPTIKRSYNNTNQEDLLVLWGIHHPNDAAE QTRLYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKK</INSD Seq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="59"> <INSDSeq> <INSDSeq_length>208</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..208</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q59">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> 2022279441
</INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>HQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCFPYDVPDYASLRSLVASSG TLEFNNESFNWTGVTQNGTSSACIRRSNNSFFSRLNWLTQLNFKYPALNVTMPNNEQFDKLYIWGVHHPVTDKDQIFLY AQSSGRITVSTKRSQQAVIPNIGYRPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSG</INSDSeq_s equence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="60"> <INSDSeq> <INSDSeq_length>231</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..231</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q60">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>KTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLA NLLRGYENIRLSTQNVIDAEKAPGGPYRLGTSGSCPNATSKSGFFATMAWAVPKDNNKNATNPLTVEVPYICAEGEDQI TVWGFHSDDKTQMKNLYGDSNPQKFTSSANGVTTHYVSQIGGFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGV LLPQKVWCASGR</INSDSeq_sequence> </INSDSeq>
</SequenceData> Nov 2022
<SequenceData sequenceIDNumber="61"> <INSDSeq> <INSDSeq_length>232</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> 2022279441
<INSDFeature_location>1..232</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q61">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ETRGKLCPKCLNCTDLDVALGRPKCTGKIPSARVSILHEVRPVTSGCFPIMHDRTKIRQLP NLLRGYEHIRLSTHNVINAENAPGGPYKIGTSGSCPNITNGNGFFATMAWAVPKNDKNKTATNPLTIEVPYICTEGEDQ ITVWGFHSDNETQMAKLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQRG ILLPQKVWCASGR</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="62"> <INSDSeq> <INSDSeq_length>208</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..208</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q62">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Influenza virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>QILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGT LEFNNESFNWNGVTQNGTSSACIRRSNNSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPVTDKDQIFLYA 2022279441
QPSGRITVSTKRSQQAVIPNIGFRPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGK</INSDSeq_s equence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="63"> <INSDSeq> <INSDSeq_length>504</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..504</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>genomic DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q63">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Helicobacter pylori</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atgttatcaaaagacatcattaagttgctaaacgaacaagtgaataaggaaatgaactctt ccaacttgtatatgagcatgagttcatggtgctatacccatagcttagatggcgcggggcttttcttgtttgaccatgc ggctgaagaatacgagcatgctaaaaagcttattatcttcttgaatgaaaacaatgtgcctgtgcaattgaccagcatc agcgcgcctgagcataagtttgaaggtttgactcaaattttccaaaaagcctatgaacatgagcaacacatcagcgagt ctattaacaatatcgtagatcacgccataaaaagcaaagatcatgcgactttcaatttcttgcaatggtatgtggctga acagcatgaagaagaagtgcttttcaaggatattttggataaaattgagttgattggtaatgaaaaccatggcttgtat ttagccgatcagtatgtcaaagggatcgctaaaagcaggaaatcttaa</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="64"> <INSDSeq>
<INSDSeq_length>167</INSDSeq_length> Nov 2022
<INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..167</INSDFeature_location> <INSDFeature_quals> <INSDQualifier> 2022279441
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q64">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Helicobacter pylori</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MLSKDIIKLLNEQVNKEMNSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFL NENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDK VELIGNENHGLYLADQYVKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="65"> <INSDSeq> <INSDSeq_length>504</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..504</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>genomic DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q65">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Helicobacter pylori</INSDQualifier_value>
</INSDQualifier> Nov 2022
</INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ttaagatttcctgcttttagcgatccctttgacatactgatcggctaaatacaagccatgg ttttcattaccaatcaactcaattttatccaaaatatccttgaaaagcacttcttcttcatgctgttcagccacatacc attgcaagaaattgaaagtcgcatgatctttgctttttatggcgtgatctacgatattgttaatagactcgctgatgtg ttgctcatgttcataggctttttggaaaatttgagtcaaaccttcaaacttatgctcaggcgcgctgatgctggtcaat tgcacaggcacattgttttcattcaagaagataataagctttttagcatgctcgtattcttcagccgcatggtcaaaca agaaaagccccgcgccatctaagctatgggtatagcaccatgaactcatgctcatatacaagttggaagagttcatttc 2022279441
cttattcacttgttcgtttagcaacttaatgatgtcttttgataacat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="66"> <INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="67"> <INSDSeq> <INSDSeq_length>165</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..165</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q66">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Escherichia coli</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MLKPEMIEKLNEQMNLELYSSLLYQQMSAWCSYHTFEGAAAFLRRHAQEEMTHMQRLFDYL TDTGNLPRINTVESPFAEYSSLDELFQETYKHEQLITQKINELAHAAMTNQDYPTFNFLQWYVSEQHEEEKLFKSIIDK LSLAGKSGEGLYFIDKELSTLDAQN</INSDSeq_sequence> </INSDSeq>
</SequenceData> Nov 2022
<SequenceData sequenceIDNumber="68"> <INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="69"> <INSDSeq> 2022279441
<INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="70"> <INSDSeq> <INSDSeq_length>173</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..173</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q67">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Rana catesbeiana</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MESQVRQNFHQDCEAGLNRTVNLKFHSSYVYLSMASYFNRDDVALSNFAKFFRERSEEEKE HAEKLIEYQNQRGGRVFLQSVEKPERDDWANGLEALQTALKLQKSVNQALLDLHAVAADKSDPHMTDFLESPYLSESVE TIKKLGDHITSLKKLWSSHPGMAEYLFNKHTLG</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="71"> <INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/>
<INSDSeq_division/> Nov 2022
<INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="72"> <INSDSeq> <INSDSeq_length>531</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature> 2022279441
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..531</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q68">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..531</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q69">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tccggagagagccaggtgaggcagcagttcagcaaggacatcgagaagctgctgaacgagc aggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgctacacccacagcctggacggcgc cggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatcatcttcctgaacgagaacaac gtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgacccagatcttccagaaggcctacg agcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagagcaaggaccacgccaccttcaa cttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatcctggacaagatcgagctgatc ggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaagagcaggaagagcggatcc</IN SDSeq_sequence>
</INSDSeq> Nov 2022
</SequenceData> <SequenceData sequenceIDNumber="73"> <INSDSeq> <INSDSeq_length>177</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key> 2022279441
<INSDFeature_location>1..177</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q70">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..177</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q71">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>SGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEH AKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEV LFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="74"> <INSDSeq> <INSDSeq_length>531</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature‐table> Nov 2022
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..531</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q72">
<INSDQualifier_name>note</INSDQualifier_name> 2022279441
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..531</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q73">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacaggccg tggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggccacgt accactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgctgat gtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctggtc agctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggtcga acaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctgcat ctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccgga</IN SDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="75"> <INSDSeq> <INSDSeq_length>516</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..516</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q74">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> 2022279441
</INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..516</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q75">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tccggagagagccaggtgaggcagaacttcaagcccgagatggaggagaagctgaacgagc agatgaacctggagctgtacagcagcctgctgtaccagcagatgagcgcctggtgcagctaccacaccttcgagggcgc cgccgccttcctgaggaggcacgcccaggaggagatgacccacatgcagaggctgttcgactacctgaccgacaccggc aacctgcccaggatcaacaccgtggagagccccttcgccgagtacagcagcctggacgagctgttccaggagacctaca agcacgagcagctgatcacccagaagatcaacgagctggcccacgccgccatgaccaaccaggactaccccaccttcaa cttcctgcagtggtacgtgagcgagcagcacgaggaggagaagctgttcaagagcatcatcgacaagctgagcctggcc ggcaagagcggcgagggcctgtacttcatcgacaaggagctgagcaccctggacggatcc</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="76"> <INSDSeq> <INSDSeq_length>172</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..172</INSDFeature_location> Nov 2022
<INSDFeature_quals> <INSDQualifier id="q76">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature> 2022279441
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..172</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q77">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>SGESQVRQNFKPEMEEKLNEQMNLELYSSLLYQQMSAWCSYHTFEGAAAFLRRHAQEEMTH MQRLFDYLTDTGNLPRINTVESPFAEYSSLDELFQETYKHEQLITQKINELAHAAMTNQDYPTFNFLQWYVSEQHEEEK LFKSIIDKLSLAGKSGEGLYFIDKELSTLDGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="77"> <INSDSeq> <INSDSeq_length>516</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..516</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q78">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier> Nov 2022
</INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..516</INSDFeature_location> <INSDFeature_quals> <INSDQualifier> 2022279441
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q79">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ggatccgtccagggtgctcagctccttgtcgatgaagtacaggccctcgccgctcttgccg gccaggctcagcttgtcgatgatgctcttgaacagcttctcctcctcgtgctgctcgctcacgtaccactgcaggaagt tgaaggtggggtagtcctggttggtcatggcggcgtgggccagctcgttgatcttctgggtgatcagctgctcgtgctt gtaggtctcctggaacagctcgtccaggctgctgtactcggcgaaggggctctccacggtgttgatcctgggcaggttg ccggtgtcggtcaggtagtcgaacagcctctgcatgtgggtcatctcctcctgggcgtgcctcctcaggaaggcggcgg cgccctcgaaggtgtggtagctgcaccaggcgctcatctgctggtacagcaggctgctgtacagctccaggttcatctg ctcgttcagcttctcctccatctcgggcttgaagttctgcctcacctggctctctccgga</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="78"> <INSDSeq> <INSDSeq_length>792</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..792</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>genomic DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q80">
<INSDQualifier_name>organism</INSDQualifier_name> Nov 2022
<INSDQualifier_value>Thermotoga maritima</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggagttcctgaagaggagcttcgcccctctgaccgagaagcagtggcaggagatcgaca acagggccagggagatcttcaagacccagctgtacggcaggaagttcgtggacgtggagggcccctacggctgggagta cgccgcccaccccctgggcgaggtggaggtgctgagcgacgagaacgaggtggtgaagtggggcctgaggaagagcctg 2022279441
cccctgatcgagctgagggccaccttcaccctggacctgtgggagctggacaacctggagaggggcaagcccaacgtgg acctgagcagcctggaggagaccgtgaggaaggtggccgagttcgaggacgaggtgatcttcaggggctgcgagaagag cggcgtgaagggcctgctgagcttcgaggagaggaagatcgagtgcggcagcacccccaaggacctgctggaggccatc gtgagggccctgagcatcttcagcaaggacggcatcgagggcccctacaccctggtgatcaacaccgacaggtggatca acttcctgaaggaggaggccggccactaccccctggagaagagggtggaggagtgcctgaggggcggcaagatcatcac cacccccaggatcgaggacgccctggtggtgagcgagaggggcggcgacttcaagctgatcctgggccaggacctgagc atcggctacgaggacagggagaaggacgccgtgaggctgttcatcaccgagaccttcaccttccaggtggtgaaccccg aggccctgatcctgctgaag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="79"> <INSDSeq> <INSDSeq_length>264</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..264</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q81">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Thermotoga maritima</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MEFLKRSFAPLTEKQWQEIDNRAREIFKTQLYGRKFVDVEGPYGWEYAAHPLGEVEVLSDE NEVVKWGLRKSLPLIELRATFTLDLWELDNLERGKPNVDLSSLEETVRKVAEFEDEVIFRGCEKSGVKGLLSFEERKIE CGSTPKDLLEAIVRALSIFSKDGIEGPYTLVINTDRWINFLKEEAGHYPLEKRVEECLRGGKIITTPRIEDALVVSERG GDFKLILGQDLSIGYEDREKDAVRLFITETFTFQVVNPEALILLK</INSDSeq_sequence> </INSDSeq>
</SequenceData> Nov 2022
<SequenceData sequenceIDNumber="80"> <INSDSeq> <INSDSeq_length>792</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> 2022279441
<INSDFeature_location>1..792</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>genomic DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q82">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Thermotoga maritima</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>cttcagcaggatcagggcctcggggttcaccacctggaaggtgaaggtctcggtgatgaac agcctcacggcgtccttctccctgtcctcgtagccgatgctcaggtcctggcccaggatcagcttgaagtcgccgcccc tctcgctcaccaccagggcgtcctcgatcctgggggtggtgatgatcttgccgcccctcaggcactcctccaccctctt ctccagggggtagtggccggcctcctccttcaggaagttgatccacctgtcggtgttgatcaccagggtgtaggggccc tcgatgccgtccttgctgaagatgctcagggccctcacgatggcctccagcaggtccttgggggtgctgccgcactcga tcttcctctcctcgaagctcagcaggcccttcacgccgctcttctcgcagcccctgaagatcacctcgtcctcgaactc ggccaccttcctcacggtctcctccaggctgctcaggtccacgttgggcttgcccctctccaggttgtccagctcccac aggtccagggtgaaggtggccctcagctcgatcaggggcaggctcttcctcaggccccacttcaccacctcgttctcgt cgctcagcacctccacctcgcccagggggtgggcggcgtactcccagccgtaggggccctccacgtccacgaacttcct gccgtacagctgggtcttgaagatctccctggccctgttgtcgatctcctgccactgcttctcggtcagaggggcgaag ctcctcttcaggaactccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="81"> <INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="82"> <INSDSeq> <INSDSeq_length>192</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division> Nov 2022
<INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..192</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q83">
<INSDQualifier_name>note</INSDQualifier_name> 2022279441
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..192</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q84">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MSQAIGILELTSIAAGMELGDAMLKSANVDLLVSKTISPGKFLLMLGGDIGAIQQAIETGT SQAGELLVDSLVLANIHPSVLPAISGLNSVDKRQAVGIVETWSVAACISAADRAVKGSNVTLVRVHMAFGIGGKCYMVV AGDVSDVALAVTVASSSAGAYGLLVYASLIPRPHEAMWRQMVEGLEHHHHHH</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="83"> <INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="84"> <INSDSeq> <INSDSeq_length/>
<INSDSeq_moltype/> Nov 2022
<INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="85"> <INSDSeq> <INSDSeq_length>318</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> 2022279441
<INSDFeature> <INSDFeature_key>SITE</INSDFeature_key>
<INSDFeature_location>31</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q85">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>misc_feature ‐ X can be any naturally occurring amino acid</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..318</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q86">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Acidianus ambivalens</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MPKPYVAINMAELKNEPKTFEMFASVGPKVXMVTARHPGFVGFQNHIQIGILPFGNRYGGA KMDMTKESSTVRVLQYTFWKDWKDHEEMHRQNWSYLFRLCYSCASQMIWGPWEPIYEIIYANMPINTEMTDFTAVVGKK FAEGKPLDIPVISQPYGKRVVAFAEHSVIPGKEKQFEDAIVRTLEMLKKAPGFLGAMVLKEIGVSGIGSMQFGAKGFHQ VLENPGSLEPDPNNVMYSVPEAKNTPQQYIVHVEWANTDALMFGMGRVLLYPELRQVHDEVLDTLVYGPYIRILNPMME GTFWREYLNEQAWRHPQFGG</INSDSeq_sequence> </INSDSeq> </SequenceData>
<SequenceData sequenceIDNumber="86"> Nov 2022
<INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="87"> <INSDSeq> <INSDSeq_length/> 2022279441
<INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="88"> <INSDSeq> <INSDSeq_length>154</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..154</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q87">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Aquifex aeolicus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MQIYEGKLTAEGLRFGIVASRFNHALVDRLVEGAIDCIVRHGGREEDITLVRVPGSWEIPV AAGELARKEDIDAVIAIGVLIRGATPHFDYIASEVSKGLANLSLELRKPITFGVITADTLEQAIERAGTKHGNKGWEAA LSAIEMANLFKSLR</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="89"> <INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/>
<INSDSeq_sequence>000</INSDSeq_sequence> Nov 2022
</INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="90"> <INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> 2022279441
<SequenceData sequenceIDNumber="91"> <INSDSeq> <INSDSeq_length>242</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..242</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q88">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Bacillus stearothermophilus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>AAAKPATTEGEFPETREKMSGIRRAIAKAMVHSKHTAPHVTLMDEADVTKLVAHRKKFKAI AAEKGIKLTFLPYVVKALVSALREYPVLNTSIDDETEEIIQKHYYNIGIAADTDRGLLVPVIKHADRKPIFALAQEINE LAEKARDGKLTPGEMKGASCTITNIGSAGGQWFTPVINHPEVAILGIGRIAEKPIVRDGEIVAAPMLALSLSFDHRMID GATAQKALNHIKRLLSDPELLLM</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="92"> <INSDSeq> <INSDSeq_length/> <INSDSeq_moltype/> <INSDSeq_division/> <INSDSeq_sequence>000</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="93">
<INSDSeq> Nov 2022
<INSDSeq_length>3747</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..3747</INSDFeature_location> <INSDFeature_quals> 2022279441
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>genomic DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q89">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Chikungunya virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggagttcatcccgacgcaaactttctataacagaaggtaccaaccccgaccctgggccc cacgccctacaattcaagtaattagacctagaccacgtccacagaggcaggctgggcaactcgcccagctgatctccgc agtcaacaaattgaccatgcgcgcggtacctcaacagaagcctcgcagaaatcggaaaaacaagaagcaaaggcagaag aagcaggcgccgcaaaacgacccaaagcaaaagaagcaaccaccacaaaagaagccggctcaaaagaagaagaaaccag gccgtagggagagaatgtgcatgaaaattgaaaatgattgcatcttcgaagtcaagcatgaaggcaaagtgatgggcta cgcatgcctggtgggggataaagtaatgaaaccagcacatgtgaagggaactatcgacaatgccgatctggctaaactg gcctttaagcggtcgtctaaatacgatcttgaatgtgcacagataccggtgcacatgaagtctgatgcctcgaagttta cccacgagaaacccgaggggtactataactggcatcacggagcagtgcagtattcaggaggccggttcactatcccgac gggtgcaggcaagccgggagacagcggcagaccgatcttcgacaacaaaggacgggtggtggccatcgtcctaggaggg gccaacgaaggtgcccgcacggccctctccgtggtgacgtggaacaaagacatcgtcacaaaaattacccctgagggag ccgaagagtggagcctcgccctcccggtcttgtgcctgttggcaaacactacattcccctgctctcagccgccttgcac accctgctgctacgaaaaggaaccggaaagcaccttgcgcatgcttgaggacaacgtgatgagacccggatactaccag ctactaaaagcatcgctgacttgctctccccaccgccaaagacgcagtactaaggacaattttaatgtctataaagcca caagaccatatctagctcattgtcctgactgcggagaagggcattcgtgccacagccctatcgcattggagcgcatcag aaatgaagcaacggacggaacgctgaaaatccaggtctctttgcagatcgggataaagacagatgacagccacgattgg accaagctgcgctatatggatagccatacgccagcggacgcggagcgagccggattgcttgtaaggacttcagcaccgt gcacgatcaccgggaccatgggacactttattctcgcccgatgcccgaaaggagagacgctgacagtgggatttacgga cagcagaaagatcagccacacatgcacacacccgttccatcatgaaccacctgtgataggtagggagaggttccactct cgaccacaacatggtaaagagttaccttgcagcacgtacgtgcagagcaccgctgccactgctgaggagatagaggtgc atatgcccccagatactcctgaccgcacgctgatgacgcagcagtctggcaacgtgaagatcacagttaatgggcagac ggtgcggtacaagtgcaactgcggtggctcaaacgagggactgacaaccacagacaaagtgatcaataactgcaaaatt gatcagtgccatgctgcagtcactaatcacaagaattggcaatacaactcccctttagtcccgcgcaacgctgaactcg gggaccgtaaaggaaagatccacatcccattcccattggcaaacgtgacttgcagagtgccaaaagcaagaaaccctac agtaacttacggaaaaaaccaagtcaccatgctgctgtatcctgaccatccgacactcttgtcttaccgtaacatggga caggaaccaaattaccacgaggagtgggtgacacacaagaaggaggttaccttgaccgtgcctactgagggtctggagg tcacttggggcaacaacgaaccatacaagtactggccgcagatgtctacgaacggtactgctcatggtcacccacatga gataatcttgtactattatgagctgtaccccactatgactgtagtcattgtgtcggtggcctcgttcgtgcttctgtcg atggtgggcacagcagtgggaatgtgtgtgtgcgcacggcgcagatgcattacaccatatgaattaacaccaggagcca Nov 2022 ctgttcccttcctgctcagcctgctatgctgcgtcagaacgaccaaggcggccacatattacgaggctgcggcatatct atggaacgaacagcagcccctgttctggttgcaggctcttatcccgctggccgccttgatcgtcctgtgcaactgtctg aaactcttgccatgctgctgtaagaccctggcttttttagccgtaatgagcatcggtgcccacactgtgagcgcgtacg aacacgtaacagtgatcccgaacacggtgggagtaccgtataagactcttgtcaacagaccgggttacagccccatggt gttggagatggagctacaatcagtcaccttggaaccaacactgtcacttgactacatcacgtgcgagtacaaaactgtc atcccctccccgtacgtgaagtgctgtggtacagcagagtgcaaggacaagagcctaccagactacagctgcaaggtct ttactggagtctacccatttatgtggggcggcgcctactgcttttgcgacgccgaaaatacgcaattgagcgaggcaca tgtagagaaatctgaatcttgcaaaacagagtttgcatcggcctacagagcccacaccgcatcggcgtcggcgaagctc cgcgtcctttaccaaggaaacaacattaccgtagctgcctacgctaacggtgaccatgccgtcacagtaaaggacgcca agtttgtcgtgggcccaatgtcctccgcctggacaccttttgacaacaaaatcgtggtgtacaaaggcgacgtctacaa 2022279441 catggactacccaccttttggcgcaggaagaccaggacaatttggtgacattcaaagtcgtacaccggaaagtaaagac gtttatgccaacactcagttggtactacagaggccagcagcaggcacggtacatgtaccatactctcaggcaccatctg gcttcaagtattggctgaaggaacgaggagcatcgctacagcacacggcaccgttcggttgccagattgcgacaaaccc ggtaagagctgtaaattgcgctgtggggaacataccaatttccatcgacataccggatgcggcctttactagggttgtc gatgcaccctctgtaacggacatgtcatgcgaagtaccagcctgcactcactcctccgactttgggggcgtcgccatca tcaaatacacagctagcaagaaaggtaaatgtgcagtacattcgatgaccaacgccgttaccattcgagaagccgacgt agaagtagaggggaactcccagctgcaaatatccttctcaacagccctggcaagcgccgagtttcgcgtgcaagtgtgc tccacacaagtacactgcgcagccgcatgccaccctccaaaggaccacatagtcaattacccagcatcacacaccaccc ttggggtccaggatatatccacaacggcaatgtcttgggtgcagaagattacgggaggagtaggattaattgttgctgt tgctgccttaattttaattgtggtgctatgcgtgtcgtttagcaggcactaa</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="94"> <INSDSeq> <INSDSeq_length>1248</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1248</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q90">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Chikungunya virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MEFIPTQTFYNRRYQPRPWAPRPTIQVIRPRPRPQRQAGQLAQLISAVNKLTMRAVPQQKP RRNRKNKKQRQKKQAPQNDPKQKKQPPQKKPAQKKKKPGRRERMCMKIENDCIFEVKHEGKVMGYACLVGDKVMKPAHV KGTIDNADLAKLAFKRSSKYDLECAQIPVHMKSDASKFTHEKPEGYYNWHHGAVQYSGGRFTIPTGAGKPGDSGRPIFD
NKGRVVAIVLGGANEGARTALSVVTWNKDIVTKITPEGAEEWSLALPVLCLLANTTFPCSQPPCTPCCYEKEPESTLRM Nov 2022
LEDNVMRPGYYQLLKASLTCSPHRQRRSTKDNFNVYKATRPYLAHCPDCGEGHSCHSPIALERIRNEATDGTLKIQVSL QIGIKTDDSHDWTKLRYMDSHTPADAERAGLLVRTSAPCTITGTMGHFILARCPKGETLTVGFTDSRKISHTCTHPFHH EPPVIGRERFHSRPQHGKELPCSTYVQSTAATAEEIEVHMPPDTPDRTLMTQQSGNVKITVNGQTVRYKCNCGGSNEGL TTTDKVINNCKIDQCHAAVTNHKNWQYNSPLVPRNAELGDRKGKIHIPFPLANVTCRVPKARNPTVTYGKNQVTMLLYP DHPTLLSYRNMGQEPNYHEEWVTHKKEVTLTVPTEGLEVTWGNNEPYKYWPQMSTNGTAHGHPHEIILYYYELYPTMTV VIVSVASFVLLSMVGTAVGMCVCARRRCITPYELTPGATVPFLLSLLCCVRTTKAATYYEAAAYLWNEQQPLFWLQALI PLAALIVLCNCLKLLPCCCKTLAFLAVMSIGAHTVSAYEHVTVIPNTVGVPYKTLVNRPGYSPMVLEMELQSVTLEPTL SLDYITCEYKTVIPSPYVKCCGTAECKDKSLPDYSCKVFTGVYPFMWGGAYCFCDAENTQLSEAHVEKSESCKTEFASA YRAHTASASAKLRVLYQGNNITVAAYANGDHAVTVKDAKFVVGPMSSAWTPFDNKIVVYKGDVYNMDYPPFGAGRPGQF GDIQSRTPESKDVYANTQLVLQRPAAGTVHVPYSQAPSGFKYWLKERGASLQHTAPFGCQIATNPVRAVNCAVGNIPIS 2022279441
IDIPDAAFTRVVDAPSVTDMSCEVPACTHSSDFGGVAIIKYTASKKGKCAVHSMTNAVTIREADVEVEGNSQLQISFST ALASAEFRVQVCSTQVHCAAACHPPKDHIVNYPASHTTLGVQDISTTAMSWVQKITGGVGLIVAVAALILIVVLCVSFS RH</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="95"> <INSDSeq> <INSDSeq_length>3747</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..3747</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>genomic DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q91">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Chikungunya virus</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ttagtgcctgctaaacgacacgcatagcaccacaattaaaattaaggcagcaacagcaaca attaatcctactcctcccgtaatcttctgcacccaagacattgccgttgtggatatatcctggaccccaagggtggtgt gtgatgctgggtaattgactatgtggtcctttggagggtggcatgcggctgcgcagtgtacttgtgtggagcacacttg cacgcgaaactcggcgcttgccagggctgttgagaaggatatttgcagctgggagttcccctctacttctacgtcggct tctcgaatggtaacggcgttggtcatcgaatgtactgcacatttacctttcttgctagctgtgtatttgatgatggcga cgcccccaaagtcggaggagtgagtgcaggctggtacttcgcatgacatgtccgttacagagggtgcatcgacaaccct agtaaaggccgcatccggtatgtcgatggaaattggtatgttccccacagcgcaatttacagctcttaccgggtttgtc gcaatctggcaaccgaacggtgccgtgtgctgtagcgatgctcctcgttccttcagccaatacttgaagccagatggtg cctgagagtatggtacatgtaccgtgcctgctgctggcctctgtagtaccaactgagtgttggcataaacgtctttact ttccggtgtacgactttgaatgtcaccaaattgtcctggtcttcctgcgccaaaaggtgggtagtccatgttgtagacg tcgcctttgtacaccacgattttgttgtcaaaaggtgtccaggcggaggacattgggcccacgacaaacttggcgtcct Nov 2022 ttactgtgacggcatggtcaccgttagcgtaggcagctacggtaatgttgtttccttggtaaaggacgcggagcttcgc cgacgccgatgcggtgtgggctctgtaggccgatgcaaactctgttttgcaagattcagatttctctacatgtgcctcg ctcaattgcgtattttcggcgtcgcaaaagcagtaggcgccgccccacataaatgggtagactccagtaaagaccttgc agctgtagtctggtaggctcttgtccttgcactctgctgtaccacagcacttcacgtacggggaggggatgacagtttt gtactcgcacgtgatgtagtcaagtgacagtgttggttccaaggtgactgattgtagctccatctccaacaccatgggg ctgtaacccggtctgttgacaagagtcttatacggtactcccaccgtgttcgggatcactgttacgtgttcgtacgcgc tcacagtgtgggcaccgatgctcattacggctaaaaaagccagggtcttacagcagcatggcaagagtttcagacagtt gcacaggacgatcaaggcggccagcgggataagagcctgcaaccagaacaggggctgctgttcgttccatagatatgcc gcagcctcgtaatatgtggccgccttggtcgttctgacgcagcatagcaggctgagcaggaagggaacagtggctcctg gtgttaattcatatggtgtaatgcatctgcgccgtgcgcacacacacattcccactgctgtgcccaccatcgacagaag 2022279441 cacgaacgaggccaccgacacaatgactacagtcatagtggggtacagctcataatagtacaagattatctcatgtggg tgaccatgagcagtaccgttcgtagacatctgcggccagtacttgtatggttcgttgttgccccaagtgacctccagac cctcagtaggcacggtcaaggtaacctccttcttgtgtgtcacccactcctcgtggtaatttggttcctgtcccatgtt acggtaagacaagagtgtcggatggtcaggatacagcagcatggtgacttggttttttccgtaagttactgtagggttt cttgcttttggcactctgcaagtcacgtttgccaatgggaatgggatgtggatctttcctttacggtccccgagttcag cgttgcgcgggactaaaggggagttgtattgccaattcttgtgattagtgactgcagcatggcactgatcaattttgca gttattgatcactttgtctgtggttgtcagtccctcgtttgagccaccgcagttgcacttgtaccgcaccgtctgccca ttaactgtgatcttcacgttgccagactgctgcgtcatcagcgtgcggtcaggagtatctgggggcatatgcacctcta tctcctcagcagtggcagcggtgctctgcacgtacgtgctgcaaggtaactctttaccatgttgtggtcgagagtggaa cctctccctacctatcacaggtggttcatgatggaacgggtgtgtgcatgtgtggctgatctttctgctgtccgtaaat cccactgtcagcgtctctcctttcgggcatcgggcgagaataaagtgtcccatggtcccggtgatcgtgcacggtgctg aagtccttacaagcaatccggctcgctccgcgtccgctggcgtatggctatccatatagcgcagcttggtccaatcgtg gctgtcatctgtctttatcccgatctgcaaagagacctggattttcagcgttccgtccgttgcttcatttctgatgcgc tccaatgcgatagggctgtggcacgaatgcccttctccgcagtcaggacaatgagctagatatggtcttgtggctttat agacattaaaattgtccttagtactgcgtctttggcggtggggagagcaagtcagcgatgcttttagtagctggtagta tccgggtctcatcacgttgtcctcaagcatgcgcaaggtgctttccggttccttttcgtagcagcagggtgtgcaaggc ggctgagagcaggggaatgtagtgtttgccaacaggcacaagaccgggagggcgaggctccactcttcggctccctcag gggtaatttttgtgacgatgtctttgttccacgtcaccacggagagggccgtgcgggcaccttcgttggcccctcctag gacgatggccaccacccgtcctttgttgtcgaagatcggtctgccgctgtctcccggcttgcctgcacccgtcgggata gtgaaccggcctcctgaatactgcactgctccgtgatgccagttatagtacccctcgggtttctcgtgggtaaacttcg aggcatcagacttcatgtgcaccggtatctgtgcacattcaagatcgtatttagacgaccgcttaaaggccagtttagc cagatcggcattgtcgatagttcccttcacatgtgctggtttcattactttatcccccaccaggcatgcgtagcccatc actttgccttcatgcttgacttcgaagatgcaatcattttcaattttcatgcacattctctccctacggcctggtttct tcttcttttgagccggcttcttttgtggtggttgcttcttttgctttgggtcgttttgcggcgcctgcttcttctgcct ttgcttcttgtttttccgatttctgcgaggcttctgttgaggtaccgcgcgcatggtcaatttgttgactgcggagatc agctgggcgagttgcccagcctgcctctgtggacgtggtctaggtctaattacttgaattgtagggcgtggggcccagg gtcggggttggtaccttctgttatagaaagtttgcgtcgggatgaactccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="96"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q92">
<INSDQualifier_name>note</INSDQualifier_name> Nov 2022
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> 2022279441
<INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q93">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccattgcccctctgcagctgggcaattgttctgtggccggatggattctggg caaccccgagtgtgagctgctgatttctaaggagagctggagctacatcgtggagacccccaatcctgagaatggcacc tgctaccctggctacttcgccgattacgaggagctgcgcgagcagctgtctagcgtgtccagcttcgagagattcgaga tcttccccaaggagtccagctggcctaatcacacagtgacaggcgtgtctgccagctgtagccacaacggcaaaagcag cttctaccggaacctgctgtggctgacaggcaagaatggcctgtaccccaacctgagcaagagctacgtgaacaacaag gaaaaggaagtgctggtgctgtggggagtgcaccaccctcccaacatcggaaatcagcgggccctgtaccacacagaga acgcctatgtgagcgtggtgtccagccactacagcagaagattcacccccgagatcgccaagagacccaaagtgagaga ccaggagggccggatcaattactactggaccctgctggagcctggcgataccatcatcttcgaggccaacggcaatctg atcgccccttggtatgcctttgccctgagcagaggcgcctccggagagagccaggtgaggcagcagttcagcaaggaca tcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgcta cacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatc atcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgaccc agatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagag caaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatc ctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaaga gcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="97"> <INSDSeq> <INSDSeq_length>421</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q94">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> 2022279441
</INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q95">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGNCSVAGWILGNPECELLISKESWS YIVETPNPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGL YPNLSKSYVNNKEKEVLVLWGVHHPPNIGNQRALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEP GDTIIFEANGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="98"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location>
<INSDFeature_quals> Nov 2022
<INSDQualifier id="q96">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature> 2022279441
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q97">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcgcctctgctcagggcaaaggcataccaaggggcgatcagattgccgttggcctcgaagatgatggtatcgccaggct ccagcagggtccagtagtaattgatccggccctcctggtctctcactttgggtctcttggcgatctcgggggtgaatct tctgctgtagtggctggacaccacgctcacataggcgttctctgtgtggtacagggcccgctgatttccgatgttggga gggtggtgcactccccacagcaccagcacttccttttccttgttgttcacgtagctcttgctcaggttggggtacaggc cattcttgcctgtcagccacagcaggttccggtagaagctgcttttgccgttgtggctacagctggcagacacgcctgt cactgtgtgattaggccagctggactccttggggaagatctcgaatctctcgaagctggacacgctagacagctgctcg cgcagctcctcgtaatcggcgaagtagccagggtagcaggtgccattctcaggattgggggtctccacgatgtagctcc agctctccttagaaatcagcagctcacactcggggttgcccagaatccatccggccacagaacaattgcccagctgcag aggggcaatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttctgg ctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="99"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division> Nov 2022
<INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q98">
<INSDQualifier_name>note</INSDQualifier_name> 2022279441
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q99">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccattgcccctctgcagctgggcaattgttctgtggccggatggattctggg caaccccgagtgtgagctgctgatttctaaggagagctggagctacatcgtggagacccccaatcctgagaatggcacc tgcttccctggctacttcgccgattacgaggagctgcgcgagcagctgtctagcgtgtccagcttcgagagattcgaga tcttccccaaggagtccagctggcctaatcacacagtgacaggcgtgtctgccagctgtagccacaacggcaaaagcag cttctaccggaacctgctgtggctgacaggcaagaatggcctgtaccccaacctgagcaagagctacgtgaacaacaag gaaaaggaagtgctggtgctgtggggagtgcaccaccctcccaacatcggaaatcagcgggccctgtaccacacagaga acgcctatgtgagcgtggtgtccagccactacagcagaagattcacccccgagatcgccaagagacccaaagtgagaga ccaggagggccggatcaattactactggaccctgctggagcctggcgataccatcatcttcgaggccaacggcaatctg atcgccccttggtatgcctttgccctgagcagaggcgcctccggagagagccaggtgaggcagcagttcagcaaggaca tcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgcta cacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatc atcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgaccc agatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagag caaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatc ctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaaga gcaggaagagcggatcctag</INSDSeq_sequence> Nov 2022
</INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="100"> <INSDSeq> <INSDSeq_length>421</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature> 2022279441
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q100">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q101">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGNCSVAGWILGNPECELLISKESWS YIVETPNPENGTCFPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGL YPNLSKSYVNNKEKEVLVLWGVHHPPNIGNQRALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEP GDTIIFEANGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="101">
<INSDSeq> Nov 2022
<INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> 2022279441
<INSDQualifier id="q102">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q103">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcgcctctgctcagggcaaaggcataccaaggggcgatcagattgccgttggcctcgaagatgatggtatcgccaggct ccagcagggtccagtagtaattgatccggccctcctggtctctcactttgggtctcttggcgatctcgggggtgaatct tctgctgtagtggctggacaccacgctcacataggcgttctctgtgtggtacagggcccgctgatttccgatgttggga gggtggtgcactccccacagcaccagcacttccttttccttgttgttcacgtagctcttgctcaggttggggtacaggc cattcttgcctgtcagccacagcaggttccggtagaagctgcttttgccgttgtggctacagctggcagacacgcctgt cactgtgtgattaggccagctggactccttggggaagatctcgaatctctcgaagctggacacgctagacagctgctcg cgcagctcctcgtaatcggcgaagtagccagggaagcaggtgccattctcaggattgggggtctccacgatgtagctcc Nov 2022 agctctccttagaaatcagcagctcacactcggggttgcccagaatccatccggccacagaacaattgcccagctgcag aggggcaatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttctgg ctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="102"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> 2022279441
<INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q104">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q105">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccgtggcccccctgcacctgggcaagtgcaacatcgccggctggattctggg caaccccgagtgcgagagcctgagcaccgccagcagctggagctacatcgtggagacccccagcagcgacaacggcacc tgctaccccggcgacttcatcgactacgaggagctgcgggagcagctgagcagcgtgagcagcttcgagcggttcgaga tcttccccaagaccagcagctggcccaaccacgacagcaacaagggcgtgaccgccgcctgcccccacgccggcgccaa gagcttctacaagaacctgatctggctggtgaagaagggcaacagctaccccaagctgagcaagagctacatcaacgac aagggcaaggaggtgctggtgctgtggggcatccaccaccccagcaccagcgccgaccagcagagcctgtaccagaacg Nov 2022 ccgacacctacgtgttcgtgggcagcagccggtacagcaagaagttcaagcccgagatcgccatccggcccaaggtgcg ggaccaggagggccggatgaactactactggaccctggtggagcccggcgacaagatcaccttcgaggccaccggcaac ctggtggtgccccggtacgccttcgccatggagcggaacgcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> 2022279441
</INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="103"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q106">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q107">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVAPLHLGKCNIAGWILGNPECESLSTASSWS YIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGN SYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVE PGDKITFEATGNLVVPRYAFAMERNASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="104"> <INSDSeq> 2022279441
<INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q108">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q109">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg Nov 2022 gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcgttccgctccatggcgaaggcgtaccggggcaccaccaggttgccggtggcctcgaaggtgatcttgtcgccgggct ccaccagggtccagtagtagttcatccggccctcctggtcccgcaccttgggccggatggcgatctcgggcttgaactt cttgctgtaccggctgctgcccacgaacacgtaggtgtcggcgttctggtacaggctctgctggtcggcgctggtgctg gggtggtggatgccccacagcaccagcacctccttgcccttgtcgttgatgtagctcttgctcagcttggggtagctgt tgcccttcttcaccagccagatcaggttcttgtagaagctcttggcgccggcgtgggggcaggcggcggtcacgccctt gttgctgtcgtggttgggccagctgctggtcttggggaagatctcgaaccgctcgaagctgctcacgctgctcagctgc tcccgcagctcctcgtagtcgatgaagtcgccggggtagcaggtgccgttgtcgctgctgggggtctccacgatgtagc 2022279441 tccagctgctggcggtgctcaggctctcgcactcggggttgcccagaatccagccggcgatgttgcacttgcccaggtg caggggggccacggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="105"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q110">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q111">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier>
</INSDFeature_quals> Nov 2022
</INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccgtggcccccctgcacctgggcaagtgcaacatcgccggctggattctggg caaccccgagtgcgagagcctgagcaccgccagcagctggagctacatcgtggagacccccagcagcgacaacggcacc tgcttccccggcgacttcatcgactacgaggagctgcgggagcagctgagcagcgtgagcagcttcgagcggttcgaga tcttccccaagaccagcagctggcccaaccacgacagcaacaagggcgtgaccgccgcctgcccccacgccggcgccaa gagcttctacaagaacctgatctggctggtgaagaagggcaacagctaccccaagctgagcaagagctacatcaacgac aagggcaaggaggtgctggtgctgtggggcatccaccaccccagcaccagcgccgaccagcagagcctgtaccagaacg 2022279441
ccgacacctacgtgttcgtgggcagcagccggtacagcaagaagttcaagcccgagatcgccatccggcccaaggtgcg ggaccaggagggccggatgaactactactggaccctggtggagcccggcgacaagatcaccttcgaggccaccggcaac ctggtggtgccccggtacgccttcgccatggagcggaacgcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="106"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q112">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier> Nov 2022
<INSDQualifier id="q113">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table> 2022279441
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVAPLHLGKCNIAGWILGNPECESLSTASSWS YIVETPSSDNGTCFPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGN SYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVE PGDKITFEATGNLVVPRYAFAMERNASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="107"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q114">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q115">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg 2022279441
gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcgttccgctccatggcgaaggcgtaccggggcaccaccaggttgccggtggcctcgaaggtgatcttgtcgccgggct ccaccagggtccagtagtagttcatccggccctcctggtcccgcaccttgggccggatggcgatctcgggcttgaactt cttgctgtaccggctgctgcccacgaacacgtaggtgtcggcgttctggtacaggctctgctggtcggcgctggtgctg gggtggtggatgccccacagcaccagcacctccttgcccttgtcgttgatgtagctcttgctcagcttggggtagctgt tgcccttcttcaccagccagatcaggttcttgtagaagctcttggcgccggcgtgggggcaggcggcggtcacgccctt gttgctgtcgtggttgggccagctgctggtcttggggaagatctcgaaccgctcgaagctgctcacgctgctcagctgc tcccgcagctcctcgtagtcgatgaagtcgccggggaagcaggtgccgttgtcgctgctgggggtctccacgatgtagc tccagctgctggcggtgctcaggctctcgcactcggggttgcccagaatccagccggcgatgttgcacttgcccaggtg caggggggccacggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="108"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q116">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name> Nov 2022
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q117">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> 2022279441
</INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccatcgcccctctgcagctgggcaagtgtaatatcgccggatggctgctggg aaaccccgagtgtgattctctgctgcctgccaagagctggagctacatcgtggagacccccaattctgagaatggcgcc tgcttccctggcgacttcatcgattacgaggagctgaaggagcagctgagttctgtctctagcctggagagattcgaga tcttccccaaggagagcagctggcccaatcacaataccctgaagggagtgacagccgcctgtagccacagaggcaagag cagcttctaccggaatctgctgtggctgaccaagaccggcgatagctaccccaagctgaacaacagctacgtgaacaac aagggcaaggaagtgctggtgctgtggggagtgcaccaccctagcagcagcaatgagcagcagagcctgtaccacaacg tgaacgcctatgtgagcgtggtgtccagcaactacaaccggagattcacccctgaaatcgccgccagacccaaagtgag agaccagcccggcaggatgaattactactggaccctgctggagcctggcgataccatcatctttgaggccaccggcaat ctgattgccccttggtacgcctttgccctgagcagaggcgcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="109"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q118">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> 2022279441
<INSDQualifier id="q119">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCNIAGWLLGNPECDSLLPAKSWS YIVETPNSENGACFPGDFIDYEELKEQLSSVSSLERFEIFPKESSWPNHNTLKGVTAACSHRGKSSFYRNLLWLTKTGD SYPKLNNSYVNNKGKEVLVLWGVHHPSSSNEQQSLYHNVNAYVSVVSSNYNRRFTPEIAARPKVRDQPGRMNYYWTLLE PGDTIIFEATGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="110"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q120">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location>
<INSDFeature_quals> Nov 2022
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q121">
<INSDQualifier_name>organism</INSDQualifier_name> 2022279441
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcgcctctgctcagggcaaaggcgtaccaaggggcaatcagattgccggtggcctcaaagatgatggtatcgccaggct ccagcagggtccagtagtaattcatcctgccgggctggtctctcactttgggtctggcggcgatttcaggggtgaatct ccggttgtagttgctggacaccacgctcacataggcgttcacgttgtggtacaggctctgctgctcattgctgctgcta gggtggtgcactccccacagcaccagcacttccttgcccttgttgttcacgtagctgttgttcagcttggggtagctat cgccggtcttggtcagccacagcagattccggtagaagctgctcttgcctctgtggctacaggcggctgtcactccctt cagggtattgtgattgggccagctgctctccttggggaagatctcgaatctctccaggctagagacagaactcagctgc tccttcagctcctcgtaatcgatgaagtcgccagggaagcaggcgccattctcagaattgggggtctccacgatgtagc tccagctcttggcaggcagcagagaatcacactcggggtttcccagcagccatccggcgatattacacttgcccagctg cagaggggcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="111"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q122">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier>
</INSDFeature_quals> Nov 2022
</INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name> 2022279441
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q123">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccattgcccccctgcagctgggcaagtgcagcattgccggctggattctggg caaccccgagtgcgagagcctgttcagcaagaagagctggtcctacattgccgagacacccaacagcgagaacggcacc tgtttccccggctacttcgccgactacgaggaactgcgggagcagctgagcagcgtgtccagcttcgagcggttcgaga tcttccccaaagagcggagctggcccaagcacaacgtgaccagaggcgtgaccgccagctgctctcacaagggcaagag cagcttctaccggaacctgctgtggctgaccgagaagaacggcagctaccccaacctgagcaagagctacgtgaacaac aaagagaaagaggtcctggtcctctggggcgtgcaccaccctagcaacatcgaggaccagaaaaccatctaccggaaag aaaacgcctacgtgtccgtggtgtccagcaactacaaccggcggttcacccccgagatcgccgagaggcctaaagtgcg gggccaggccggcagaatcaactactactggaccctgctggaacccggcgacaccatcatcttcgaggccaacggcaac ctgatcgccccttggcacgcctttgccctgagcagaggcgcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="112"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location>
<INSDFeature_quals> Nov 2022
<INSDQualifier id="q124">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature> 2022279441
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q125">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCSIAGWILGNPECESLFSKKSWS YIAETPNSENGTCFPGYFADYEELREQLSSVSSFERFEIFPKERSWPKHNVTRGVTASCSHKGKSSFYRNLLWLTEKNG SYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTIYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLE PGDTIIFEANGNLIAPWHAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="113"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q126">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> 2022279441
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q127">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcgcctctgctcagggcaaaggcgtgccaaggggcgatcaggttgccgttggcctcgaagatgatggtgtcgccgggtt ccagcagggtccagtagtagttgattctgccggcctggccccgcactttaggcctctcggcgatctcgggggtgaaccg ccggttgtagttgctggacaccacggacacgtaggcgttttctttccggtagatggttttctggtcctcgatgttgcta gggtggtgcacgccccagaggaccaggacctctttctctttgttgttcacgtagctcttgctcaggttggggtagctgc cgttcttctcggtcagccacagcaggttccggtagaagctgctcttgcccttgtgagagcagctggcggtcacgcctct ggtcacgttgtgcttgggccagctccgctctttggggaagatctcgaaccgctcgaagctggacacgctgctcagctgc tcccgcagttcctcgtagtcggcgaagtagccggggaaacaggtgccgttctcgctgttgggtgtctcggcaatgtagg accagctcttcttgctgaacaggctctcgcactcggggttgcccagaatccagccggcaatgctgcacttgcccagctg caggggggcaatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="114"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key> Nov 2022
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q128">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> 2022279441
</INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q129">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccatcgcccctctgcagctgggcaactgcagcgtggctggctggattctggg gaatccaaagtgtgagagtctgttttcaaaagaatcttggagttacatcgcagagacccccaaccctgaaaatggaaca tgcttccctggctatttcgccgattatgaggaactgagggagcagctgagctccgtgtctagtttcgagcgctttgaaa ttttcccaaaggaatcaagctggcccaaccacaccgtgacaaaaggcgtcaccacatcatgtagccataacgggaagtc ctctttttaccgcaatctgctgtggctgacagagaagaacggcctgtacccaaatctgtccaagtcttacgtgaacaat aaggagaaggaagtgctggtcctgtggggcgtccaccatcccagcaacatccgagaccagcgggcaatctaccacacag agaatgcctatgtgagcgtggtcagttcacattacagccggcggttcacccccgagatcgccaagagaccaaaagtgag gggccaggaagggcgaattaactactattggactctgctggagccaggagataccatcattttcgaagccaacggcaat ctgatcgctccctggtatgcatttgccctgtcccgcggagcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="115">
<INSDSeq> Nov 2022
<INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> 2022279441
<INSDQualifier id="q130">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q131">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGNCSVAGWILGNPKCESLFSKESWS YIAETPNPENGTCFPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVTTSCSHNGKSSFYRNLLWLTEKNG LYPNLSKSYVNNKEKEVLVLWGVHHPSNIRDQRAIYHTENAYVSVVSSHYSRRFTPEIAKRPKVRGQEGRINYYWTLLE PGDTIIFEANGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="116"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature‐table> Nov 2022
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q132">
<INSDQualifier_name>note</INSDQualifier_name> 2022279441
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q133">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gctccgcgggacagggcaaatgcataccagggagcgatcagattgccgttggcttcgaaaatgatggtatctcctggct ccagcagagtccaatagtagttaattcgcccttcctggcccctcacttttggtctcttggcgatctcgggggtgaaccg ccggctgtaatgtgaactgaccacgctcacataggcattctctgtgtggtagattgcccgctggtctcggatgttgctg ggatggtggacgccccacaggaccagcacttccttctccttattgttcacgtaagacttggacagatttgggtacaggc cgttcttctctgtcagccacagcagattgcggtaaaaagaggacttcccgttatggctacatgatgtggtgacgccttt tgtcacggtgtggttgggccagcttgattcctttgggaaaatttcaaagcgctcgaaactagacacggagctcagctgc tccctcagttcctcataatcggcgaaatagccagggaagcatgttccattttcagggttgggggtctctgcgatgtaac tccaagattcttttgaaaacagactctcacactttggattccccagaatccagccagccacgctgcagttgcccagctg cagaggggcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence>
</INSDSeq> Nov 2022
</SequenceData> <SequenceData sequenceIDNumber="117"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key> 2022279441
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q134">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q135">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccattgcccctctgcagctgggcaattgttctatcgccggctggattctggg aaatcccgagtgcgagagcctgttcagcaagaagtcctggtcctatatcgccgagacacccaacagcgagaatggcacc tgtttccctggctacttcgccgattacgaggaactgagagagcagctgtcctctgtctccagcttcgagcggttcgaga tcttccccaaagagtccagctggcccaatcacacagtgaccaagggcgtgaccgcctcttgtagccacaagggcagaag cagcttctaccggaacctgctgtggctgaccaagaagaacggcagctaccccaatctgagcaagagctacgtgaacaac aaagaaaaagaggtgctggtcctctggggagtgcaccaccctagcaacatcggagatcagcgggccatctaccacaccg agaacgcctatgtgtccgtggtgtccagccactacaacagaagattcacccccgagatcgccaaaagacccaaagtgcg ggaccaggaaggcagaatcaactactactggaccctgctggaacctggcgacaccatcatcttcgaggccaacggcaat ctgatcgccccttggtatgcctttgccctgagcagaggcgcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg Nov 2022 ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="118"> <INSDSeq> 2022279441
<INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q136">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q137">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGNCSIAGWILGNPECESLFSKKSWS YIAETPNSENGTCFPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTKGVTASCSHKGRSSFYRNLLWLTKKNG SYPNLSKSYVNNKEKEVLVLWGVHHPSNIGDQRAIYHTENAYVSVVSSHYNRRFTPEIAKRPKVRDQEGRINYYWTLLE
PGDTIIFEANGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD Nov 2022
HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="119"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> 2022279441
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q138">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q139">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcgcctctgctcagggcaaaggcataccaaggggcgatcagattgccgttggcctcgaagatgatggtgtcgccaggtt Nov 2022 ccagcagggtccagtagtagttgattctgccttcctggtcccgcactttgggtcttttggcgatctcgggggtgaatct tctgttgtagtggctggacaccacggacacataggcgttctcggtgtggtagatggcccgctgatctccgatgttgcta gggtggtgcactccccagaggaccagcacctctttttctttgttgttcacgtagctcttgctcagattggggtagctgc cgttcttcttggtcagccacagcaggttccggtagaagctgcttctgcccttgtggctacaagaggcggtcacgccctt ggtcactgtgtgattgggccagctggactctttggggaagatctcgaaccgctcgaagctggagacagaggacagctgc tctctcagttcctcgtaatcggcgaagtagccagggaaacaggtgccattctcgctgttgggtgtctcggcgatatagg accaggacttcttgctgaacaggctctcgcactcgggatttcccagaatccagccggcgatagaacaattgcccagctg cagaggggcaatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> 2022279441
</SequenceData> <SequenceData sequenceIDNumber="120"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q140">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q141">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca Nov 2022
acctgctgctgcctcagggcgtgctagccatcgctcctctgcagctggggaaatgcagcatcgcagggtggattctggg aaacccagagtgtgaaagtctgttttcaaagaaatcttggagttacattgccgagacacccaacagcgaaaatggcact tgcttccctgggtatttcgctgattatgaggaactgcgcgagcagctgagctccgtgtctagtttcgagcgatttgaaa tcttccccaaggaatcaagctggcctaagcacaacgtgaccaaaggggtcacagcctcatgtagccataagggaaaatc ctctttttaccgcaatctgctgtggctgacagagaagaacgggtcctacccaaatctgtccaagtcttacgtgaacaat aaggagaaggaagtgctggtcctgtggggcgtccaccatccctctaacatcgaggaccagaagactatctacaggaaag aaaacgcatatgtgagtgtggtcagttcacactacaatcggcggttcacccccgagatcgccaagaggcccaaagtgcg caaccaggaaggccgcattaattactattggaccctgctggagccaggcgatacaatcattttcgaagccaacgggaat ctgatcgctccctggtatgcatttgccctgtcccgaggagcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg 2022279441
ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="121"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q142">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q143">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCSIAGWILGNPECESLFSKKSWS YIAETPNSENGTCFPGYFADYEELREQLSSVSSFERFEIFPKESSWPKHNVTKGVTASCSHKGKSSFYRNLLWLTEKNG SYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTIYRKENAYVSVVSSHYNRRFTPEIAKRPKVRNQEGRINYYWTLLE PGDTIIFEANGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD 2022279441
HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="122"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q144">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q145">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals>
</INSDFeature> Nov 2022
</INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gctcctcgggacagggcaaatgcataccagggagcgatcagattcccgttggcttcgaaaatgattgtatcgcctggct 2022279441
ccagcagggtccaatagtaattaatgcggccttcctggttgcgcactttgggcctcttggcgatctcgggggtgaaccg ccgattgtagtgtgaactgaccacactcacatatgcgttttctttcctgtagatagtcttctggtcctcgatgttagag ggatggtggacgccccacaggaccagcacttccttctccttattgttcacgtaagacttggacagatttgggtaggacc cgttcttctctgtcagccacagcagattgcggtaaaaagaggattttcccttatggctacatgaggctgtgaccccttt ggtcacgttgtgcttaggccagcttgattccttggggaagatttcaaatcgctcgaaactagacacggagctcagctgc tcgcgcagttcctcataatcagcgaaatacccagggaagcaagtgccattttcgctgttgggtgtctcggcaatgtaac tccaagatttctttgaaaacagactttcacactctgggtttcccagaatccaccctgcgatgctgcatttccccagctg cagaggagcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="123"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q146">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier>
<INSDQualifier id="q147"> Nov 2022
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca 2022279441
acctgctgctgcctcagggcgtgctagccatcgccccactgcagctgggcaagtgcaacatcgctggctggattctggg gaatcccgagtgtgaatcactgctgagcaaccgctcatggagctacatcgctgagacccctaacagcgaaaatggaatt tgcttcccaggcgactttgcagattatgaggaactgcgggagcagctgagctccgtgtctagtttcgagagatttgaaa tcttccccaaagaatcaagctggcctaagcacaacattaccaggggcgtgacagtcgcctgtagccatgctaagaaatc ctctttctacaagaacctgctgtggctgacagaggccaatggcctgtacccctccctgtctaaaagttatgtgaatgac cgcgagaaggaagtgctggtcctgtggggcgtccaccatcctagcaacatcgaggatcagaggacactgtaccgcaagg aaaatgcctatgtgagcgtcgtcagttcaaactacaatcggagatttactccagagattgctgaacgaccaaaagtgcg aggacagcctggacgaatgaactactattggaccctgctggagccaggagataagatcatttttgaagcaaacggcaat ctgatcgccccctggtatgcattcgccctgtcaagaggaccttccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="124"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q148">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location>
<INSDFeature_quals> Nov 2022
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q149">
<INSDQualifier_name>organism</INSDQualifier_name> 2022279441
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCNIAGWILGNPECESLLSNRSWS YIAETPNSENGICFPGDFADYEELREQLSSVSSFERFEIFPKESSWPKHNITRGVTVACSHAKKSSFYKNLLWLTEANG LYPSLSKSYVNDREKEVLVLWGVHHPSNIEDQRTLYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQPGRMNYYWTLLE PGDKIIFEANGNLIAPWYAFALSRGPSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="125"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q150">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q151">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> 2022279441
</INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggaa ggtcctcttgacagggcgaatgcataccagggggcgatcagattgccgtttgcttcaaaaatgatcttatctcctggct ccagcagggtccaatagtagttcattcgtccaggctgtcctcgcacttttggtcgttcagcaatctctggagtaaatct ccgattgtagtttgaactgacgacgctcacataggcattttccttgcggtacagtgtcctctgatcctcgatgttgcta ggatggtggacgccccacaggaccagcacttccttctcgcggtcattcacataacttttagacagggaggggtacaggc cattggcctctgtcagccacagcaggttcttgtagaaagaggatttcttagcatggctacaggcgactgtcacgcccct ggtaatgttgtgcttaggccagcttgattctttggggaagatttcaaatctctcgaaactagacacggagctcagctgc tcccgcagttcctcataatctgcaaagtcgcctgggaagcaaattccattttcgctgttaggggtctcagcgatgtagc tccatgagcggttgctcagcagtgattcacactcgggattccccagaatccagccagcgatgttgcacttgcccagctg cagtggggcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="126"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q152">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> Nov 2022
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q153"> 2022279441
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccatcgccccactgcagctgggaaaatgcaacatcgctggatggattctggg caatcccgagtgtgaatcactgctgagcgagcgctcttggagttacatcgtggagacccctaacagcgaaaatgggaca tgcttcccaggagactttattgattatgaggaactgcgcgagcagctgagctccgtgtctagtttcgagcgatttgaaa tcttctctaaggaatcaagctggccaaaacacaccacaggcggggtgactgccgcttgtagtcatgccggcaagtcctc tttctaccggaacctgctgtggctgaccgagaaagacgggtcctaccccaacctgaacaactcttacgtgaataagaag ggcaaggaagtgctggtcctgtggggggtccaccatcctagcaacatcaaggatcagcagacactgtaccagaaagaga atgcctatgtgtccgtggtcagttcaaactacaatcggcggttcacccccgagatcgctgaaaggcctaaggtccgcgg acaggcaggccgaattaactactattggactctgctgaaacccggggacaccatcatgttcgaggcaaacggaaatctg attgccccttggtatgcttttgcactgtctcgcggggcctccggagagagccaggtgaggcagcagttcagcaaggaca tcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgcta cacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatc atcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgaccc agatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagag caaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatc ctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaaga gcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="127"> <INSDSeq> <INSDSeq_length>421</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q154">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> 2022279441
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q155">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCNIAGWILGNPECESLLSERSWS YIVETPNSENGTCFPGDFIDYEELREQLSSVSSFERFEIFSKESSWPKHTTGGVTAACSHAGKSSFYRNLLWLTEKDGS YPNLNNSYVNKKGKEVLVLWGVHHPSNIKDQQTLYQKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLKP GDTIMFEANGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="128"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q156">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals>
</INSDFeature> Nov 2022
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name> 2022279441
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q157">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gccccgcgagacagtgcaaaagcataccaaggggcaatcagatttccgtttgcctcgaacatgatggtgtccccgggtt tcagcagagtccaatagtagttaattcggcctgcctgtccgcggaccttaggcctttcagcgatctcgggggtgaaccg ccgattgtagtttgaactgaccacggacacataggcattctctttctggtacagtgtctgctgatccttgatgttgcta ggatggtggaccccccacaggaccagcacttccttgcccttcttattcacgtaagagttgttcaggttggggtaggacc cgtctttctcggtcagccacagcaggttccggtagaaagaggacttgccggcatgactacaagcggcagtcaccccgcc tgtggtgtgttttggccagcttgattccttagagaagatttcaaatcgctcgaaactagacacggagctcagctgctcg cgcagttcctcataatcaataaagtctcctgggaagcatgtcccattttcgctgttaggggtctccacgatgtaactcc aagagcgctcgctcagcagtgattcacactcgggattgcccagaatccatccagcgatgttgcattttcccagctgcag tggggcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttctgg ctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="129"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals>
<INSDQualifier id="q158"> Nov 2022
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> 2022279441
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q159">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccatcgcccctctgcagctgggcaagtgctctatcgctggctggattctggg gaatccagagtgtgaaagtctgttttcaaagaaatcttggagttacattgctgagacccccaacagcgaaaatggaaca tgcttccctggctatttcgcagattatgaggaactgagggagcagctgagctccgtgtctagtttcgagagatttgaaa tcttccccaaagaaaggagctggcctaagcacaacgtgacccggggagtcacagcctcatgtagccataagggcaaatc aagcttttacagaaatctgctgtggctgacagagaaaaacgggtcctacccaaatctgtccaagtcttatgtgaacaat aaggagaaagaagtgctggtcctgtggggcgtccaccatcccagcaacatcgaggaccagaagactatttaccgaaaag aaaatgcctatgtgtccgtggtctcctctaactacaatcggagatttaccccagagatcgctgaaaggccaaaggtgcg aggacaggcaggacgaattaactactattggactctgctggagccaggggataccatcattttcgaagccaacggaaat ctgatcgctccctggtatgcatttgccctgagtcggggagcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="130"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature‐table> Nov 2022
<INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q160">
<INSDQualifier_name>note</INSDQualifier_name> 2022279441
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q161">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCSIAGWILGNPECESLFSKKSWS YIAETPNSENGTCFPGYFADYEELREQLSSVSSFERFEIFPKERSWPKHNVTRGVTASCSHKGKSSFYRNLLWLTEKNG SYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTIYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLE PGDTIIFEANGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="131"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q162">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> 2022279441
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q163">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gctccccgactcagggcaaatgcataccagggagcgatcagatttccgttggcttcgaaaatgatggtatcccctggct ccagcagagtccaatagtagttaattcgtcctgcctgtcctcgcacctttggcctttcagcgatctctggggtaaatct ccgattgtagttagaggagaccacggacacataggcattttcttttcggtaaatagtcttctggtcctcgatgttgctg ggatggtggacgccccacaggaccagcacttctttctccttattgttcacataagacttggacagatttgggtaggacc cgtttttctctgtcagccacagcagatttctgtaaaagcttgatttgcccttatggctacatgaggctgtgactccccg ggtcacgttgtgcttaggccagctcctttctttggggaagatttcaaatctctcgaaactagacacggagctcagctgc tccctcagttcctcataatctgcgaaatagccagggaagcatgttccattttcgctgttgggggtctcagcaatgtaac tccaagatttctttgaaaacagactttcacactctggattccccagaatccagccagcgatagagcacttgcccagctg cagaggggcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="132"> <INSDSeq>
<INSDSeq_length>1269</INSDSeq_length> Nov 2022
<INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q164"> 2022279441
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q165">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccatcgctcctctgcagctgggaaagtgcaacatcgcaggatggattctggg caatccagagtgtgaatccctgctgtctaaacggtcttggagttacattgccgagacacccaactctgaaaatggggcc tgcttccctggagactttgctgattatgaggaactgagagagcagctgagctccgtgtctagtttcgagagatttgaaa tcttccccaaggaaaggtcctggcctaaacacaacattactaggggggtgaccgccgcttgttctcatgccggaaaatc aagcttctacaagaatctgctgtggctgacagagactgacggctcctacccaaagctgtcaaaaagctatgtgaacaat aaggagaaagaagtgctggtcctgtggggcgtccaccatcccagtaacatcgaggatcagaaaactctgtaccgcaagg aaaatgcttatgtgagcgtggtctcctctaactacaatcggagatttaccccagagatcgcagaaaggccaaaggtgcg aggacaggcaggacgaattaactactattggactctgctggagccaggcgacaccatcattttcgaagcaaacgggaat ctgatcgccccctggtatgcttttgcactgtcccgcgatgcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac Nov 2022 atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="133"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> 2022279441
<INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q166">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q167">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCNIAGWILGNPECESLLSKRSWS YIAETPNSENGACFPGDFADYEELREQLSSVSSFERFEIFPKERSWPKHNITRGVTAACSHAGKSSFYKNLLWLTETDG SYPKLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTLYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLE PGDTIIFEANGNLIAPWYAFALSRDASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq>
</SequenceData> Nov 2022
<SequenceData sequenceIDNumber="134"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key> 2022279441
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q168">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q169">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcatcgcgggacagtgcaaaagcataccagggggcgatcagattcccgtttgcttcgaaaatgatggtgtcgcctggct ccagcagagtccaatagtagttaattcgtcctgcctgtcctcgcacctttggcctttctgcgatctctggggtaaatct ccgattgtagttagaggagaccacgctcacataagcattttccttgcggtacagagttttctgatcctcgatgttactg ggatggtggacgccccacaggaccagcacttctttctccttattgttcacatagctttttgacagctttgggtaggagc cgtcagtctctgtcagccacagcagattcttgtagaagcttgattttccggcatgagaacaagcggcggtcacccccct Nov 2022 agtaatgttgtgtttaggccaggacctttccttggggaagatttcaaatctctcgaaactagacacggagctcagctgc tctctcagttcctcataatcagcaaagtctccagggaagcaggccccattttcagagttgggtgtctcggcaatgtaac tccaagaccgtttagacagcagggattcacactctggattgcccagaatccatcctgcgatgttgcactttcccagctg cagaggagcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="135"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> 2022279441
<INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q170">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q171">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccattgcccctctgcagctgggaaattgtagcgtggccggctggattctggg caatcctgagtgcgagctgctgatttccaaagagtcctggtcctacatcgtggagaagcccaaccctgagaatggcacc tgcttccctggccacttcgccgattacgaggaactgagagaacagctgtccagcgtgtccagcttcgagagattcgaga tcttccccaaagagagcagctggcccaatcatacagtgaccggcgtgagcgcctcttgtagccacaatggcgagagcag Nov 2022 cttctacagaaacctgctgtggctgaccggcaagaacggcctgtaccccaacctgagcaagagctacgccaacaacaaa gaaaaagaagtgctggtcctctggggagtgcaccaccctcctaacatcggcatccagaaggccctgtaccacaccgaga atgcctacgtgtccgtggtgtccagccactacagcagaaagttcacccccgagatcgccaaaagacccaaagtgcggga ccaggaaggcaggatcaactactactggaccctgctggaacctggcgacaccatcatcttcgaggccaacggcaatctg atcgcccctagatacgcctttgccctgagcagaggcgcctccggagagagccaggtgaggcagcagttcagcaaggaca tcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgcta cacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatc atcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgaccc agatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagag caaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatc 2022279441 ctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaaga gcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="136"> <INSDSeq> <INSDSeq_length>421</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q172">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q173">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals>
</INSDFeature> Nov 2022
</INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGNCSVAGWILGNPECELLISKESWS YIVEKPNPENGTCFPGHFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTGKNGL YPNLSKSYANNKEKEVLVLWGVHHPPNIGIQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEP GDTIIFEANGNLIAPRYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> 2022279441
<SequenceData sequenceIDNumber="137"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q174">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q175">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca Nov 2022 cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gcgcctctgctcagggcaaaggcgtatctaggggcgatcagattgccgttggcctcgaagatgatggtgtcgccaggtt ccagcagggtccagtagtagttgatcctgccttcctggtcccgcactttgggtcttttggcgatctcgggggtgaactt tctgctgtagtggctggacaccacggacacgtaggcattctcggtgtggtacagggccttctggatgccgatgttagga gggtggtgcactccccagaggaccagcacttctttttctttgttgttggcgtagctcttgctcaggttggggtacaggc cgttcttgccggtcagccacagcaggtttctgtagaagctgctctcgccattgtggctacaagaggcgctcacgccggt 2022279441 cactgtatgattgggccagctgctctctttggggaagatctcgaatctctcgaagctggacacgctggacagctgttct ctcagttcctcgtaatcggcgaagtggccagggaagcaggtgccattctcagggttgggcttctccacgatgtaggacc aggactctttggaaatcagcagctcgcactcaggattgcccagaatccagccggccacgctacaatttcccagctgcag aggggcaatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttctgg ctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="138"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q176">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q177">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> Nov 2022
</INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccatcgctcctctgcagctggggaagtgcagcatcgcagggtggattctggg aaatccagagtgtgaatccctgttttctaagaaaagctggtcctacattgccgagacacccaactccgaaaatggcact tgtttccctgggtatttcgctgattatgaggaactgcgcgagcagctgagctccgtgtctagtttcgagcgatttgaaa tcttccccaaggaatcaagctggcctaaacacaacgtgacccggggggtcacagcctcttgcagtcataagggaaaatg 2022279441
ttctttctacagaaatctgctgtggctgacagagaagaacgggagttacccaaatctgtcaaagagctacgtgaacaat aaggagaaagaagtgctggtcctgtggggcgtccaccatccctctaacatcgaggaccagaagactatctaccgaaaag aaaacgcatatgtgagcgtggtctcctctcactacaatcggcggttcacccccgagatcgccaagaggcccaaagtgcg cgaccaggaaggccgcattaactactattggaccctgctggagccaggcgatacaatcattttcgaagccaacgggaat ctgatcgctccctggtatgcatttgccctgtcaagaggagcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="139"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q178">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q179">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> 2022279441
</INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCSIAGWILGNPECESLFSKKSWS YIAETPNSENGTCFPGYFADYEELREQLSSVSSFERFEIFPKESSWPKHNVTRGVTASCSHKGKCSFYRNLLWLTEKNG SYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTIYRKENAYVSVVSSHYNRRFTPEIAKRPKVRDQEGRINYYWTLLE PGDTIIFEANGNLIAPWYAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="140"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q180">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q181">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca 2022279441
cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gctcctcttgacagggcaaatgcataccagggagcgatcagattcccgttggcttcgaaaatgattgtatcgcctggct ccagcagggtccaatagtagttaatgcggccttcctggtcgcgcactttgggcctcttggcgatctcgggggtgaaccg ccgattgtagtgagaggagaccacgctcacatatgcgttttcttttcggtagatagtcttctggtcctcgatgttagag ggatggtggacgccccacaggaccagcacttctttctccttattgttcacgtagctctttgacagatttgggtaactcc cgttcttctctgtcagccacagcagatttctgtagaaagaacattttcccttatgactgcaagaggctgtgaccccccg ggtcacgttgtgtttaggccagcttgattccttggggaagatttcaaatcgctcgaaactagacacggagctcagctgc tcgcgcagttcctcataatcagcgaaatacccagggaaacaagtgccattttcggagttgggtgtctcggcaatgtagg accagcttttcttagaaaacagggattcacactctggatttcccagaatccaccctgcgatgctgcacttccccagctg cagaggagcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="141"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q182">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals>
<INSDQualifier> Nov 2022
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q183">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> 2022279441
</INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccatcgcccctctgcagctgggcaagtgcaacatcgctggctggattctggg gaatccagagtgtgaatctctgtttagtaagaaaagctggtcctacattgctgagacccccaacagcgaaaatggaaca tgcttccctggctatttcgcagattatgaggaactgagggagcagctgagctccgtgtctagtttcgagagatttgaaa tcttccccaaggaaaggtcttggcctaaacacaacattacccggggcgtgacagccgcttgtagtcataaggggaaatc aagcttttacagaaacctgctgtggctgacagagaagaatggctcatacccaaacctgaacaagagctatgtgaacaat aaggagaaagaagtgctggtcctgtggggcgtccaccatccctctaacatcgaggaccagaagactctgtaccgaaaag aaaatgcctatgtgtccgtggtctcctctaactacaatcggcggttcacccccgagatcgctgaaaggccaaaggtgcg cggacaggcaggacgcattaactactattggactctgctggagccaggagataccatcattttcgaagcaaacggcaat ctgatcgccccctggcacgcttttgcactgagccggggagcctccggagagagccaggtgaggcagcagttcagcaagg acatcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtg ctacacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctga cccagatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaa gagcaaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgcca agagcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="142"> <INSDSeq> <INSDSeq_length>422</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q184">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals>
</INSDFeature> Nov 2022
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..422</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name> 2022279441
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q185">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAIAPLQLGKCNIAGWILGNPECESLFSKKSWS YIAETPNSENGTCFPGYFADYEELREQLSSVSSFERFEIFPKERSWPKHNITRGVTAACSHKGKSSFYRNLLWLTEKNG SYPNLNKSYVNNKEKEVLVLWGVHHPSNIEDQKTLYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLE PGDTIIFEANGNLIAPWHAFALSRGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="143"> <INSDSeq> <INSDSeq_length>1269</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q186">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1269</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q187"> 2022279441
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gctccccggctcagtgcaaaagcgtgccagggggcgatcagattgccgtttgcttcgaaaatgatggtatctcctggct ccagcagagtccaatagtagttaatgcgtcctgcctgtccgcgcacctttggcctttcagcgatctcgggggtgaaccg ccgattgtagttagaggagaccacggacacataggcattttcttttcggtacagagtcttctggtcctcgatgttagag ggatggtggacgccccacaggaccagcacttctttctccttattgttcacatagctcttgttcaggtttgggtatgagc cattcttctctgtcagccacagcaggtttctgtaaaagcttgatttccccttatgactacaagcggctgtcacgccccg ggtaatgttgtgtttaggccaagacctttccttggggaagatttcaaatctctcgaaactagacacggagctcagctgc tccctcagttcctcataatctgcgaaatagccagggaagcatgttccattttcgctgttgggggtctcagcaatgtagg accagcttttcttactaaacagagattcacactctggattccccagaatccagccagcgatgttgcacttgcccagctg cagaggggcgatggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttc tggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="144"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q188">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> Nov 2022
</INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier> 2022279441
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q189">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccgtgaagcctctgatcctgagagattgtagcgtggctggatggctgctggg caaccctatgtgcgacgagttcatcaacgtgcccgagtggagctatatcgtggagaaggccaaccccaccaacgatctg tgtttccccggcagcttcaacgattacgaggaactgaagcacctgctgtcccggatcaaccacttcgagaagatccaga tcatccccaagtcctcttggagcgatcacgaagcctctagcggagtgtctagcgcctgtccttacctgggcagccccag cttcttcagaaacgtggtgtggctgatcaagaagaacagcacctaccccaccatcaagaagagctacaacaacaccaac caggaagatctgctggtcctgtggggaatccaccaccctaatgatgccgccgagcagaccagactgtaccagaacccca ccacctatatcagcatcggcaccagcaccctgaatcagagactggtgcccaagatcgccaccagatccaaggtgaacgg ccagagcggcaggatggaattcttctggaccatcctgaagcccaacgacgccatcaacttcgagagcaacggcaacttt atcgcccctgagtacgcctacaagatcgtgaagaagggctccggagagagccaggtgaggcagcagttcagcaaggaca tcgagaagctgctgaacgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgcta cacccacagcctggacggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatc atcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgaccc agatcttccagaaggcctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagag caaggaccacgccaccttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatc ctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaaga gcaggaagagcggatcctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="145"> <INSDSeq> <INSDSeq_length>421</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q190">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> 2022279441
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..421</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q191">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVKPLILRDCSVAGWLLGNPMCDEFINVPEWS YIVEKANPTNDLCFPGSFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYLGSPSFFRNVVWLIKKNST YPTIKKSYNNTNQEDLLVLWGIHHPNDAAEQTRLYQNPTTYISIGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKP NDAINFESNGNFIAPEYAYKIVKKGSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="146"> <INSDSeq> <INSDSeq_length>1266</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q192">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> 2022279441
<INSDFeature_location>1..1266</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q193">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag cccttcttcacgatcttgtaggcgtactcaggggcgataaagttgccgttgctctcgaagttgatggcgtcgttgggct tcaggatggtccagaagaattccatcctgccgctctggccgttcaccttggatctggtggcgatcttgggcaccagtct ctgattcagggtgctggtgccgatgctgatataggtggtggggttctggtacagtctggtctgctcggcggcatcatta gggtggtggattccccacaggaccagcagatcttcctggttggtgttgttgtagctcttcttgatggtggggtaggtgc tgttcttcttgatcagccacaccacgtttctgaagaagctggggctgcccaggtaaggacaggcgctagacactccgct agaggcttcgtgatcgctccaagaggacttggggatgatctggatcttctcgaagtggttgatccgggacagcaggtgc ttcagttcctcgtaatcgttgaagctgccggggaaacacagatcgttggtggggttggccttctccacgatatagctcc actcgggcacgttgatgaactcgtcgcacatagggttgcccagcagccatccagccacgctacaatctctcaggatcag aggcttcacggctagcacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttctgg ctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="147"> <INSDSeq> <INSDSeq_length>1263</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table>
<INSDFeature> Nov 2022
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q194">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> 2022279441
</INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q195">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagtaaggggtcttcacagaaagggtcacggctgctgctgctgctggtcgtcagta acctgctgctgcctcagggagtgctagccgtgaaacccctgattctgcgcgactgtagcgtggccggatggctgctggg caaccctatgtgcgatgagtttattaacgtccctgagtggagctacatcgtggagaaggcatccccagccaacgacctg tgcttccccggcaacttcaatgattatgaggaactgaaacacctgctgtctcgaatcaaccatttcgaaaagatccaga tcatcccaaagagctcctggagcaatcacgacgcctctagtggagtctcaagcgcttgtccctatctgggccggtcctc tttctttagaaacgtggtctggctgatcaagaaaaattctgcctaccctacaattaagagaagttacaacaacactaat caggaggacctgctggtgctgtggggcgtccaccatcctaacgatgccgctgaacagaccaaactgtaccagaatccaa ccacatatatcagtgtggggacttcaaccctgaaccagaggctggtgcccgagattgcaacccgccctaaggtcaatgg ccagtccgggcggatggaattcttttggacaatcctgaaacccaacgatgctattaatttcgagagcaacgggaatttt atcgctcctgaatacgcatataagattgtgaagaaaggctccggagaaagtcaggtgaggcagcagttcagtaaggata tcgagaaactgctgaacgaacaggtgaacaaggagatgcagtctagtaacctgtacatgagtatgtcaagctggtgtta tacccactcactggacggagccggcctgttcctgtttgatcacgcagccgaggaatacgaacatgctaagaaactgatc atttttctgaacgagaacaacgtcccagtgcagctgacaagtatctcagcccccgagcataagttcgaaggcctgactc agatctttcagaaagcctacgaacacgagcagcatattagcgagtccatcaacaatattgtggaccacgcaattaagag caaagatcatgccaccttcaattttctgcagtggtacgtggccgagcagcacgaggaagaggtgctgttcaaggacatc ctggataaaatcgaactgattggcaacgagaatcatgggctgtacctggcagaccagtatgtgaagggcattgctaagt caagaaaaagctgatga</INSDSeq_sequence> </INSDSeq>
</SequenceData> Nov 2022
<SequenceData sequenceIDNumber="148"> <INSDSeq> <INSDSeq_length>419</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key> 2022279441
<INSDFeature_location>1..419</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q196">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..419</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q197">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVKPLILRDCSVAGWLLGNPMCDEFINVPEWS YIVEKASPANDLCFPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSNHDASSGVSSACPYLGRSSFFRNVVWLIKKNSA YPTIKRSYNNTNQEDLLVLWGVHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPEIATRPKVNGQSGRMEFFWTILKP NDAINFESNGNFIAPEYAYKIVKKGSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="149"> <INSDSeq> <INSDSeq_length>1263</INSDSeq_length>
<INSDSeq_moltype>DNA</INSDSeq_moltype> Nov 2022
<INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q198"> 2022279441
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q199">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcagctttttcttgacttagcaatgcccttcacatactggtctgccaggtacagccca tgattctcgttgccaatcagttcgattttatccaggatgtccttgaacagcacctcttcctcgtgctgctcggccacgt accactgcagaaaattgaaggtggcatgatctttgctcttaattgcgtggtccacaatattgttgatggactcgctaat atgctgctcgtgttcgtaggctttctgaaagatctgagtcaggccttcgaacttatgctcgggggctgagatacttgtc agctgcactgggacgttgttctcgttcagaaaaatgatcagtttcttagcatgttcgtattcctcggctgcgtgatcaa acaggaacaggccggctccgtccagtgagtgggtataacaccagcttgacatactcatgtacaggttactagactgcat ctccttgttcacctgttcgttcagcagtttctcgatatccttactgaactgctgcctcacctgactttctccggagcct ttcttcacaatcttatatgcgtattcaggagcgataaaattcccgttgctctcgaaattaatagcatcgttgggtttca ggattgtccaaaagaattccatccgcccggactggccattgaccttagggcgggttgcaatctcgggcaccagcctctg gttcagggttgaagtccccacactgatatatgtggttggattctggtacagtttggtctgttcagcggcatcgttagga tggtggacgccccacagcaccagcaggtcctcctgattagtgttgttgtaacttctcttaattgtagggtaggcagaat ttttcttgatcagccagaccacgtttctaaagaaagaggaccggcccagatagggacaagcgcttgagactccactaga ggcgtcgtgattgctccaggagctctttgggatgatctggatcttttcgaaatggttgattcgagacagcaggtgtttc agttcctcataatcattgaagttgccggggaagcacaggtcgttggctggggatgccttctccacgatgtagctccact cagggacgttaataaactcatcgcacatagggttgcccagcagccatccggccacgctacagtcgcgcagaatcagggg tttcacggctagcactccctgaggcagcagcaggttactgacgaccagcagcagcagcagccgtgaccctttctgtgaa Nov 2022 gaccccttactgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="150"> <INSDSeq> <INSDSeq_length>1263</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature> 2022279441
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q200">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q201">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagtaaggggtcttcacagaaagggtcacggctgctgctgctgctggtcgtcagta acctgctgctgcctcagggagtgctagccgtgaagcctctgattctgaaagactgctccgtcgctggatggctgctggg gaaccctatgtgtgatgagtttattaacgtgcctgagtggagctacatcgtggagaaggccaaccccgctaatgacctg tgcttccctggcaacttcaatgattatgaggaactgaaacacctgctgagccgaatcaaccattttgagaagattcaga tcattcccaaagactcatggagcgatcacgaagcttccctgggagtgagctccgcatgtccttatcagggcaactctag tttctttagaaatgtggtctggctgatcaagaaaggcaacgcctacccaacaattaagaaatcttacaacaacactaat caggaagacctgctggtcctgtggggcatccaccatccaaacgatgaggccgaacagaccaggctgtaccagaatccca ccacatatatctccattggcacttctaccctgaaccagcggctggtgcccaagatcgccaccagaagtaaagtcaatgg ccagtcagggcgcatcgacttcttttggacaattctgaagcctaacgatgctattaatttcgagtccaacgggaatttt Nov 2022 atcgcaccagaatacgcctataagattgtgaagaaaggctccggagaaagtcaggtgaggcagcagttcagtaaggata tcgagaaactgctgaacgaacaggtgaacaaggagatgcagtctagtaacctgtacatgagtatgtcaagctggtgtta tacccactcactggacggagccggcctgttcctgtttgatcacgcagccgaggaatacgaacatgctaagaaactgatc atttttctgaacgagaacaacgtcccagtgcagctgacaagtatctcagcccccgagcataagttcgaaggcctgactc agatctttcagaaagcctacgaacacgagcagcatattagcgagtccatcaacaatattgtggaccacgcaattaagag caaagatcatgccaccttcaattttctgcagtggtacgtggccgagcagcacgaggaagaggtgctgttcaaggacatc ctggataaaatcgaactgattggcaacgagaatcatgggctgtacctggcagaccagtatgtgaagggcattgctaagt caagaaaaagctgatga</INSDSeq_sequence> </INSDSeq> </SequenceData> 2022279441
<SequenceData sequenceIDNumber="151"> <INSDSeq> <INSDSeq_length>419</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..419</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q202">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..419</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q203">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVKPLILKDCSVAGWLLGNPMCDEFINVPEWS
YIVEKANPANDLCFPGNFNDYEELKHLLSRINHFEKIQIIPKDSWSDHEASLGVSSACPYQGNSSFFRNVVWLIKKGNA Nov 2022
YPTIKKSYNNTNQEDLLVLWGIHHPNDEAEQTRLYQNPTTYISIGTSTLNQRLVPKIATRSKVNGQSGRIDFFWTILKP NDAINFESNGNFIAPEYAYKIVKKGSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="152"> <INSDSeq> <INSDSeq_length>1263</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> 2022279441
<INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q204">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q205">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcagctttttcttgacttagcaatgcccttcacatactggtctgccaggtacagccca tgattctcgttgccaatcagttcgattttatccaggatgtccttgaacagcacctcttcctcgtgctgctcggccacgt accactgcagaaaattgaaggtggcatgatctttgctcttaattgcgtggtccacaatattgttgatggactcgctaat atgctgctcgtgttcgtaggctttctgaaagatctgagtcaggccttcgaacttatgctcgggggctgagatacttgtc agctgcactgggacgttgttctcgttcagaaaaatgatcagtttcttagcatgttcgtattcctcggctgcgtgatcaa acaggaacaggccggctccgtccagtgagtgggtataacaccagcttgacatactcatgtacaggttactagactgcat Nov 2022 ctccttgttcacctgttcgttcagcagtttctcgatatccttactgaactgctgcctcacctgactttctccggagcct ttcttcacaatcttataggcgtattctggtgcgataaaattcccgttggactcgaaattaatagcatcgttaggcttca gaattgtccaaaagaagtcgatgcgccctgactggccattgactttacttctggtggcgatcttgggcaccagccgctg gttcagggtagaagtgccaatggagatatatgtggtgggattctggtacagcctggtctgttcggcctcatcgtttgga tggtggatgccccacaggaccagcaggtcttcctgattagtgttgttgtaagatttcttaattgttgggtaggcgttgc ctttcttgatcagccagaccacatttctaaagaaactagagttgccctgataaggacatgcggagctcactcccaggga agcttcgtgatcgctccatgagtctttgggaatgatctgaatcttctcaaaatggttgattcggctcagcaggtgtttc agttcctcataatcattgaagttgccagggaagcacaggtcattagcggggttggccttctccacgatgtagctccact caggcacgttaataaactcatcacacatagggttccccagcagccatccagcgacggagcagtctttcagaatcagagg cttcacggctagcactccctgaggcagcagcaggttactgacgaccagcagcagcagcagccgtgaccctttctgtgaa 2022279441 gaccccttactgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="153"> <INSDSeq> <INSDSeq_length>1260</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1260</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q206">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1260</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q207">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature>
</INSDSeq_feature‐table> Nov 2022
<INSDSeq_sequence>atggacagtaaggggtcttcacagaaagggtcacggctgctgctgctgctggtcgtcagta acctgctgctgcctcagggagtgctagccgtgaaacccctgattctgaaagactgctctgtggctggatggctgctggg caaccctatgtgcgatgagttcctgaatgtgtccgaatggtcttacatcgtggagaaggccagtccagctaacggactg tgcttccccggcgacttcaatgattatgaggaactgaagcacctgctgtctaggatcaaccatttcgagaagatcaaga tcatcccaaagagctcctggtccaatcacgaagcttctggggtgtctagtgcatgtagttatctgggaaagccctcatt ctttcgcaacctggtctggctgatcaagaaaaacaatacttacccccccatcaaggtcaattatactaacaccaatcag gaagacctgctggtcctgtggggcatccaccatcctaacgatgagacagaacaggtgaagatctaccagaatccaacca catatatttcagtcggcacaagcactctgaaccagcggctggtgcctaagattgccaccagaagcaaagtcaatggcca gtccgggcgaatggagttcttttggacaatcctgaagcccaacgacgctattaatttcgatagcaacggcaacttcatc 2022279441
gcacctgaatacgcctataaaattgtgaagaaagggtccggagaaagtcaggtgaggcagcagttcagtaaggatatcg agaaactgctgaacgaacaggtgaacaaggagatgcagtctagtaacctgtacatgagtatgtcaagctggtgttatac ccactcactggacggagccggcctgttcctgtttgatcacgcagccgaggaatacgaacatgctaagaaactgatcatt tttctgaacgagaacaacgtcccagtgcagctgacaagtatctcagcccccgagcataagttcgaaggcctgactcaga tctttcagaaagcctacgaacacgagcagcatattagcgagtccatcaacaatattgtggaccacgcaattaagagcaa agatcatgccaccttcaattttctgcagtggtacgtggccgagcagcacgaggaagaggtgctgttcaaggacatcctg gataaaatcgaactgattggcaacgagaatcatgggctgtacctggcagaccagtatgtgaagggcattgctaagtcaa gaaaaagctgatga</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="154"> <INSDSeq> <INSDSeq_length>418</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..418</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q208">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..418</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q209">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVKPLILKDCSVAGWLLGNPMCDEFLNVSEWS YIVEKASPANGLCFPGDFNDYEELKHLLSRINHFEKIKIIPKSSWSNHEASGVSSACSYLGKPSFFRNLVWLIKKNNTY 2022279441
PPIKVNYTNTNQEDLLVLWGIHHPNDETEQVKIYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPN DAINFDSNGNFIAPEYAYKIVKKGSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHA AEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAE QHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="155"> <INSDSeq> <INSDSeq_length>1260</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1260</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q210">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1260</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q211">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier> Nov 2022
</INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcagctttttcttgacttagcaatgcccttcacatactggtctgccaggtacagccca tgattctcgttgccaatcagttcgattttatccaggatgtccttgaacagcacctcttcctcgtgctgctcggccacgt accactgcagaaaattgaaggtggcatgatctttgctcttaattgcgtggtccacaatattgttgatggactcgctaat atgctgctcgtgttcgtaggctttctgaaagatctgagtcaggccttcgaacttatgctcgggggctgagatacttgtc agctgcactgggacgttgttctcgttcagaaaaatgatcagtttcttagcatgttcgtattcctcggctgcgtgatcaa acaggaacaggccggctccgtccagtgagtgggtataacaccagcttgacatactcatgtacaggttactagactgcat 2022279441
ctccttgttcacctgttcgttcagcagtttctcgatatccttactgaactgctgcctcacctgactttctccggaccct ttcttcacaattttataggcgtattcaggtgcgatgaagttgccgttgctatcgaaattaatagcgtcgttgggcttca ggattgtccaaaagaactccattcgcccggactggccattgactttgcttctggtggcaatcttaggcaccagccgctg gttcagagtgcttgtgccgactgaaatatatgtggttggattctggtagatcttcacctgttctgtctcatcgttagga tggtggatgccccacaggaccagcaggtcttcctgattggtgttagtataattgaccttgatgggggggtaagtattgt ttttcttgatcagccagaccaggttgcgaaagaatgagggctttcccagataactacatgcactagacaccccagaagc ttcgtgattggaccaggagctctttgggatgatcttgatcttctcgaaatggttgatcctagacagcaggtgcttcagt tcctcataatcattgaagtcgccggggaagcacagtccgttagctggactggccttctccacgatgtaagaccattcgg acacattcaggaactcatcgcacatagggttgcccagcagccatccagccacagagcagtctttcagaatcaggggttt cacggctagcactccctgaggcagcagcaggttactgacgaccagcagcagcagcagccgtgaccctttctgtgaagac cccttactgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="156"> <INSDSeq> <INSDSeq_length>1263</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q212">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> Nov 2022
</INSDQualifier> <INSDQualifier id="q213">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table> 2022279441
<INSDSeq_sequence>atggacagtaaggggtcttcacagaaagggtcacggctgctgctgctgctggtcgtcagta acctgctgctgcctcagggagtgctagccgtcaaacccctgattctgagagattgtagtgtcgctggctggctgctggg caaccctatgtgtgatgagtttattaacgtccctgaatggtcttacatcgtggagaaagcaagtcccgccaacgacctg tgcttccctggcgacttcaatgattatgaggaactgaaacacctgctgtcccgaatcaaccattttgagaagattcaga tcattcccaaaagctcctggtctaatcacgaagcctctagtggagtctcaagcgcttgtccttatctgggcaagtcctc tttctttaggaacgtggtctggctgatcaagaaaaattcaacatacccaaccatcaagcgcagttataacaatactaac caggaggacctgctggtgctgtggggcatccaccatccaaacgatgccgctgaacagacaaagctgtaccagaatccca ccacatatatcagtgtcgggacttcaaccctgaaccagcggctggtgcccaagattgccaccagaagcaaagtcaatgg ccagtccgggagaatggaattcttttggacaatcctgaagcctaacgatgccattaatttcgagagcaacgggaatttt atcgctccagaatacgcatataaaattgtgaagaaaggctccggagaaagtcaggtgaggcagcagttcagtaaggata tcgagaaactgctgaacgaacaggtgaacaaggagatgcagtctagtaacctgtacatgagtatgtcaagctggtgtta tacccactcactggacggagccggcctgttcctgtttgatcacgcagccgaggaatacgaacatgctaagaaactgatc atttttctgaacgagaacaacgtcccagtgcagctgacaagtatctcagcccccgagcataagttcgaaggcctgactc agatctttcagaaagcctacgaacacgagcagcatattagcgagtccatcaacaatattgtggaccacgcaattaagag caaagatcatgccaccttcaattttctgcagtggtacgtggccgagcagcacgaggaagaggtgctgttcaaggacatc ctggataaaatcgaactgattggcaacgagaatcatgggctgtacctggcagaccagtatgtgaagggcattgctaagt caagaaaaagctgatga</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="157"> <INSDSeq> <INSDSeq_length>419</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..419</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q214">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..419</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q215"> 2022279441
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVKPLILRDCSVAGWLLGNPMCDEFINVPEWS YIVEKASPANDLCFPGDFNDYEELKHLLSRINHFEKIQIIPKSSWSNHEASSGVSSACPYLGKSSFFRNVVWLIKKNST YPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKP NDAINFESNGNFIAPEYAYKIVKKGSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="158"> <INSDSeq> <INSDSeq_length>1263</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q216">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q217">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> 2022279441
</INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcagctttttcttgacttagcaatgcccttcacatactggtctgccaggtacagccca tgattctcgttgccaatcagttcgattttatccaggatgtccttgaacagcacctcttcctcgtgctgctcggccacgt accactgcagaaaattgaaggtggcatgatctttgctcttaattgcgtggtccacaatattgttgatggactcgctaat atgctgctcgtgttcgtaggctttctgaaagatctgagtcaggccttcgaacttatgctcgggggctgagatacttgtc agctgcactgggacgttgttctcgttcagaaaaatgatcagtttcttagcatgttcgtattcctcggctgcgtgatcaa acaggaacaggccggctccgtccagtgagtgggtataacaccagcttgacatactcatgtacaggttactagactgcat ctccttgttcacctgttcgttcagcagtttctcgatatccttactgaactgctgcctcacctgactttctccggagcct ttcttcacaattttatatgcgtattctggagcgataaaattcccgttgctctcgaaattaatggcatcgttaggcttca ggattgtccaaaagaattccattctcccggactggccattgactttgcttctggtggcaatcttgggcaccagccgctg gttcagggttgaagtcccgacactgatatatgtggtgggattctggtacagctttgtctgttcagcggcatcgtttgga tggtggatgccccacagcaccagcaggtcctcctggttagtattgttataactgcgcttgatggttgggtatgttgaat ttttcttgatcagccagaccacgttcctaaagaaagaggacttgcccagataaggacaagcgcttgagactccactaga ggcttcgtgattagaccaggagcttttgggaatgatctgaatcttctcaaaatggttgattcgggacagcaggtgtttc agttcctcataatcattgaagtcgccagggaagcacaggtcgttggcgggacttgctttctccacgatgtaagaccatt cagggacgttaataaactcatcacacatagggttgcccagcagccagccagcgacactacaatctctcagaatcagggg tttgacggctagcactccctgaggcagcagcaggttactgacgaccagcagcagcagcagccgtgaccctttctgtgaa gaccccttactgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="159"> <INSDSeq> <INSDSeq_length>1263</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q218">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature>
<INSDFeature> Nov 2022
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> 2022279441
</INSDQualifier> <INSDQualifier id="q219">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagtaaggggtcttcacagaaagggtcacggctgctgctgctgctggtcgtcagta acctgctgctgcctcagggagtgctagccgtcaaacctctgattctgagagactgttccgtggctggatggctgctggg caaccctatgtgcgatgagtttatcaatgtccccgagtggtcttacatcgtggagaaagcaagtcccgccaacggactg tgcttccctggcgacttcaatgattatgaggaactgaaacacctgctgtcccggatcaaccattttgagaagattcaga tcattcccaaaagctcctggtctaatcacgaagcctctagtggggtctcaagcgcttgtccttatcagggaaagtcctc tttctttaggaacgtggtctggctgatcaagaaaaattcaacatacccaaccatcaagcgcagttataacaatactaac caggaggacctgctggtgctgtggggcatccaccatccaaacgatgccgctgaacagacacgactgtaccagaatccca ccacatatatcagtgtcggcacttcaaccctgaaccagcggctggtgcccaagattgccaccagaagcaaagtcaatgg ccagtccgggagaatggaattcttttggacaatcctgaagcctaacgacgccattaatttcgagagcaacggcaatttt atcgctccagaatacgcatataagattgtgaagaaagggtccggagaaagtcaggtgaggcagcagttcagtaaggata tcgagaaactgctgaacgaacaggtgaacaaggagatgcagtctagtaacctgtacatgagtatgtcaagctggtgtta tacccactcactggacggagccggcctgttcctgtttgatcacgcagccgaggaatacgaacatgctaagaaactgatc atttttctgaacgagaacaacgtcccagtgcagctgacaagtatctcagcccccgagcataagttcgaaggcctgactc agatctttcagaaagcctacgaacacgagcagcatattagcgagtccatcaacaatattgtggaccacgcaattaagag caaagatcatgccaccttcaattttctgcagtggtacgtggccgagcagcacgaggaagaggtgctgttcaaggacatc ctggataaaatcgaactgattggcaacgagaatcatgggctgtacctggcagaccagtatgtgaagggcattgctaagt caagaaaaagctgatga</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="160"> <INSDSeq> <INSDSeq_length>419</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..419</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q220">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> 2022279441
<INSDFeature_location>1..419</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q221">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVKPLILRDCSVAGWLLGNPMCDEFINVPEWS YIVEKASPANGLCFPGDFNDYEELKHLLSRINHFEKIQIIPKSSWSNHEASSGVSSACPYQGKSSFFRNVVWLIKKNST YPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTRLYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKP NDAINFESNGNFIAPEYAYKIVKKGSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="161"> <INSDSeq> <INSDSeq_length>1263</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q222">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier> Nov 2022
</INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1263</INSDFeature_location> <INSDFeature_quals> <INSDQualifier> 2022279441
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q223">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcagctttttcttgacttagcaatgcccttcacatactggtctgccaggtacagccca tgattctcgttgccaatcagttcgattttatccaggatgtccttgaacagcacctcttcctcgtgctgctcggccacgt accactgcagaaaattgaaggtggcatgatctttgctcttaattgcgtggtccacaatattgttgatggactcgctaat atgctgctcgtgttcgtaggctttctgaaagatctgagtcaggccttcgaacttatgctcgggggctgagatacttgtc agctgcactgggacgttgttctcgttcagaaaaatgatcagtttcttagcatgttcgtattcctcggctgcgtgatcaa acaggaacaggccggctccgtccagtgagtgggtataacaccagcttgacatactcatgtacaggttactagactgcat ctccttgttcacctgttcgttcagcagtttctcgatatccttactgaactgctgcctcacctgactttctccggaccct ttcttcacaatcttatatgcgtattctggagcgataaaattgccgttgctctcgaaattaatggcgtcgttaggcttca ggattgtccaaaagaattccattctcccggactggccattgactttgcttctggtggcaatcttgggcaccagccgctg gttcagggttgaagtgccgacactgatatatgtggtgggattctggtacagtcgtgtctgttcagcggcatcgtttgga tggtggatgccccacagcaccagcaggtcctcctggttagtattgttataactgcgcttgatggttgggtatgttgaat ttttcttgatcagccagaccacgttcctaaagaaagaggactttccctgataaggacaagcgcttgagaccccactaga ggcttcgtgattagaccaggagcttttgggaatgatctgaatcttctcaaaatggttgatccgggacagcaggtgtttc agttcctcataatcattgaagtcgccagggaagcacagtccgttggcgggacttgctttctccacgatgtaagaccact cggggacattgataaactcatcgcacatagggttgcccagcagccatccagccacggaacagtctctcagaatcagagg tttgacggctagcactccctgaggcagcagcaggttactgacgaccagcagcagcagcagccgtgaccctttctgtgaa gaccccttactgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="162"> <INSDSeq> <INSDSeq_length>1251</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1251</INSDFeature_location> Nov 2022
<INSDFeature_quals> <INSDQualifier id="q224">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature> 2022279441
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1251</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q225">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagcccaccagatcctggatggcgaaaactgtacactgattgacgctctgctggg agaccctcagtgcgatggcttccagaataagaaatgggatctgtttgtggagaggtctaaggcatacagtaactgtttc ccctatgacgtgcctgattatgcaagcctgcgctccctggtcgcctctagtggcacactggagttcaacaatgaaagct ttaattggacaggggtgactcagaacggaacttcaagcgcctgcatccggagatctaacaacagtttcttttcaagact gaactggctgacccagctgaatttcaagtaccctgctctgaacgtgacaatgccaaacaatgagcagtttgacaagctg tatatctggggcgtgcaccatcccgtcaccgacaaagatcagatcttcctgtacgcacagtcctctggcaggattaccg tgtcaacaaagcgcagccagcaggccgtcatccctaatattgggtacaggccacgcatccgaaacattcccagccgcat ctccatctactggactatcgtgaaaccaggcgatatcctgctgattaactccaccggaaatctgattgccccccggggc tatttcaagattagaagtggggcctccggagagagccaggtgaggcagcagttcagcaaggacatcgagaagctgctga acgagcaggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgctacacccacagcctgga cggcgccggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatcatcttcctgaacgag aacaacgtgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgacccagatcttccagaagg cctacgagcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagagcaaggaccacgccac cttcaacttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatcctggacaagatcgag ctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaagagcaggaagagcggat cctag</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="163"> <INSDSeq> <INSDSeq_length>416</INSDSeq_length>
<INSDSeq_moltype>AA</INSDSeq_moltype> Nov 2022
<INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..416</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q226"> 2022279441
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..416</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q227">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAHQILDGENCTLIDALLGDPQCDGFQNKKWDL FVERSKAYSNCFPYDVPDYASLRSLVASSGTLEFNNESFNWTGVTQNGTSSACIRRSNNSFFSRLNWLTQLNFKYPALN VTMPNNEQFDKLYIWGVHHPVTDKDQIFLYAQSSGRITVSTKRSQQAVIPNIGYRPRIRNIPSRISIYWTIVKPGDILL INSTGNLIAPRGYFKIRSGASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEY EHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEE EVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="164"> <INSDSeq> <INSDSeq_length>1251</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1251</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q228">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> 2022279441
</INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1251</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q229">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gccccacttctaatcttgaaatagccccggggggcaatcagatttccggtggagttaatcagcaggatatcgcctggtt tcacgatagtccagtagatggagatgcggctgggaatgtttcggatgcgtggcctgtacccaatattagggatgacggc ctgctggctgcgctttgttgacacggtaatcctgccagaggactgtgcgtacaggaagatctgatctttgtcggtgacg ggatggtgcacgccccagatatacagcttgtcaaactgctcattgtttggcattgtcacgttcagagcagggtacttga aattcagctgggtcagccagttcagtcttgaaaagaaactgttgttagatctccggatgcaggcgcttgaagttccgtt ctgagtcacccctgtccaattaaagctttcattgttgaactccagtgtgccactagaggcgaccagggagcgcaggctt gcataatcaggcacgtcataggggaaacagttactgtatgccttagacctctccacaaacagatcccatttcttattct ggaagccatcgcactgagggtctcccagcagagcgtcaatcagtgtacagttttcgccatccaggatctggtgggctag cacgccctgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttctggctgctgcccttgctg tccat</INSDSeq_sequence> </INSDSeq> </SequenceData>
<SequenceData sequenceIDNumber="165"> Nov 2022
<INSDSeq> <INSDSeq_length>1320</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1320</INSDFeature_location> 2022279441
<INSDFeature_quals> <INSDQualifier id="q230">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1320</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q231">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccaaaacacgcggaaaactgtgccccgactgtctgaactgcaccgacctgga tgtggcactgggacgacctatgtgtgtcggaaccacaccatccgcaaaagcctctattctgcacgaggtgcggcccgtc acttctggctgcttccctatcatgcatgaccggaccaagattagacagctggccaacctgctgagggggtacgaaaata tccgcctgtccacacagaacgtgattgatgctgagaaggcaccaggaggaccatatcgcctgggaacctccgggtcttg tcccaatgctacaagtaaatcaggcttctttgcaactatggcttgggcagtgcctaaggacaacaacaagaacgctaca aatcccctgactgtggaagtcccttacatctgcgcagagggggaagaccagattaccgtgtggggatttcactctgacg ataagacacagatgaaaaacctgtacggggatagtaatcctcagaagttcaccagctccgccaacggagtgactaccca ttatgtcagtcagatcggaggcttcccagaccagactgaggatgggggactgccccagtcaggcagaatcgtggtcgac tacatgatgcagaagcctggaaaaactggcaccattgtgtatcagagaggagtcctgctgccacagaaagtgtggtgtg catcaggcaggagctccggagagagccaggtgaggcagcagttcagcaaggacatcgagaagctgctgaacgagcaggt gaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgctacacccacagcctggacggcgccggc ctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatcatcttcctgaacgagaacaacgtgc Nov 2022 ccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgacccagatcttccagaaggcctacgagca cgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagagcaaggaccacgccaccttcaacttc ctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatcctggacaagatcgagctgatcggca acgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaagagcaggaagagcggatcctag</INS DSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="166"> <INSDSeq> <INSDSeq_length>439</INSDSeq_length> 2022279441
<INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..439</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q232">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..439</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q233">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAKTRGKLCPDCLNCTDLDVALGRPMCVGTTPS AKASILHEVRPVTSGCFPIMHDRTKIRQLANLLRGYENIRLSTQNVIDAEKAPGGPYRLGTSGSCPNATSKSGFFATMA WAVPKDNNKNATNPLTVEVPYICAEGEDQITVWGFHSDDKTQMKNLYGDSNPQKFTSSANGVTTHYVSQIGGFPDQTED GGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRSSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMS
SWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDH Nov 2022
AIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequenc e> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="167"> <INSDSeq> <INSDSeq_length>1320</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> 2022279441
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1320</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q234">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1320</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q235">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag ctcctgcctgatgcacaccacactttctgtggcagcaggactcctctctgatacacaatggtgccagtttttccaggct Nov 2022 tctgcatcatgtagtcgaccacgattctgcctgactggggcagtcccccatcctcagtctggtctgggaagcctccgat ctgactgacataatgggtagtcactccgttggcggagctggtgaacttctgaggattactatccccgtacaggtttttc atctgtgtcttatcgtcagagtgaaatccccacacggtaatctggtcttccccctctgcgcagatgtaagggacttcca cagtcaggggatttgtagcgttcttgttgttgtccttaggcactgcccaagccatagttgcaaagaagcctgatttact tgtagcattgggacaagacccggaggttcccaggcgatatggtcctcctggtgccttctcagcatcaatcacgttctgt gtggacaggcggatattttcgtaccccctcagcaggttggccagctgtctaatcttggtccggtcatgcatgataggga agcagccagaagtgacgggccgcacctcgtgcagaatagaggcttttgcggatggtgtggttccgacacacataggtcg tcccagtgccacatccaggtcggtgcagttcagacagtcggggcacagttttccgcgtgttttggctagcacgccctga ggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttctggctgctgcccttgctgtccat</INS DSeq_sequence> 2022279441
</INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="168"> <INSDSeq> <INSDSeq_length>1323</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1323</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q236">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1323</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q237">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggcagcagactgctgctgctgctggtggtgagca acctgctgctgcctcagggcgtgctagccgagacaagaggcaagctgtgccccaagtgcctgaactgtaccgatctgga tgtggccctgggcagacctaagtgtaccggcaagatccctagcgccagagtgtctatcctgcacgaagtgcggcctgtg accagcggctgcttccccatcatgcacgaccggaccaagatcagacagctgcccaatctgctgagaggctacgagcaca tcagactgagcacccacaacgtgatcaatgccgagaatgcccctggcggcccttacaagatcggcacctccggcagctg tcccaacatcaccaacggcaacggcttttttgccacaatggcctgggccgtgcctaagaacgacaagaacaagaccgcc accaaccctctgacaatcgaggtgccctacatctgtaccgagggcgaggatcagatcacagtgtggggcttccacagcg acaacgagactcagatggccaagctgtacggcgacagcaagccccagaagtttaccagcagcgccaatggcgtgaccac ccactacgtgtctcagatcggcggcttccctaatcagacagaggatggcggcctgcctcagagcggcagaatcgtggtg gactacatggtgcagaagtccggcaagaccggcaccatcacctaccagagaggcatcctgctgcctcagaaagtgtggt 2022279441
gtgccagcggcagatcctccggagagagccaggtgaggcagcagttcagcaaggacatcgagaagctgctgaacgagca ggtgaacaaggagatgcagagcagcaacctgtacatgagcatgagcagctggtgctacacccacagcctggacggcgcc ggcctgttcctgttcgaccacgccgccgaggagtacgagcacgccaagaagctgatcatcttcctgaacgagaacaacg tgcccgtgcagctgaccagcatcagcgcccccgagcacaagttcgagggcctgacccagatcttccagaaggcctacga gcacgagcagcacatcagcgagagcatcaacaacatcgtggaccacgccatcaagagcaaggaccacgccaccttcaac ttcctgcagtggtacgtggccgagcagcacgaggaggaggtgctgttcaaggacatcctggacaagatcgagctgatcg gcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcatcgccaagagcaggaagagcggatcctag</ INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="169"> <INSDSeq> <INSDSeq_length>440</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..440</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q238">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..440</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q239">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAETRGKLCPKCLNCTDLDVALGRPKCTGKIPS ARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHNVINAENAPGGPYKIGTSGSCPNITNGNGFFATMA 2022279441
WAVPKNDKNKTATNPLTIEVPYICTEGEDQITVWGFHSDNETQMAKLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQTE DGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGRSSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSM SSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVD HAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSGS</INSDSeq_sequen ce> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="170"> <INSDSeq> <INSDSeq_length>1323</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1323</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q240">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1323</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q241">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> Nov 2022
</INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ctaggatccgctcttcctgctcttggcgatgcccttcacgtactggtcggccaggtacagg ccgtggttctcgttgccgatcagctcgatcttgtccaggatgtccttgaacagcacctcctcctcgtgctgctcggcca cgtaccactgcaggaagttgaaggtggcgtggtccttgctcttgatggcgtggtccacgatgttgttgatgctctcgct gatgtgctgctcgtgctcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctcgggggcgctgatgctg gtcagctgcacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtactcctcggcggcgtggt 2022279441
cgaacaggaacaggccggcgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctg catctccttgttcacctgctcgttcagcagcttctcgatgtccttgctgaactgctgcctcacctggctctctccggag gatctgccgctggcacaccacactttctgaggcagcaggatgcctctctggtaggtgatggtgccggtcttgccggact tctgcaccatgtagtccaccacgattctgccgctctgaggcaggccgccatcctctgtctgattagggaagccgccgat ctgagacacgtagtgggtggtcacgccattggcgctgctggtaaacttctggggcttgctgtcgccgtacagcttggcc atctgagtctcgttgtcgctgtggaagccccacactgtgatctgatcctcgccctcggtacagatgtagggcacctcga ttgtcagagggttggtggcggtcttgttcttgtcgttcttaggcacggcccaggccattgtggcaaaaaagccgttgcc gttggtgatgttgggacagctgccggaggtgccgatcttgtaagggccgccaggggcattctcggcattgatcacgttg tgggtgctcagtctgatgtgctcgtagcctctcagcagattgggcagctgtctgatcttggtccggtcgtgcatgatgg ggaagcagccgctggtcacaggccgcacttcgtgcaggatagacactctggcgctagggatcttgccggtacacttagg tctgcccagggccacatccagatcggtacagttcaggcacttggggcacagcttgcctcttgtctcggctagcacgccc tgaggcagcagcaggttgctcaccaccagcagcagcagcagtctgctgcccttctggctgctgcccttgctgtccat</ INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="171"> <INSDSeq> <INSDSeq_length>2604</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..2604</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q242">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..2604</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name> Nov 2022
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q243">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> 2022279441
</INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggctccagactgctgctgctcctggtggtgtcca acctcctgctgcctcagggcgtgctagccgtggctcctctgcacctgggcaagtgcaatatcgccggctggattctggg caaccccgagtgcgagagcctgagcacagccagcagctggtcctacatcgtggaaacccctagcagcgacaacggcacc tgtttccccggcgacttcatcgactacgaggaactgcgcgagcagctgagcagcgtgtccagcttcgagagattcgaga tcttccccaagacctccagctggcccaaccacgacagcaacaaaggcgtgaccgccgcctgtcctcacgctggcgccaa gagcttctacaagaacctgatctggctggtcaagaagggcaacagctaccccaagctgagcaagagctacatcaacgac aagggcaaagaggtgctggtcctctggggcatccaccaccctagcacaagcgccgaccagcagagcctgtaccagaacg ccgacgcctacgtgttcgtgggcagctcccggtacagcaagaagttcaagcccgagatcgccatccggcccaaagtgcg ggaccaggaaggccggatgaactactactggaccctggtggaacccggcgacaagatcaccttcgaggccaccggcaat ctggtggtgcccagatacgccttcgccatggaaagaaacgccagcggcgagagccaagtccgacagcagttcagcaagg acatcgagaagctgctgaacgagcaggtcaacaaagagatgcagagcagcaacctgtacatgagcatgtccagctggtg ttacacccacagcctggacggcgctggcctgttcctgtttgatcacgccgccgaggaatacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgccccagagcacaagttcgagggcctga cccagatcttccagaaggcctacgaacacgagcagcacatcagcgagagcatcaacaatatcgtggaccacgccatcaa gagcaaggatcacgccaccttcaactttctgcaatggtacgtggccgaacagcacgaggaagaagtgctgtttaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcattgcca agagcagaaagagccggaagcggagatctggcagcggcgctcctgtgaagcagaccctgaacttcgacctgctgaagct ggccggcgacgtggaaagcaaccctgggcccatggactccaagggctcctcccagaaaggatctcggctgctcctcctg ctcgtggtgtctaatctgctgctgccacagggtgtcctggcccaccagatcctggatggcgagaactgcaccctgatcg acgccctgctgggcgaccctcagtgcgacggcttccagaacaagaagtgggacctgttcgtcgagcggagcaaggccta cagcaactgcttcccctacgacgtgcccgactacgccagcctgagaagcctggtggccagcagcggcaccctggaattc aacaacgagagcttcaactggaacggcgtgacccagaacggcaccagctccgcctgcatcagaagaagcaacaacagct tcttctcccggctgaactggctgacccacctgaatttcaagtaccccgccctgaacgtgaccatgcccaacaatgagca gttcgacaagctgtacatctggggagtgcaccaccccgtgaccgacaaggaccagatctttctgtacgcccagcccagc ggccggatcaccgtgtctaccaagagaagccagcaggccgtgatccccaacatcggcttccggcccaggatcagaaaca tccccagccggatcagcatctactggacaatcgtgaagcctggcgacatcctgctgatcaacagcaccggcaacctgat cgcccctcggggctacttcaagatcagaagcggcgcctccggagaatctcaagtccgccagcagttttctaaggacatc gaaaagctgctcaatgaacaggtcaacaaagagatgcagtcctctaacctgtatatgagtatgagttcctggtgctata cccactctctcgacggtgcagggctgttcctcttcgaccacgctgcagaggaatatgaacatgctaagaaactgattat ctttctcaacgaaaacaacgtgccagtccagctcaccagtatctctgcccctgaacataagtttgaggggctcactcag atctttcagaaagcttacgagcacgagcagcatatctctgagtctattaacaacatcgtcgaccatgctatcaaatcta aagaccacgctacttttaactttctccaatggtacgtcgcagagcagcatgaggaagaggtcctcttcaaggacattct cgacaaaattgaactcatcggaaacgaaaaccatgggctctacctggctgatcagtacgtcaagggaatcgcaaaaagc cggaagtcttgatga</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="172"> <INSDSeq> <INSDSeq_length>865</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division> Nov 2022
<INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..865</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q244">
<INSDQualifier_name>note</INSDQualifier_name> 2022279441
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..865</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q245">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>DSKGSSQKGSRLLLLLVVSNLLLPQGVLAVAPLHLGKCNIAGWILGNPECESLSTASSWSY IVETPSSDNGTCFPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNS YPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEP GDKITFEATGNLVVPRYAFAMERNASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDH AAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVA EQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSRKRRSGSGAPVKQTLNFDLLKLAGDVESNPGPMDSKG SSQKGSRLLLLLVVSNLLLPQGVLAHQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCFPYDVPDYASLR SLVASSGTLEFNNESFNWNGVTQNGTSSACIRRSNNSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPVTD KDQIFLYAQPSGRITVSTKRSQQAVIPNIGFRPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGASGE SQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSIS APEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYL ADQYVKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="173"> <INSDSeq>
<INSDSeq_length>2604</INSDSeq_length> Nov 2022
<INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..2604</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q246"> 2022279441
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..2604</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q247">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcaagacttccggctttttgcgattcccttgacgtactgatcagccaggtagagccca tggttttcgtttccgatgagttcaattttgtcgagaatgtccttgaagaggacctcttcctcatgctgctctgcgacgt accattggagaaagttaaaagtagcgtggtctttagatttgatagcatggtcgacgatgttgttaatagactcagagat atgctgctcgtgctcgtaagctttctgaaagatctgagtgagcccctcaaacttatgttcaggggcagagatactggtg agctggactggcacgttgttttcgttgagaaagataatcagtttcttagcatgttcatattcctctgcagcgtggtcga agaggaacagccctgcaccgtcgagagagtgggtatagcaccaggaactcatactcatatacaggttagaggactgcat ctctttgttgacctgttcattgagcagcttttcgatgtccttagaaaactgctggcggacttgagattctccggaggcg ccgcttctgatcttgaagtagccccgaggggcgatcaggttgccggtgctgttgatcagcaggatgtcgccaggcttca cgattgtccagtagatgctgatccggctggggatgtttctgatcctgggccggaagccgatgttggggatcacggcctg ctggcttctcttggtagacacggtgatccggccgctgggctgggcgtacagaaagatctggtccttgtcggtcacgggg tggtgcactccccagatgtacagcttgtcgaactgctcattgttgggcatggtcacgttcagggcggggtacttgaaat tcaggtgggtcagccagttcagccgggagaagaagctgttgttgcttcttctgatgcaggcggagctggtgccgttctg ggtcacgccgttccagttgaagctctcgttgttgaattccagggtgccgctgctggccaccaggcttctcaggctggcg tagtcgggcacgtcgtaggggaagcagttgctgtaggccttgctccgctcgacgaacaggtcccacttcttgttctgga agccgtcgcactgagggtcgcccagcagggcgtcgatcagggtgcagttctcgccatccaggatctggtgggccaggac Nov 2022 accctgtggcagcagcagattagacaccacgagcaggaggagcagccgagatcctttctgggaggagcccttggagtcc atgggcccagggttgctttccacgtcgccggccagcttcagcaggtcgaagttcagggtctgcttcacaggagcgccgc tgccagatctccgcttccggctctttctgctcttggcaatgcccttcacgtactggtcggccaggtacaggccgtggtt ctcgttgccgatcagctcgatcttgtccaggatgtccttaaacagcacttcttcctcgtgctgttcggccacgtaccat tgcagaaagttgaaggtggcgtgatccttgctcttgatggcgtggtccacgatattgttgatgctctcgctgatgtgct gctcgtgttcgtaggccttctggaagatctgggtcaggccctcgaacttgtgctctggggcgctgatgctggtcagctg cacgggcacgttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtattcctcggcggcgtgatcaaacagg aacaggccagcgccgtccaggctgtgggtgtaacaccagctggacatgctcatgtacaggttgctgctctgcatctctt tgttgacctgctcgttcagcagcttctcgatgtccttgctgaactgctgtcggacttggctctcgccgctggcgtttct ttccatggcgaaggcgtatctgggcaccaccagattgccggtggcctcgaaggtgatcttgtcgccgggttccaccagg 2022279441 gtccagtagtagttcatccggccttcctggtcccgcactttgggccggatggcgatctcgggcttgaacttcttgctgt accgggagctgcccacgaacacgtaggcgtcggcgttctggtacaggctctgctggtcggcgcttgtgctagggtggtg gatgccccagaggaccagcacctctttgcccttgtcgttgatgtagctcttgctcagcttggggtagctgttgcccttc ttgaccagccagatcaggttcttgtagaagctcttggcgccagcgtgaggacaggcggcggtcacgcctttgttgctgt cgtggttgggccagctggaggtcttggggaagatctcgaatctctcgaagctggacacgctgctcagctgctcgcgcag ttcctcgtagtcgatgaagtcgccggggaaacaggtgccgttgtcgctgctaggggtttccacgatgtaggaccagctg ctggctgtgctcaggctctcgcactcggggttgcccagaatccagccggcgatattgcacttgcccaggtgcagaggag ccacggctagcacgccctgaggcagcaggaggttggacaccaccaggagcagcagcagtctggagcccttctggctgct gcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="174"> <INSDSeq> <INSDSeq_length>2727</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..2727</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q248">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..2727</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier>
<INSDQualifier id="q249"> Nov 2022
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggctccagactgctgctgctcctggtggtgtcca 2022279441
acctcctgctgcctcagggcgtgctagccgagacaagaggcaagctgtgccccaagtgcctgaactgcaccgacctgga tgtggccctgggcagacctaagtgcaccggcaagatccccagcgccagagtgtccatcctgcacgaagtgcggcctgtg accagcggctgcttccccatcatgcacgaccggaccaagatcagacagctgcccaacctgctgcggggctacgagcaca tcagactgagcacccacaacgtgatcaacgccgagaatgcccctggcggcccttacaagatcggcaccagcggaagctg ccccaacatcaccaacggcaacggctttttcgccaccatggcctgggccgtgcccaagaacgacaagaacaagaccgcc accaaccctctgaccatcgaggtgccctacatctgcaccgagggcgaggaccagatcaccgtgtggggcttccacagcg acgacgagactcagatggccaagctgtacggcgacagcaagccccagaagttcaccagcagcgccaacggcgtgaccac ccactatgtgtcccagatcggcggcttccctaaccagacagaggatggcggcctgccccagagcggcagaatcgtggtg gactacatggtgcagaagtccggcaagaccggcacaatcacctaccagagaggcatcctgctgcctcagaaagtgtggt gcgccagcggcagatctagcggcgaatctcaagtccgacagcagttcagcaaggacatcgagaagctgctgaacgagca ggtcaacaaagagatgcagagcagcaacctgtacatgagcatgagcagctggtgctacacccacagcctggacggcgct ggcctgttcctgtttgatcacgccgccgaggaatacgagcacgccaagaagctgatcatcttcctgaacgagaacaacg tgcccgtgcagctgaccagcatcagcgcccctgagcacaagttcgagggcctgacccagatcttccagaaggcctacga acacgagcagcacatctccgagagcatcaacaacatcgtggaccacgccatcaagagcaaggatcacgccaccttcaac tttctgcagtggtacgtggccgaacagcacgaggaagaggtgctgtttaaggacatcctggacaagatcgagctgatcg gcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggaatcgccaagagcagaaagagccggaagcggag atctggcagcggcgctcctgtgaagcagaccctgaacttcgacctgctgaagctggccggcgacgtggaatctaatcct gggcccatggatagcaaaggctctagccagaaaggcagccgactcctgctcctgctggtcgtcagtaacctgctgctgc cccagggcgtcctcgccaagacaagaggcaagctgtgccccgactgcctgaattgcaccgacctggatgtggccctggg cagacctatgtgcgtgggcacaacacctagcgccaaggccagcatcctgcacgaagtgcggcctgtgaccagcggctgc ttccctatcatgcacgaccggaccaagatcaggcagctggccaatctgctgagaggctacgagaacatccggctgagca cccagaatgtgatcgatgccgagaaggcccctggcggcccttacagactgggcacaagcggcagctgtcccaacgccac cagcaagagcggctttttcgccacaatggcctgggccgtgcccaaggacaacaacaagaatgccaccaaccctctgacc gtggaagtgccctacatctgcgccgagggcgaggatcagatcacagtgtggggcttccacagcgacgacaagacccaga tgaagaacctgtacggcgacagcaatccccagaagttcacctccagcgccaatggcgtgaccacccactacgtgtccca gatcggcggcttccccgatcagacagaggatggcggactgccccagtccggcagaatcgtggtggactacatgatgcag aagcccggcaagaccggcaccatcgtgtaccagagaggcgtgctgctccctcagaaagtgtggtgcgcctctggcagaa gctccggagaatctcaagtccgccagcagttttctaaggacatcgaaaagctgctcaatgaacaggtcaacaaagagat gcagtcctctaacctgtatatgagtatgagttcctggtgctatacccactctctcgacggtgcagggctgttcctcttc gaccacgctgcagaggaatatgaacatgctaagaaactgattatctttctcaacgaaaacaacgtgccagtccagctca ccagtatctctgcccctgaacataagtttgaggggctcactcagatctttcagaaagcttacgagcacgagcagcatat ctctgagtctattaacaacatcgtcgaccatgctatcaaatctaaagaccacgctacttttaactttctccaatggtac gtcgcagagcagcatgaggaagaggtcctcttcaaggacattctcgacaaaattgaactcatcggaaacgaaaaccatg ggctctacctggctgatcagtacgtcaagggaatcgcaaaaagccggaagtcttgatga</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="175"> <INSDSeq> <INSDSeq_length>907</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..907</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q250">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> 2022279441
</INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..907</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q251">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAETRGKLCPKCLNCTDLDVALGRPKCTGKIPS ARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHNVINAENAPGGPYKIGTSGSCPNITNGNGFFATMA WAVPKNDKNKTATNPLTIEVPYICTEGEDQITVWGFHSDDETQMAKLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQTE DGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGRSSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSM SSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVD HAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSRKRRSGSGAPVKQTLNFD LLKLAGDVESNPGPMDSKGSSQKGSRLLLLLVVSNLLLPQGVLAKTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKAS ILHEVRPVTSGCFPIMHDRTKIRQLANLLRGYENIRLSTQNVIDAEKAPGGPYRLGTSGSCPNATSKSGFFATMAWAVP KDNNKNATNPLTVEVPYICAEGEDQITVWGFHSDDKTQMKNLYGDSNPQKFTSSANGVTTHYVSQIGGFPDQTEDGGLP QSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRSSGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCY THSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKS KDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="176"> <INSDSeq> <INSDSeq_length>2727</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature‐table> Nov 2022
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..2727</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q252">
<INSDQualifier_name>note</INSDQualifier_name> 2022279441
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..2727</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q253">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcaagacttccggctttttgcgattcccttgacgtactgatcagccaggtagagccca tggttttcgtttccgatgagttcaattttgtcgagaatgtccttgaagaggacctcttcctcatgctgctctgcgacgt accattggagaaagttaaaagtagcgtggtctttagatttgatagcatggtcgacgatgttgttaatagactcagagat atgctgctcgtgctcgtaagctttctgaaagatctgagtgagcccctcaaacttatgttcaggggcagagatactggtg agctggactggcacgttgttttcgttgagaaagataatcagtttcttagcatgttcatattcctctgcagcgtggtcga agaggaacagccctgcaccgtcgagagagtgggtatagcaccaggaactcatactcatatacaggttagaggactgcat ctctttgttgacctgttcattgagcagcttttcgatgtccttagaaaactgctggcggacttgagattctccggagctt ctgccagaggcgcaccacactttctgagggagcagcacgcctctctggtacacgatggtgccggtcttgccgggcttct gcatcatgtagtccaccacgattctgccggactggggcagtccgccatcctctgtctgatcggggaagccgccgatctg ggacacgtagtgggtggtcacgccattggcgctggaggtgaacttctggggattgctgtcgccgtacaggttcttcatc tgggtcttgtcgtcgctgtggaagccccacactgtgatctgatcctcgccctcggcgcagatgtagggcacttccacgg tcagagggttggtggcattcttgttgttgtccttgggcacggcccaggccattgtggcgaaaaagccgctcttgctggt ggcgttgggacagctgccgcttgtgcccagtctgtaagggccgccaggggccttctcggcatcgatcacattctgggtg ctcagccggatgttctcgtagcctctcagcagattggccagctgcctgatcttggtccggtcgtgcatgatagggaagc agccgctggtcacaggccgcacttcgtgcaggatgctggccttggcgctaggtgttgtgcccacgcacataggtctgcc cagggccacatccaggtcggtgcaattcaggcagtcggggcacagcttgcctcttgtcttggcgaggacgccctggggc agcagcaggttactgacgaccagcaggagcaggagtcggctgcctttctggctagagcctttgctatccatgggcccag gattagattccacgtcgccggccagcttcagcaggtcgaagttcagggtctgcttcacaggagcgccgctgccagatct Nov 2022 ccgcttccggctctttctgctcttggcgattcccttcacgtactggtcggccaggtacaggccgtggttctcgttgccg atcagctcgatcttgtccaggatgtccttaaacagcacctcttcctcgtgctgttcggccacgtaccactgcagaaagt tgaaggtggcgtgatccttgctcttgatggcgtggtccacgatgttgttgatgctctcggagatgtgctgctcgtgttc gtaggccttctggaagatctgggtcaggccctcgaacttgtgctcaggggcgctgatgctggtcagctgcacgggcacg ttgttctcgttcaggaagatgatcagcttcttggcgtgctcgtattcctcggcggcgtgatcaaacaggaacaggccag cgccgtccaggctgtgggtgtagcaccagctgctcatgctcatgtacaggttgctgctctgcatctctttgttgacctg ctcgttcagcagcttctcgatgtccttgctgaactgctgtcggacttgagattcgccgctagatctgccgctggcgcac cacactttctgaggcagcaggatgcctctctggtaggtgattgtgccggtcttgccggacttctgcaccatgtagtcca ccacgattctgccgctctggggcaggccgccatcctctgtctggttagggaagccgccgatctgggacacatagtgggt ggtcacgccgttggcgctgctggtgaacttctggggcttgctgtcgccgtacagcttggccatctgagtctcgtcgtcg 2022279441 ctgtggaagccccacacggtgatctggtcctcgccctcggtgcagatgtagggcacctcgatggtcagagggttggtgg cggtcttgttcttgtcgttcttgggcacggcccaggccatggtggcgaaaaagccgttgccgttggtgatgttggggca gcttccgctggtgccgatcttgtaagggccgccaggggcattctcggcgttgatcacgttgtgggtgctcagtctgatg tgctcgtagccccgcagcaggttgggcagctgtctgatcttggtccggtcgtgcatgatggggaagcagccgctggtca caggccgcacttcgtgcaggatggacactctggcgctggggatcttgccggtgcacttaggtctgcccagggccacatc caggtcggtgcagttcaggcacttggggcacagcttgcctcttgtctcggctagcacgccctgaggcagcaggaggttg gacaccaccaggagcagcagcagtctggagcccttctggctgctgcccttgctgtccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="177"> <INSDSeq> <INSDSeq_length>4011</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..4011</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q254">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..4011</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q255">
<INSDQualifier_name>organism</INSDQualifier_name> Nov 2022
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggacagcaagggcagcagccagaagggctccagactgctgctgctcctggtggtgtcca acctcctgctgcctcagggcgtgctagccgtggctcctctgcacctgggcaagtgcaatatcgccggctggattctggg caaccccgagtgcgagagcctgagcacagccagcagctggtcctacatcgtggaaacccctagcagcgacaacggcacc 2022279441
tgtttccccggcgacttcatcgactacgaggaactgcgcgagcagctgagcagcgtgtccagcttcgagagattcgaga tcttccccaagacctccagctggcccaaccacgacagcaacaaaggcgtgaccgccgcctgtcctcacgctggcgccaa gagcttctacaagaacctgatctggctggtcaagaagggcaacagctaccccaagctgagcaagagctacatcaacgac aagggcaaagaggtgctggtcctctggggcatccaccaccctagcacaagcgccgaccagcagagcctgtaccagaacg ccgacgcctacgtgttcgtgggcagctcccggtacagcaagaagttcaagcccgagatcgccatccggcccaaagtgcg ggaccaggaaggccggatgaactactactggaccctggtggaacccggcgacaagatcaccttcgaggccaccggcaat ctggtggtgcccagatacgccttcgccatggaaagaaacgccagcggcgagagccaagtccgacagcagttcagcaagg acatcgagaagctgctgaacgagcaggtcaacaaagagatgcagagcagcaacctgtacatgagcatgtccagctggtg ttacacccacagcctggacggcgctggcctgttcctgtttgatcacgccgccgaggaatacgagcacgccaagaagctg atcatcttcctgaacgagaacaacgtgcccgtgcagctgaccagcatcagcgccccagagcacaagttcgagggcctga cccagatcttccagaaggcctacgaacacgagcagcacatcagcgagagcatcaacaatatcgtggaccacgccatcaa gagcaaggatcacgccaccttcaactttctgcaatggtacgtggccgaacagcacgaggaagaagtgctgtttaaggac atcctggacaagatcgagctgatcggcaacgagaaccacggcctgtacctggccgaccagtacgtgaagggcattgcca agagcagaaagagccggaagcggagatctggcagcggcgctcctgtgaagcagaccctgaacttcgacctgctgaagct ggccggcgacgtggaaagcaaccctgggcccatggactccaagggctcctcccagaaaggatctcggctgctcctcctg ctcgtggtgtctaatctgctgctgccacagggtgtcctggcccaccagatcctggatggcgagaactgcaccctgatcg acgccctgctgggcgaccctcagtgcgacggcttccagaacaagaagtgggacctgttcgtcgagcggagcaaggccta cagcaactgcttcccctacgacgtgcccgactacgccagcctgagaagcctggtggccagcagcggcaccctggaattc aacaacgagagcttcaactggaacggcgtgacccagaacggcaccagctccgcctgcatcagaagaagcaacaacagct tcttctcccggctgaactggctgacccacctgaatttcaagtaccccgccctgaacgtgaccatgcccaacaatgagca gttcgacaagctgtacatctggggagtgcaccaccccgtgaccgacaaggaccagatctttctgtacgcccagcccagc ggccggatcaccgtgtctaccaagagaagccagcaggccgtgatccccaacatcggcttccggcccaggatcagaaaca tccccagccggatcagcatctactggacaatcgtgaagcctggcgacatcctgctgatcaacagcaccggcaacctgat cgcccctcggggctacttcaagatcagaagcggcgcctccggagagtcccaagtgcgccagcagttttccaaggatatt gagaaactcctcaatgaacaggtcaacaaggaaatgcagtcctccaacctctacatgtctatgtcctcttggtgctaca cacactccctggatggggccggactgtttctgttcgaccatgccgctgaagagtatgaacacgccaaaaaactcatcat ttttctcaatgagaacaatgtccctgtccagctcacctccatctccgctcccgagcacaaatttgaaggactcacacag atttttcagaaagcctatgagcatgaacagcacatttccgagtccatcaacaacattgtcgatcatgccattaagtcca aggaccatgctacattcaatttcctccaatggtatgtcgctgagcagcatgaagaggaagtcctgttcaaagatatcct cgataagatcgaactcattgggaatgagaatcacgggctctatctcgccgatcagtatgtgaaagggatcgctaagtcc cggaagtccagaaagcggagaagcggctctggcgccccagtcaaacagacactgaattttgatctgctcaagctcgctg gggacgtcgagtccaatccagggcccatggatagcaaaggctctagccagaaaggcagccgactcctgctcctgctggt cgtcagtaacctgctgctgccccagggcgtcctcgccaagacaagaggcaagctgtgccccgactgcctgaattgcacc gacctggatgtggccctgggcagacctatgtgcgtgggcacaacacctagcgccaaggccagcatcctgcacgaagtgc ggcctgtgaccagcggctgcttccctatcatgcacgaccggaccaagatcaggcagctggccaatctgctgagaggcta cgagaacatccggctgagcacccagaatgtgatcgatgccgagaaggcccctggcggcccttacagactgggcacaagc ggcagctgtcccaacgccaccagcaagagcggctttttcgccacaatggcctgggccgtgcccaaggacaacaacaaga atgccaccaaccctctgaccgtggaagtgccctacatctgcgccgagggcgaggatcagatcacagtgtggggcttcca cagcgacgacaagacccagatgaagaacctgtacggcgacagcaatccccagaagttcacctccagcgccaatggcgtg accacccactacgtgtcccagatcggcggcttccccgatcagacagaggatggcggactgccccagtccggcagaatcg tggtggactacatgatgcagaagcccggcaagaccggcaccatcgtgtaccagagaggcgtgctgctccctcagaaagt gtggtgcgcctctggcagaagctccggagaatctcaagtccgccagcagttttctaaggacatcgaaaagctgctcaat gaacaggtcaacaaagagatgcagtcctctaacctgtatatgagtatgagttcctggtgctatacccactctctcgacg gtgcagggctgttcctcttcgaccacgctgcagaggaatatgaacatgctaagaaactgattatctttctcaacgaaaa Nov 2022 caacgtgccagtccagctcaccagtatctctgcccctgaacataagtttgaggggctcactcagatctttcagaaagct tacgagcacgagcagcatatctctgagtctattaacaacatcgtcgaccatgctatcaaatctaaagaccacgctactt ttaactttctccaatggtacgtcgcagagcagcatgaggaagaggtcctcttcaaggacattctcgacaaaattgaact catcggaaacgaaaaccatgggctctacctggctgatcagtacgtcaagggaatcgcaaaaagccggaagtcttgatga </INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="178"> <INSDSeq> <INSDSeq_length>1335</INSDSeq_length> 2022279441
<INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..1335</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q256">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1335</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q257">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MDSKGSSQKGSRLLLLLVVSNLLLPQGVLAVAPLHLGKCNIAGWILGNPECESLSTASSWS YIVETPSSDNGTCFPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGN SYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVE PGDKITFEATGNLVVPRYAFAMERNASGESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD
HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYV Nov 2022
AEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKSRKRRSGSGAPVKQTLNFDLLKLAGDVESNPGPMDSK GSSQKGSRLLLLLVVSNLLLPQGVLAHQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCFPYDVPDYASL RSLVASSGTLEFNNESFNWNGVTQNGTSSACIRRSNNSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPVT DKDQIFLYAQPSGRITVSTKRSQQAVIPNIGFRPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGASG ESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSI SAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLY LADQYVKGIAKSRKSRKRRSGSGAPVKQTLNFDLLKLAGDVESNPGPMDSKGSSQKGSRLLLLLVVSNLLLPQGVLAKT RGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLANLLRGYENIRLSTQNVIDAE KAPGGPYRLGTSGSCPNATSKSGFFATMAWAVPKDNNKNATNPLTVEVPYICAEGEDQITVWGFHSDDKTQMKNLYGDS NPQKFTSSANGVTTHYVSQIGGFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRSSGESQVR 2022279441
QQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEH KFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQY VKGIAKSRKS</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="179"> <INSDSeq> <INSDSeq_length>4011</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..4011</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q258">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..4011</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q259">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier>
</INSDFeature_quals> Nov 2022
</INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcaagacttccggctttttgcgattcccttgacgtactgatcagccaggtagagccca tggttttcgtttccgatgagttcaattttgtcgagaatgtccttgaagaggacctcttcctcatgctgctctgcgacgt accattggagaaagttaaaagtagcgtggtctttagatttgatagcatggtcgacgatgttgttaatagactcagagat atgctgctcgtgctcgtaagctttctgaaagatctgagtgagcccctcaaacttatgttcaggggcagagatactggtg agctggactggcacgttgttttcgttgagaaagataatcagtttcttagcatgttcatattcctctgcagcgtggtcga agaggaacagccctgcaccgtcgagagagtgggtatagcaccaggaactcatactcatatacaggttagaggactgcat ctctttgttgacctgttcattgagcagcttttcgatgtccttagaaaactgctggcggacttgagattctccggagctt 2022279441
ctgccagaggcgcaccacactttctgagggagcagcacgcctctctggtacacgatggtgccggtcttgccgggcttct gcatcatgtagtccaccacgattctgccggactggggcagtccgccatcctctgtctgatcggggaagccgccgatctg ggacacgtagtgggtggtcacgccattggcgctggaggtgaacttctggggattgctgtcgccgtacaggttcttcatc tgggtcttgtcgtcgctgtggaagccccacactgtgatctgatcctcgccctcggcgcagatgtagggcacttccacgg tcagagggttggtggcattcttgttgttgtccttgggcacggcccaggccattgtggcgaaaaagccgctcttgctggt ggcgttgggacagctgccgcttgtgcccagtctgtaagggccgccaggggccttctcggcatcgatcacattctgggtg ctcagccggatgttctcgtagcctctcagcagattggccagctgcctgatcttggtccggtcgtgcatgatagggaagc agccgctggtcacaggccgcacttcgtgcaggatgctggccttggcgctaggtgttgtgcccacgcacataggtctgcc cagggccacatccaggtcggtgcaattcaggcagtcggggcacagcttgcctcttgtcttggcgaggacgccctggggc agcagcaggttactgacgaccagcaggagcaggagtcggctgcctttctggctagagcctttgctatccatgggccctg gattggactcgacgtccccagcgagcttgagcagatcaaaattcagtgtctgtttgactggggcgccagagccgcttct ccgctttctggacttccgggacttagcgatccctttcacatactgatcggcgagatagagcccgtgattctcattccca atgagttcgatcttatcgaggatatctttgaacaggacttcctcttcatgctgctcagcgacataccattggaggaaat tgaatgtagcatggtccttggacttaatggcatgatcgacaatgttgttgatggactcggaaatgtgctgttcatgctc ataggctttctgaaaaatctgtgtgagtccttcaaatttgtgctcgggagcggagatggaggtgagctggacagggaca ttgttctcattgagaaaaatgatgagttttttggcgtgttcatactcttcagcggcatggtcgaacagaaacagtccgg ccccatccagggagtgtgtgtagcaccaagaggacatagacatgtagaggttggaggactgcatttccttgttgacctg ttcattgaggagtttctcaatatccttggaaaactgctggcgcacttgggactctccggaggcgccgcttctgatcttg aagtagccccgaggggcgatcaggttgccggtgctgttgatcagcaggatgtcgccaggcttcacgattgtccagtaga tgctgatccggctggggatgtttctgatcctgggccggaagccgatgttggggatcacggcctgctggcttctcttggt agacacggtgatccggccgctgggctgggcgtacagaaagatctggtccttgtcggtcacggggtggtgcactccccag atgtacagcttgtcgaactgctcattgttgggcatggtcacgttcagggcggggtacttgaaattcaggtgggtcagcc agttcagccgggagaagaagctgttgttgcttcttctgatgcaggcggagctggtgccgttctgggtcacgccgttcca gttgaagctctcgttgttgaattccagggtgccgctgctggccaccaggcttctcaggctggcgtagtcgggcacgtcg taggggaagcagttgctgtaggccttgctccgctcgacgaacaggtcccacttcttgttctggaagccgtcgcactgag ggtcgcccagcagggcgtcgatcagggtgcagttctcgccatccaggatctggtgggccaggacaccctgtggcagcag cagattagacaccacgagcaggaggagcagccgagatcctttctgggaggagcccttggagtccatgggcccagggttg ctttccacgtcgccggccagcttcagcaggtcgaagttcagggtctgcttcacaggagcgccgctgccagatctccgct tccggctctttctgctcttggcaatgcccttcacgtactggtcggccaggtacaggccgtggttctcgttgccgatcag ctcgatcttgtccaggatgtccttaaacagcacttcttcctcgtgctgttcggccacgtaccattgcagaaagttgaag gtggcgtgatccttgctcttgatggcgtggtccacgatattgttgatgctctcgctgatgtgctgctcgtgttcgtagg ccttctggaagatctgggtcaggccctcgaacttgtgctctggggcgctgatgctggtcagctgcacgggcacgttgtt ctcgttcaggaagatgatcagcttcttggcgtgctcgtattcctcggcggcgtgatcaaacaggaacaggccagcgccg tccaggctgtgggtgtaacaccagctggacatgctcatgtacaggttgctgctctgcatctctttgttgacctgctcgt tcagcagcttctcgatgtccttgctgaactgctgtcggacttggctctcgccgctggcgtttctttccatggcgaaggc gtatctgggcaccaccagattgccggtggcctcgaaggtgatcttgtcgccgggttccaccagggtccagtagtagttc atccggccttcctggtcccgcactttgggccggatggcgatctcgggcttgaacttcttgctgtaccgggagctgccca cgaacacgtaggcgtcggcgttctggtacaggctctgctggtcggcgcttgtgctagggtggtggatgccccagaggac cagcacctctttgcccttgtcgttgatgtagctcttgctcagcttggggtagctgttgcccttcttgaccagccagatc aggttcttgtagaagctcttggcgccagcgtgaggacaggcggcggtcacgcctttgttgctgtcgtggttgggccagc tggaggtcttggggaagatctcgaatctctcgaagctggacacgctgctcagctgctcgcgcagttcctcgtagtcgat gaagtcgccggggaaacaggtgccgttgtcgctgctaggggtttccacgatgtaggaccagctgctggctgtgctcagg ctctcgcactcggggttgcccagaatccagccggcgatattgcacttgcccaggtgcagaggagccacggctagcacgc cctgaggcagcaggaggttggacaccaccaggagcagcagcagtctggagcccttctggctgctgcccttgctgtccat Nov 2022
</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="180"> <INSDSeq> <INSDSeq_length>1518</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature> 2022279441
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1518</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q260">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1518</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q261">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atgcccatgggcagcctgcagcccctggccaccctgtacctgctgggcatgctggtggcta gcgtgctggccatggagttcctgaagaggagcttcgcccctctgaccgagaagcagtggcaggagatcgacaacagggc cagggagatcttcaagacccagctgtacggcaggaagttcgtggacgtggagggcccctacggctgggagtacgccgcc caccccctgggcgaggtggaggtgctgagcgacgagaacgaggtggtgaagtggggcctgaggaagagcctgcccctga tcgagctgagggccaccttcaccctggacctgtgggagctggacaacctggagaggggcaagcccaacgtggacctgag cagcctggaggagaccgtgaggaaggtggccgagttcgaggacgaggtgatcttcaggggctgcgagaagagcggcgtg aagggcctgctgagcttcgaggagaggaagatcgagtgcggcagcacccccaaggacctgctggaggccatcgtgaggg ccctgagcatcttcagcaaggacggcatcgagggcccctacaccctggtgatcaacaccgacaggtggatcaacttcct gaaggaggaggccggccactaccccctggagaagagggtggaggagtgcctgaggggcggcaagatcatcaccaccccc Nov 2022 aggatcgaggacgccctggtggtgagcgagaggggcggcgacttcaagctgatcctgggccaggacctgagcatcggct acgaggacagggagaaggacgccgtgaggctgttcatcaccgagaccttcaccttccaggtggtgaaccccgaggccct gatcctgctgaagtccggaattgcccctctgcagctgggcaattgttctgtggccggatggattctgggcaaccccgag tgtgagctgctgatttctaaggagagctggagctacatcgtggagacccccaatcctgagaatggcacctgctaccctg gctacttcgccgattacgaggagctgcgcgagcagctgtctagcgtgtccagcttcgagagattcgagatcttccccaa ggagtccagctggcctaatcacacagtgacaggcgtgtctgccagctgtagccacaacggcaaaagcagcttctaccgg aacctgctgtggctgacaggcaagaatggcctgtaccccaacctgagcaagagctacgtgaacaacaaggaaaaggaag tgctggtgctgtggggagtgcaccaccctcccaacatcggaaatcagcgggccctgtaccacacagagaacgcctatgt gagcgtggtgtccagccactacagcagaagattcacccccgagatcgccaagagacccaaagtgagagaccaggagggc cggatcaattactactggaccctgctggagcctggcgataccatcatcttcgaggccaacggcaatctgatcgcccctt 2022279441 ggtatgcctttgccctgagcagaggcgcctgatga</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="181"> <INSDSeq> <INSDSeq_length>504</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..504</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q262">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..504</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q263">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature>
</INSDSeq_feature‐table> Nov 2022
<INSDSeq_sequence>MPMGSLQPLATLYLLGMLVASVLAMEFLKRSFAPLTEKQWQEIDNRAREIFKTQLYGRKFV DVEGPYGWEYAAHPLGEVEVLSDENEVVKWGLRKSLPLIELRATFTLDLWELDNLERGKPNVDLSSLEETVRKVAEFED EVIFRGCEKSGVKGLLSFEERKIECGSTPKDLLEAIVRALSIFSKDGIEGPYTLVINTDRWINFLKEEAGHYPLEKRVE ECLRGGKIITTPRIEDALVVSERGGDFKLILGQDLSIGYEDREKDAVRLFITETFTFQVVNPEALILLKSGIAPLQLGN CSVAGWILGNPECELLISKESWSYIVETPNPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSA SCSHNGKSSFYRNLLWLTGKNGLYPNLSKSYVNNKEKEVLVLWGVHHPPNIGNQRALYHTENAYVSVVSSHYSRRFTPE IAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGA</INSDSeq_sequence> </INSDSeq> </SequenceData> 2022279441
<SequenceData sequenceIDNumber="182"> <INSDSeq> <INSDSeq_length>1518</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1518</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q264">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1518</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q265">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcaggcgcctctgctcagggcaaaggcataccaaggggcgatcagattgccgttggcc tcgaagatgatggtatcgccaggctccagcagggtccagtagtaattgatccggccctcctggtctctcactttgggtc Nov 2022 tcttggcgatctcgggggtgaatcttctgctgtagtggctggacaccacgctcacataggcgttctctgtgtggtacag ggcccgctgatttccgatgttgggagggtggtgcactccccacagcaccagcacttccttttccttgttgttcacgtag ctcttgctcaggttggggtacaggccattcttgcctgtcagccacagcaggttccggtagaagctgcttttgccgttgt ggctacagctggcagacacgcctgtcactgtgtgattaggccagctggactccttggggaagatctcgaatctctcgaa gctggacacgctagacagctgctcgcgcagctcctcgtaatcggcgaagtagccagggtagcaggtgccattctcagga ttgggggtctccacgatgtagctccagctctccttagaaatcagcagctcacactcggggttgcccagaatccatccgg ccacagaacaattgcccagctgcagaggggcaattccggacttcagcaggatcagggcctcggggttcaccacctggaa ggtgaaggtctcggtgatgaacagcctcacggcgtccttctccctgtcctcgtagccgatgctcaggtcctggcccagg atcagcttgaagtcgccgcccctctcgctcaccaccagggcgtcctcgatcctgggggtggtgatgatcttgccgcccc tcaggcactcctccaccctcttctccagggggtagtggccggcctcctccttcaggaagttgatccacctgtcggtgtt 2022279441 gatcaccagggtgtaggggccctcgatgccgtccttgctgaagatgctcagggccctcacgatggcctccagcaggtcc ttgggggtgctgccgcactcgatcttcctctcctcgaagctcagcaggcccttcacgccgctcttctcgcagcccctga agatcacctcgtcctcgaactcggccaccttcctcacggtctcctccaggctgctcaggtccacgttgggcttgcccct ctccaggttgtccagctcccacaggtccagggtgaaggtggccctcagctcgatcaggggcaggctcttcctcaggccc cacttcaccacctcgttctcgtcgctcagcacctccacctcgcccagggggtgggcggcgtactcccagccgtaggggc cctccacgtccacgaacttcctgccgtacagctgggtcttgaagatctccctggccctgttgtcgatctcctgccactg cttctcggtcagaggggcgaagctcctcttcaggaactccatggccagcacgctagccaccagcatgcccagcaggtac agggtggccaggggctgcaggctgcccatgggcat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="183"> <INSDSeq> <INSDSeq_length>1521</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1521</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q266">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1521</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q267">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atgcccatgggcagcctgcagcccctggccaccctgtacctgctgggcatgctggtggcta gcgtgctggccatggagttcctgaagaggagcttcgcccctctgaccgagaagcagtggcaggagatcgacaacagggc 2022279441
cagggagatcttcaagacccagctgtacggcaggaagttcgtggacgtggagggcccctacggctgggagtacgccgcc caccccctgggcgaggtggaggtgctgagcgacgagaacgaggtggtgaagtggggcctgaggaagagcctgcccctga tcgagctgagggccaccttcaccctggacctgtgggagctggacaacctggagaggggcaagcccaacgtggacctgag cagcctggaggagaccgtgaggaaggtggccgagttcgaggacgaggtgatcttcaggggctgcgagaagagcggcgtg aagggcctgctgagcttcgaggagaggaagatcgagtgcggcagcacccccaaggacctgctggaggccatcgtgaggg ccctgagcatcttcagcaaggacggcatcgagggcccctacaccctggtgatcaacaccgacaggtggatcaacttcct gaaggaggaggccggccactaccccctggagaagagggtggaggagtgcctgaggggcggcaagatcatcaccaccccc aggatcgaggacgccctggtggtgagcgagaggggcggcgacttcaagctgatcctgggccaggacctgagcatcggct acgaggacagggagaaggacgccgtgaggctgttcatcaccgagaccttcaccttccaggtggtgaaccccgaggccct gatcctgctgaagtccggagtggcccccctgcacctgggcaagtgcaacatcgccggctggattctgggcaaccccgag tgcgagagcctgagcaccgccagcagctggagctacatcgtggagacccccagcagcgacaacggcacctgctaccccg gcgacttcatcgactacgaggagctgcgggagcagctgagcagcgtgagcagcttcgagcggttcgagatcttccccaa gaccagcagctggcccaaccacgacagcaacaagggcgtgaccgccgcctgcccccacgccggcgccaagagcttctac aagaacctgatctggctggtgaagaagggcaacagctaccccaagctgagcaagagctacatcaacgacaagggcaagg aggtgctggtgctgtggggcatccaccaccccagcaccagcgccgaccagcagagcctgtaccagaacgccgacaccta cgtgttcgtgggcagcagccggtacagcaagaagttcaagcccgagatcgccatccggcccaaggtgcgggaccaggag ggccggatgaactactactggaccctggtggagcccggcgacaagatcaccttcgaggccaccggcaacctggtggtgc cccggtacgccttcgccatggagcggaacgcctgatga</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="184"> <INSDSeq> <INSDSeq_length>505</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..505</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q268">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..505</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q269"> 2022279441
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MPMGSLQPLATLYLLGMLVASVLAMEFLKRSFAPLTEKQWQEIDNRAREIFKTQLYGRKFV DVEGPYGWEYAAHPLGEVEVLSDENEVVKWGLRKSLPLIELRATFTLDLWELDNLERGKPNVDLSSLEETVRKVAEFED EVIFRGCEKSGVKGLLSFEERKIECGSTPKDLLEAIVRALSIFSKDGIEGPYTLVINTDRWINFLKEEAGHYPLEKRVE ECLRGGKIITTPRIEDALVVSERGGDFKLILGQDLSIGYEDREKDAVRLFITETFTFQVVNPEALILLKSGVAPLHLGK CNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVT AACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADTYVFVGSSRYSKKFKP EIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNA</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="185"> <INSDSeq> <INSDSeq_length>1521</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..1521</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q270">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1521</INSDFeature_location> <INSDFeature_quals>
<INSDQualifier> Nov 2022
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q271">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> 2022279441
</INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>tcatcaggcgttccgctccatggcgaaggcgtaccggggcaccaccaggttgccggtggcc tcgaaggtgatcttgtcgccgggctccaccagggtccagtagtagttcatccggccctcctggtcccgcaccttgggcc ggatggcgatctcgggcttgaacttcttgctgtaccggctgctgcccacgaacacgtaggtgtcggcgttctggtacag gctctgctggtcggcgctggtgctggggtggtggatgccccacagcaccagcacctccttgcccttgtcgttgatgtag ctcttgctcagcttggggtagctgttgcccttcttcaccagccagatcaggttcttgtagaagctcttggcgccggcgt gggggcaggcggcggtcacgcccttgttgctgtcgtggttgggccagctgctggtcttggggaagatctcgaaccgctc gaagctgctcacgctgctcagctgctcccgcagctcctcgtagtcgatgaagtcgccggggtagcaggtgccgttgtcg ctgctgggggtctccacgatgtagctccagctgctggcggtgctcaggctctcgcactcggggttgcccagaatccagc cggcgatgttgcacttgcccaggtgcaggggggccactccggacttcagcaggatcagggcctcggggttcaccacctg gaaggtgaaggtctcggtgatgaacagcctcacggcgtccttctccctgtcctcgtagccgatgctcaggtcctggccc aggatcagcttgaagtcgccgcccctctcgctcaccaccagggcgtcctcgatcctgggggtggtgatgatcttgccgc ccctcaggcactcctccaccctcttctccagggggtagtggccggcctcctccttcaggaagttgatccacctgtcggt gttgatcaccagggtgtaggggccctcgatgccgtccttgctgaagatgctcagggccctcacgatggcctccagcagg tccttgggggtgctgccgcactcgatcttcctctcctcgaagctcagcaggcccttcacgccgctcttctcgcagcccc tgaagatcacctcgtcctcgaactcggccaccttcctcacggtctcctccaggctgctcaggtccacgttgggcttgcc cctctccaggttgtccagctcccacaggtccagggtgaaggtggccctcagctcgatcaggggcaggctcttcctcagg ccccacttcaccacctcgttctcgtcgctcagcacctccacctcgcccagggggtgggcggcgtactcccagccgtagg ggccctccacgtccacgaacttcctgccgtacagctgggtcttgaagatctccctggccctgttgtcgatctcctgcca ctgcttctcggtcagaggggcgaagctcctcttcaggaactccatggccagcacgctagccaccagcatgcccagcagg tacagggtggccaggggctgcaggctgcccatgggcat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="186"> <INSDSeq> <INSDSeq_length>4359</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..4359</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q272">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> Nov 2022
</INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..4359</INSDFeature_location> <INSDFeature_quals> <INSDQualifier> 2022279441
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q273">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggagttcatcccgacgcaaactttctataacagaaggtaccaaccccgaccctgggccc cacgccctacaattcaagtaattagacctagaccacgtccacagaggcaggctgggcaactcgcccagctgatctccgc agtcaacaaattgaccatgcgcgcggtacctcaacagaagcctcgcagaaatcggaaaaacaagaagcaaaggcagaag aagcaggcgccgcaaaacgacccaaagcaaaagaagcaaccaccacaaaagaagccggctcaaaagaagaagaaaccag gccgtagggagagaatgtgcatgaaaattgaaaatgattgcatcttcgaagtcaagcatgaaggcaaagtgatgggcta cgcatgcctggtgggggataaagtaatgaaaccagcacatgtgaagggaactatcgacaatgccgatctggctaaactg gcctttaagcggtcgtctaaatacgatcttgaatgtgcacagataccggtgcacatgaagtctgatgcctcgaagttta cccacgagaaacccgaggggtactataactggcatcacggagcagtgcagtattcaggaggccggttcactatcccgac gggtgcaggcaagccgggagacagcggcagaccgatcttcgacaacaaaggacgggtggtggccatcgtcctaggaggg gccaacgaaggtgcccgcacggccctctccgtggtgacgtggaacaaagacatcgtcacaaaaattacccctgagggag ccgaagagtggagcctcgccctcccggtcttgtgcctgttggcaaacactacattcccctgctctcagccgccttgcac accctgctgctacgaaaaggaaccggaaagcaccttgcgcatgcttgaggacaacgtgatgagacccggatactaccag ctactaaaagcatcgctgacttgccgccaaagacgcctgcagctggggaattgttctgtggccggatggattctgggca accccgagtgtgagctgctgatttctaaggagagctggagctacatcgtggagacccccaatcctgagaatggcacctg cttccctggctacttcgccgattacgaggagctgcgcgagcagctgtctagcgtgtccagcttcgagagattcgagatc ttccccaaggagtccagctggcctaatcacacagtgacaggcgtgtctgccagctgtagccacaacggcaaaagcagct tctaccggaacctgctgtggctgacaggcaagaatggcctgtaccccaacctgagcaagagctacgtgaacaacaagga aaaggaagtgctggtgctgtggggagtgcaccaccctcccaacatcggaaatcagcgggccctgtaccacacagagaac gcctatgtgagcgtggtgtccagccactacagcagaagattcacccccgagatcgccaagagacccaaagtgagagacc aggagggccggatcaattactactggaccctgctggagcctggcgataccatcatcttcgaggccaacggcaatctgat cgccccttggtatgcctttgccctgagcagaggcgccaattttaatgtctataaagccacaagaccatatctagctcat tgtcctgactgcggagaagggcattcgtgccacagccctatcgcattggagcgcatcagaaatgaagcaacggacggaa cgctgaaaatccaggtctctttgcagatcgggataaagacagatgacagccacgattggaccaagctgcgctatatgga tagccatacgccagcggacgcggagcgagccggattgcttgtaaggacttcagcaccgtgcacgatcaccgggaccatg ggacactttattctcgcccgatgcccgaaaggagagacgctgacagtgggatttacggacagcagaaagatcagccaca catgcacacacccgttccatcatgaaccacctgtgataggtagggagaggttccactctcgaccacaacatggtaaaga gttaccttgcagcacgtacgtgcagagcaccgctgccactgctgaggagatagaggtgcatatgcccccagatactcct gaccgcacgctgatgacgcagcagtctggcaacgtgaagatcacagttaatgggcagacggtgcggtacaagtgcaact gcggtggctcaaacgagggactgacaaccacagacaaagtgatcaataactgcaaaattgatcagtgccatgctgcagt Nov 2022 cactaatcacaagaattggcaatacaactcccctttagtcccgcgcaacgctgaactcggggaccgtaaaggaaagatc cacatcccattcccattggcaaacgtgacttgcagagtgccaaaagcaagaaaccctacagtaacttacggaaaaaacc aagtcaccatgctgctgtatcctgaccatccgacactcttgtcttaccgtaacatgggacaggaaccaaattaccacga ggagtgggtgacacacaagaaggaggttaccttgaccgtgcctactgagggtctggaggtcacttggggcaacaacgaa ccatacaagtactggccgcagatgtctacgaacggtactgctcatggtcacccacatgagataatcttgtactattatg agctgtaccccactatgactgtagtcattgtgtcggtggcctcgttcgtgcttctgtcgatggtgggcacagcagtggg aatgtgtgtgtgcgcacggcgcagatgcattacaccatatgaattaacaccaggagccactgttcccttcctgctcagc ctgctatgctgcgtcagaacgaccaaggcggccacatattacgaggctgcggcatatctatggaacgaacagcagcccc tgttctggttgcaggctcttatcccgctggccgccttgatcgtcctgtgcaactgtctgaaactcttgccatgctgctg taagaccctggcttttttagccgtaatgagcatcggtgcccacactgtgagcgcgtacgaacacgtaacagtgatcccg 2022279441 aacacggtgggagtaccgtataagactcttgtcaacagaccgggttacagccccatggtgttggagatggagctacaat cagtcaccttggaaccaacactgtcacttgactacatcacgtgcgagtacaaaactgtcatcccctccccgtacgtgaa gtgctgtggtacagcagagtgcaaggacaagagcctaccagactacagctgcaaggtctttactggagtctacccattt atgtggggcggcgcctactgcttttgcgacgccgaaaatacgcaattgagcgaggcacatgtagagaaatctgaatctt gcaaaacagagtttgcatcggcctacagagcccacaccgcatcggcgtcggcgaagctccgcgtcctttaccaaggaaa caacattaccgtagctgcctacgctaacggtgaccatgccgtcacagtaaaggacgccaagtttgtcgtgggcccaatg tcctccgcctggacaccttttgacaacaaaatcgtggtgtacaaaggcgacgtctacaacatggactacccaccttttg gcgcaggaagaccaggacaatttggtgacattcaaagtcgtacaccggaaagtaaagacgtttatgccaacactcagtt ggtactacagaggccagcagcaggcacggtacatgtaccatactctcaggcaccatctggcttcaagtattggctgaag gaacgaggagcatcgctacagcacacggcaccgttcggttgccagattgcgacaaacccggtaagagctgtaaattgcg ctgtggggaacataccaatttccatcgacataccggatgcggcctttactagggttgtcgatgcaccctctgtaacgga catgtcatgcgaagtaccagcctgcactcactcctccgactttgggggcgtcgccatcatcaaatacacagctagcaag aaaggtaaatgtgcagtacattcgatgaccaacgccgttaccattcgagaagccgacgtagaagtagaggggaactccc agctgcaaatatccttctcaacagccctggcaagcgccgagtttcgcgtgcaagtgtgctccacacaagtacactgcgc agccgcatgccaccctccaaaggaccacatagtcaattacccagcatcacacaccacccttggggtccaggatatatcc acaacggcaatgtcttgggtgcagaagattacgggaggagtaggattaattgttgctgttgctgccttaattttaattg tggtgctatgcgtgtcgtttagcaggcactaa</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="187"> <INSDSeq> <INSDSeq_length>1452</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..1452</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q274">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1452</INSDFeature_location> Nov 2022
<INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q275">
<INSDQualifier_name>organism</INSDQualifier_name> 2022279441
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>MEFIPTQTFYNRRYQPRPWAPRPTIQVIRPRPRPQRQAGQLAQLISAVNKLTMRAVPQQKP RRNRKNKKQRQKKQAPQNDPKQKKQPPQKKPAQKKKKPGRRERMCMKIENDCIFEVKHEGKVMGYACLVGDKVMKPAHV KGTIDNADLAKLAFKRSSKYDLECAQIPVHMKSDASKFTHEKPEGYYNWHHGAVQYSGGRFTIPTGAGKPGDSGRPIFD NKGRVVAIVLGGANEGARTALSVVTWNKDIVTKITPEGAEEWSLALPVLCLLANTTFPCSQPPCTPCCYEKEPESTLRM LEDNVMRPGYYQLLKASLTCRQRRLQLGNCSVAGWILGNPECELLISKESWSYIVETPNPENGTCFPGYFADYEELREQ LSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPNLSKSYVNNKEKEVLVLWGVHHPPN IGNQRALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGANF NVYKATRPYLAHCPDCGEGHSCHSPIALERIRNEATDGTLKIQVSLQIGIKTDDSHDWTKLRYMDSHTPADAERAGLLV RTSAPCTITGTMGHFILARCPKGETLTVGFTDSRKISHTCTHPFHHEPPVIGRERFHSRPQHGKELPCSTYVQSTAATA EEIEVHMPPDTPDRTLMTQQSGNVKITVNGQTVRYKCNCGGSNEGLTTTDKVINNCKIDQCHAAVTNHKNWQYNSPLVP RNAELGDRKGKIHIPFPLANVTCRVPKARNPTVTYGKNQVTMLLYPDHPTLLSYRNMGQEPNYHEEWVTHKKEVTLTVP TEGLEVTWGNNEPYKYWPQMSTNGTAHGHPHEIILYYYELYPTMTVVIVSVASFVLLSMVGTAVGMCVCARRRCITPYE LTPGATVPFLLSLLCCVRTTKAATYYEAAAYLWNEQQPLFWLQALIPLAALIVLCNCLKLLPCCCKTLAFLAVMSIGAH TVSAYEHVTVIPNTVGVPYKTLVNRPGYSPMVLEMELQSVTLEPTLSLDYITCEYKTVIPSPYVKCCGTAECKDKSLPD YSCKVFTGVYPFMWGGAYCFCDAENTQLSEAHVEKSESCKTEFASAYRAHTASASAKLRVLYQGNNITVAAYANGDHAV TVKDAKFVVGPMSSAWTPFDNKIVVYKGDVYNMDYPPFGAGRPGQFGDIQSRTPESKDVYANTQLVLQRPAAGTVHVPY SQAPSGFKYWLKERGASLQHTAPFGCQIATNPVRAVNCAVGNIPISIDIPDAAFTRVVDAPSVTDMSCEVPACTHSSDF GGVAIIKYTASKKGKCAVHSMTNAVTIREADVEVEGNSQLQISFSTALASAEFRVQVCSTQVHCAAACHPPKDHIVNYP ASHTTLGVQDISTTAMSWVQKITGGVGLIVAVAALILIVVLCVSFSRH</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="188"> <INSDSeq> <INSDSeq_length>4359</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..4359</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q276">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..4359</INSDFeature_location> <INSDFeature_quals> 2022279441
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q277">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ttagtgcctgctaaacgacacgcatagcaccacaattaaaattaaggcagcaacagcaaca attaatcctactcctcccgtaatcttctgcacccaagacattgccgttgtggatatatcctggaccccaagggtggtgt gtgatgctgggtaattgactatgtggtcctttggagggtggcatgcggctgcgcagtgtacttgtgtggagcacacttg cacgcgaaactcggcgcttgccagggctgttgagaaggatatttgcagctgggagttcccctctacttctacgtcggct tctcgaatggtaacggcgttggtcatcgaatgtactgcacatttacctttcttgctagctgtgtatttgatgatggcga cgcccccaaagtcggaggagtgagtgcaggctggtacttcgcatgacatgtccgttacagagggtgcatcgacaaccct agtaaaggccgcatccggtatgtcgatggaaattggtatgttccccacagcgcaatttacagctcttaccgggtttgtc gcaatctggcaaccgaacggtgccgtgtgctgtagcgatgctcctcgttccttcagccaatacttgaagccagatggtg cctgagagtatggtacatgtaccgtgcctgctgctggcctctgtagtaccaactgagtgttggcataaacgtctttact ttccggtgtacgactttgaatgtcaccaaattgtcctggtcttcctgcgccaaaaggtgggtagtccatgttgtagacg tcgcctttgtacaccacgattttgttgtcaaaaggtgtccaggcggaggacattgggcccacgacaaacttggcgtcct ttactgtgacggcatggtcaccgttagcgtaggcagctacggtaatgttgtttccttggtaaaggacgcggagcttcgc cgacgccgatgcggtgtgggctctgtaggccgatgcaaactctgttttgcaagattcagatttctctacatgtgcctcg ctcaattgcgtattttcggcgtcgcaaaagcagtaggcgccgccccacataaatgggtagactccagtaaagaccttgc agctgtagtctggtaggctcttgtccttgcactctgctgtaccacagcacttcacgtacggggaggggatgacagtttt gtactcgcacgtgatgtagtcaagtgacagtgttggttccaaggtgactgattgtagctccatctccaacaccatgggg ctgtaacccggtctgttgacaagagtcttatacggtactcccaccgtgttcgggatcactgttacgtgttcgtacgcgc tcacagtgtgggcaccgatgctcattacggctaaaaaagccagggtcttacagcagcatggcaagagtttcagacagtt gcacaggacgatcaaggcggccagcgggataagagcctgcaaccagaacaggggctgctgttcgttccatagatatgcc gcagcctcgtaatatgtggccgccttggtcgttctgacgcagcatagcaggctgagcaggaagggaacagtggctcctg gtgttaattcatatggtgtaatgcatctgcgccgtgcgcacacacacattcccactgctgtgcccaccatcgacagaag cacgaacgaggccaccgacacaatgactacagtcatagtggggtacagctcataatagtacaagattatctcatgtggg tgaccatgagcagtaccgttcgtagacatctgcggccagtacttgtatggttcgttgttgccccaagtgacctccagac cctcagtaggcacggtcaaggtaacctccttcttgtgtgtcacccactcctcgtggtaatttggttcctgtcccatgtt acggtaagacaagagtgtcggatggtcaggatacagcagcatggtgacttggttttttccgtaagttactgtagggttt cttgcttttggcactctgcaagtcacgtttgccaatgggaatgggatgtggatctttcctttacggtccccgagttcag cgttgcgcgggactaaaggggagttgtattgccaattcttgtgattagtgactgcagcatggcactgatcaattttgca gttattgatcactttgtctgtggttgtcagtccctcgtttgagccaccgcagttgcacttgtaccgcaccgtctgccca Nov 2022 ttaactgtgatcttcacgttgccagactgctgcgtcatcagcgtgcggtcaggagtatctgggggcatatgcacctcta tctcctcagcagtggcagcggtgctctgcacgtacgtgctgcaaggtaactctttaccatgttgtggtcgagagtggaa cctctccctacctatcacaggtggttcatgatggaacgggtgtgtgcatgtgtggctgatctttctgctgtccgtaaat cccactgtcagcgtctctcctttcgggcatcgggcgagaataaagtgtcccatggtcccggtgatcgtgcacggtgctg aagtccttacaagcaatccggctcgctccgcgtccgctggcgtatggctatccatatagcgcagcttggtccaatcgtg gctgtcatctgtctttatcccgatctgcaaagagacctggattttcagcgttccgtccgttgcttcatttctgatgcgc tccaatgcgatagggctgtggcacgaatgcccttctccgcagtcaggacaatgagctagatatggtcttgtggctttat agacattaaaattggcgcctctgctcagggcaaaggcataccaaggggcgatcagattgccgttggcctcgaagatgat ggtatcgccaggctccagcagggtccagtagtaattgatccggccctcctggtctctcactttgggtctcttggcgatc tcgggggtgaatcttctgctgtagtggctggacaccacgctcacataggcgttctctgtgtggtacagggcccgctgat 2022279441 ttccgatgttgggagggtggtgcactccccacagcaccagcacttccttttccttgttgttcacgtagctcttgctcag gttggggtacaggccattcttgcctgtcagccacagcaggttccggtagaagctgcttttgccgttgtggctacagctg gcagacacgcctgtcactgtgtgattaggccagctggactccttggggaagatctcgaatctctcgaagctggacacgc tagacagctgctcgcgcagctcctcgtaatcggcgaagtagccagggaagcaggtgccattctcaggattgggggtctc cacgatgtagctccagctctccttagaaatcagcagctcacactcggggttgcccagaatccatccggccacagaacaa ttccccagctgcaggcgtctttggcggcaagtcagcgatgcttttagtagctggtagtatccgggtctcatcacgttgt cctcaagcatgcgcaaggtgctttccggttccttttcgtagcagcagggtgtgcaaggcggctgagagcaggggaatgt agtgtttgccaacaggcacaagaccgggagggcgaggctccactcttcggctccctcaggggtaatttttgtgacgatg tctttgttccacgtcaccacggagagggccgtgcgggcaccttcgttggcccctcctaggacgatggccaccacccgtc ctttgttgtcgaagatcggtctgccgctgtctcccggcttgcctgcacccgtcgggatagtgaaccggcctcctgaata ctgcactgctccgtgatgccagttatagtacccctcgggtttctcgtgggtaaacttcgaggcatcagacttcatgtgc accggtatctgtgcacattcaagatcgtatttagacgaccgcttaaaggccagtttagccagatcggcattgtcgatag ttcccttcacatgtgctggtttcattactttatcccccaccaggcatgcgtagcccatcactttgccttcatgcttgac ttcgaagatgcaatcattttcaattttcatgcacattctctccctacggcctggtttcttcttcttttgagccggcttc ttttgtggtggttgcttcttttgctttgggtcgttttgcggcgcctgcttcttctgcctttgcttcttgtttttccgat ttctgcgaggcttctgttgaggtaccgcgcgcatggtcaatttgttgactgcggagatcagctgggcgagttgcccagc ctgcctctgtggacgtggtctaggtctaattacttgaattgtagggcgtggggcccagggtcggggttggtaccttctg ttatagaaagtttgcgtcgggatgaactccat</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="189"> <INSDSeq> <INSDSeq_length>4362</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..4362</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q278">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..4362</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q279"> 2022279441
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>atggagttcatcccgacgcaaactttctataacagaaggtaccaaccccgaccctgggccc cacgccctacaattcaagtaattagacctagaccacgtccacagaggcaggctgggcaactcgcccagctgatctccgc agtcaacaaattgaccatgcgcgcggtacctcaacagaagcctcgcagaaatcggaaaaacaagaagcaaaggcagaag aagcaggcgccgcaaaacgacccaaagcaaaagaagcaaccaccacaaaagaagccggctcaaaagaagaagaaaccag gccgtagggagagaatgtgcatgaaaattgaaaatgattgcatcttcgaagtcaagcatgaaggcaaagtgatgggcta cgcatgcctggtgggggataaagtaatgaaaccagcacatgtgaagggaactatcgacaatgccgatctggctaaactg gcctttaagcggtcgtctaaatacgatcttgaatgtgcacagataccggtgcacatgaagtctgatgcctcgaagttta cccacgagaaacccgaggggtactataactggcatcacggagcagtgcagtattcaggaggccggttcactatcccgac gggtgcaggcaagccgggagacagcggcagaccgatcttcgacaacaaaggacgggtggtggccatcgtcctaggaggg gccaacgaaggtgcccgcacggccctctccgtggtgacgtggaacaaagacatcgtcacaaaaattacccctgagggag ccgaagagtggagcctcgccctcccggtcttgtgcctgttggcaaacactacattcccctgctctcagccgccttgcac accctgctgctacgaaaaggaaccggaaagcaccttgcgcatgcttgaggacaacgtgatgagacccggatactaccag ctactaaaagcatcgctgacttgccgccaaagacgcctgcacctgggcaagtgcaacatcgccggctggattctgggca accccgagtgcgagagcctgagcaccgccagcagctggagctacatcgtggagacccccagcagcgacaacggcacctg cttccccggcgacttcatcgactacgaggagctgcgggagcagctgagcagcgtgagcagcttcgagcggttcgagatc ttccccaagaccagcagctggcccaaccacgacagcaacaagggcgtgaccgccgcctgcccccacgccggcgccaaga gcttctacaagaacctgatctggctggtgaagaagggcaacagctaccccaagctgagcaagagctacatcaacgacaa gggcaaggaggtgctggtgctgtggggcatccaccaccccagcaccagcgccgaccagcagagcctgtaccagaacgcc gacacctacgtgttcgtgggcagcagccggtacagcaagaagttcaagcccgagatcgccatccggcccaaggtgcggg accaggagggccggatgaactactactggaccctggtggagcccggcgacaagatcaccttcgaggccaccggcaacct ggtggtgccccggtacgccttcgccatggagcggaacgccaattttaatgtctataaagccacaagaccatatctagct cattgtcctgactgcggagaagggcattcgtgccacagccctatcgcattggagcgcatcagaaatgaagcaacggacg gaacgctgaaaatccaggtctctttgcagatcgggataaagacagatgacagccacgattggaccaagctgcgctatat ggatagccatacgccagcggacgcggagcgagccggattgcttgtaaggacttcagcaccgtgcacgatcaccgggacc atgggacactttattctcgcccgatgcccgaaaggagagacgctgacagtgggatttacggacagcagaaagatcagcc acacatgcacacacccgttccatcatgaaccacctgtgataggtagggagaggttccactctcgaccacaacatggtaa agagttaccttgcagcacgtacgtgcagagcaccgctgccactgctgaggagatagaggtgcatatgcccccagatact cctgaccgcacgctgatgacgcagcagtctggcaacgtgaagatcacagttaatgggcagacggtgcggtacaagtgca actgcggtggctcaaacgagggactgacaaccacagacaaagtgatcaataactgcaaaattgatcagtgccatgctgc agtcactaatcacaagaattggcaatacaactcccctttagtcccgcgcaacgctgaactcggggaccgtaaaggaaag atccacatcccattcccattggcaaacgtgacttgcagagtgccaaaagcaagaaaccctacagtaacttacggaaaaa accaagtcaccatgctgctgtatcctgaccatccgacactcttgtcttaccgtaacatgggacaggaaccaaattacca cgaggagtgggtgacacacaagaaggaggttaccttgaccgtgcctactgagggtctggaggtcacttggggcaacaac gaaccatacaagtactggccgcagatgtctacgaacggtactgctcatggtcacccacatgagataatcttgtactatt atgagctgtaccccactatgactgtagtcattgtgtcggtggcctcgttcgtgcttctgtcgatggtgggcacagcagt gggaatgtgtgtgtgcgcacggcgcagatgcattacaccatatgaattaacaccaggagccactgttcccttcctgctc Nov 2022 agcctgctatgctgcgtcagaacgaccaaggcggccacatattacgaggctgcggcatatctatggaacgaacagcagc ccctgttctggttgcaggctcttatcccgctggccgccttgatcgtcctgtgcaactgtctgaaactcttgccatgctg ctgtaagaccctggcttttttagccgtaatgagcatcggtgcccacactgtgagcgcgtacgaacacgtaacagtgatc ccgaacacggtgggagtaccgtataagactcttgtcaacagaccgggttacagccccatggtgttggagatggagctac aatcagtcaccttggaaccaacactgtcacttgactacatcacgtgcgagtacaaaactgtcatcccctccccgtacgt gaagtgctgtggtacagcagagtgcaaggacaagagcctaccagactacagctgcaaggtctttactggagtctaccca tttatgtggggcggcgcctactgcttttgcgacgccgaaaatacgcaattgagcgaggcacatgtagagaaatctgaat cttgcaaaacagagtttgcatcggcctacagagcccacaccgcatcggcgtcggcgaagctccgcgtcctttaccaagg aaacaacattaccgtagctgcctacgctaacggtgaccatgccgtcacagtaaaggacgccaagtttgtcgtgggccca atgtcctccgcctggacaccttttgacaacaaaatcgtggtgtacaaaggcgacgtctacaacatggactacccacctt 2022279441 ttggcgcaggaagaccaggacaatttggtgacattcaaagtcgtacaccggaaagtaaagacgtttatgccaacactca gttggtactacagaggccagcagcaggcacggtacatgtaccatactctcaggcaccatctggcttcaagtattggctg aaggaacgaggagcatcgctacagcacacggcaccgttcggttgccagattgcgacaaacccggtaagagctgtaaatt gcgctgtggggaacataccaatttccatcgacataccggatgcggcctttactagggttgtcgatgcaccctctgtaac ggacatgtcatgcgaagtaccagcctgcactcactcctccgactttgggggcgtcgccatcatcaaatacacagctagc aagaaaggtaaatgtgcagtacattcgatgaccaacgccgttaccattcgagaagccgacgtagaagtagaggggaact cccagctgcaaatatccttctcaacagccctggcaagcgccgagtttcgcgtgcaagtgtgctccacacaagtacactg cgcagccgcatgccaccctccaaaggaccacatagtcaattacccagcatcacacaccacccttggggtccaggatata tccacaacggcaatgtcttgggtgcagaagattacgggaggagtaggattaattgttgctgttgctgccttaattttaa ttgtggtgctatgcgtgtcgtttagcaggcactaa</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="190"> <INSDSeq> <INSDSeq_length>1453</INSDSeq_length> <INSDSeq_moltype>AA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..1453</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q280">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..1453</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier> Nov 2022
<INSDQualifier id="q281">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table> 2022279441
<INSDSeq_sequence>MEFIPTQTFYNRRYQPRPWAPRPTIQVIRPRPRPQRQAGQLAQLISAVNKLTMRAVPQQKP RRNRKNKKQRQKKQAPQNDPKQKKQPPQKKPAQKKKKPGRRERMCMKIENDCIFEVKHEGKVMGYACLVGDKVMKPAHV KGTIDNADLAKLAFKRSSKYDLECAQIPVHMKSDASKFTHEKPEGYYNWHHGAVQYSGGRFTIPTGAGKPGDSGRPIFD NKGRVVAIVLGGANEGARTALSVVTWNKDIVTKITPEGAEEWSLALPVLCLLANTTFPCSQPPCTPCCYEKEPESTLRM LEDNVMRPGYYQLLKASLTCRQRRLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCFPGDFIDYEELREQ LSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPS TSADQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAN FNVYKATRPYLAHCPDCGEGHSCHSPIALERIRNEATDGTLKIQVSLQIGIKTDDSHDWTKLRYMDSHTPADAERAGLL VRTSAPCTITGTMGHFILARCPKGETLTVGFTDSRKISHTCTHPFHHEPPVIGRERFHSRPQHGKELPCSTYVQSTAAT AEEIEVHMPPDTPDRTLMTQQSGNVKITVNGQTVRYKCNCGGSNEGLTTTDKVINNCKIDQCHAAVTNHKNWQYNSPLV PRNAELGDRKGKIHIPFPLANVTCRVPKARNPTVTYGKNQVTMLLYPDHPTLLSYRNMGQEPNYHEEWVTHKKEVTLTV PTEGLEVTWGNNEPYKYWPQMSTNGTAHGHPHEIILYYYELYPTMTVVIVSVASFVLLSMVGTAVGMCVCARRRCITPY ELTPGATVPFLLSLLCCVRTTKAATYYEAAAYLWNEQQPLFWLQALIPLAALIVLCNCLKLLPCCCKTLAFLAVMSIGA HTVSAYEHVTVIPNTVGVPYKTLVNRPGYSPMVLEMELQSVTLEPTLSLDYITCEYKTVIPSPYVKCCGTAECKDKSLP DYSCKVFTGVYPFMWGGAYCFCDAENTQLSEAHVEKSESCKTEFASAYRAHTASASAKLRVLYQGNNITVAAYANGDHA VTVKDAKFVVGPMSSAWTPFDNKIVVYKGDVYNMDYPPFGAGRPGQFGDIQSRTPESKDVYANTQLVLQRPAAGTVHVP YSQAPSGFKYWLKERGASLQHTAPFGCQIATNPVRAVNCAVGNIPISIDIPDAAFTRVVDAPSVTDMSCEVPACTHSSD FGGVAIIKYTASKKGKCAVHSMTNAVTIREADVEVEGNSQLQISFSTALASAEFRVQVCSTQVHCAAACHPPKDHIVNY PASHTTLGVQDISTTAMSWVQKITGGVGLIVAVAALILIVVLCVSFSRH</INSDSeq_sequence> </INSDSeq> </SequenceData> <SequenceData sequenceIDNumber="191"> <INSDSeq> <INSDSeq_length>4362</INSDSeq_length> <INSDSeq_moltype>DNA</INSDSeq_moltype> <INSDSeq_division>PAT</INSDSeq_division> <INSDSeq_feature‐table> <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..4362</INSDFeature_location> <INSDFeature_quals> <INSDQualifier id="q282">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> <INSDFeature>
<INSDFeature_key>source</INSDFeature_key> Nov 2022
<INSDFeature_location>1..4362</INSDFeature_location> <INSDFeature_quals> <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value> </INSDQualifier> <INSDQualifier id="q283"> 2022279441
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value> </INSDQualifier> </INSDFeature_quals> </INSDFeature> </INSDSeq_feature‐table>
<INSDSeq_sequence>ttagtgcctgctaaacgacacgcatagcaccacaattaaaattaaggcagcaacagcaaca attaatcctactcctcccgtaatcttctgcacccaagacattgccgttgtggatatatcctggaccccaagggtggtgt gtgatgctgggtaattgactatgtggtcctttggagggtggcatgcggctgcgcagtgtacttgtgtggagcacacttg cacgcgaaactcggcgcttgccagggctgttgagaaggatatttgcagctgggagttcccctctacttctacgtcggct tctcgaatggtaacggcgttggtcatcgaatgtactgcacatttacctttcttgctagctgtgtatttgatgatggcga cgcccccaaagtcggaggagtgagtgcaggctggtacttcgcatgacatgtccgttacagagggtgcatcgacaaccct agtaaaggccgcatccggtatgtcgatggaaattggtatgttccccacagcgcaatttacagctcttaccgggtttgtc gcaatctggcaaccgaacggtgccgtgtgctgtagcgatgctcctcgttccttcagccaatacttgaagccagatggtg cctgagagtatggtacatgtaccgtgcctgctgctggcctctgtagtaccaactgagtgttggcataaacgtctttact ttccggtgtacgactttgaatgtcaccaaattgtcctggtcttcctgcgccaaaaggtgggtagtccatgttgtagacg tcgcctttgtacaccacgattttgttgtcaaaaggtgtccaggcggaggacattgggcccacgacaaacttggcgtcct ttactgtgacggcatggtcaccgttagcgtaggcagctacggtaatgttgtttccttggtaaaggacgcggagcttcgc cgacgccgatgcggtgtgggctctgtaggccgatgcaaactctgttttgcaagattcagatttctctacatgtgcctcg ctcaattgcgtattttcggcgtcgcaaaagcagtaggcgccgccccacataaatgggtagactccagtaaagaccttgc agctgtagtctggtaggctcttgtccttgcactctgctgtaccacagcacttcacgtacggggaggggatgacagtttt gtactcgcacgtgatgtagtcaagtgacagtgttggttccaaggtgactgattgtagctccatctccaacaccatgggg ctgtaacccggtctgttgacaagagtcttatacggtactcccaccgtgttcgggatcactgttacgtgttcgtacgcgc tcacagtgtgggcaccgatgctcattacggctaaaaaagccagggtcttacagcagcatggcaagagtttcagacagtt gcacaggacgatcaaggcggccagcgggataagagcctgcaaccagaacaggggctgctgttcgttccatagatatgcc gcagcctcgtaatatgtggccgccttggtcgttctgacgcagcatagcaggctgagcaggaagggaacagtggctcctg gtgttaattcatatggtgtaatgcatctgcgccgtgcgcacacacacattcccactgctgtgcccaccatcgacagaag cacgaacgaggccaccgacacaatgactacagtcatagtggggtacagctcataatagtacaagattatctcatgtggg tgaccatgagcagtaccgttcgtagacatctgcggccagtacttgtatggttcgttgttgccccaagtgacctccagac cctcagtaggcacggtcaaggtaacctccttcttgtgtgtcacccactcctcgtggtaatttggttcctgtcccatgtt acggtaagacaagagtgtcggatggtcaggatacagcagcatggtgacttggttttttccgtaagttactgtagggttt cttgcttttggcactctgcaagtcacgtttgccaatgggaatgggatgtggatctttcctttacggtccccgagttcag cgttgcgcgggactaaaggggagttgtattgccaattcttgtgattagtgactgcagcatggcactgatcaattttgca gttattgatcactttgtctgtggttgtcagtccctcgtttgagccaccgcagttgcacttgtaccgcaccgtctgccca ttaactgtgatcttcacgttgccagactgctgcgtcatcagcgtgcggtcaggagtatctgggggcatatgcacctcta tctcctcagcagtggcagcggtgctctgcacgtacgtgctgcaaggtaactctttaccatgttgtggtcgagagtggaa cctctccctacctatcacaggtggttcatgatggaacgggtgtgtgcatgtgtggctgatctttctgctgtccgtaaat cccactgtcagcgtctctcctttcgggcatcgggcgagaataaagtgtcccatggtcccggtgatcgtgcacggtgctg aagtccttacaagcaatccggctcgctccgcgtccgctggcgtatggctatccatatagcgcagcttggtccaatcgtg gctgtcatctgtctttatcccgatctgcaaagagacctggattttcagcgttccgtccgttgcttcatttctgatgcgc tccaatgcgatagggctgtggcacgaatgcccttctccgcagtcaggacaatgagctagatatggtcttgtggctttat Nov 2022 agacattaaaattggcgttccgctccatggcgaaggcgtaccggggcaccaccaggttgccggtggcctcgaaggtgat cttgtcgccgggctccaccagggtccagtagtagttcatccggccctcctggtcccgcaccttgggccggatggcgatc tcgggcttgaacttcttgctgtaccggctgctgcccacgaacacgtaggtgtcggcgttctggtacaggctctgctggt cggcgctggtgctggggtggtggatgccccacagcaccagcacctccttgcccttgtcgttgatgtagctcttgctcag cttggggtagctgttgcccttcttcaccagccagatcaggttcttgtagaagctcttggcgccggcgtgggggcaggcg gcggtcacgcccttgttgctgtcgtggttgggccagctgctggtcttggggaagatctcgaaccgctcgaagctgctca cgctgctcagctgctcccgcagctcctcgtagtcgatgaagtcgccggggaagcaggtgccgttgtcgctgctgggggt ctccacgatgtagctccagctgctggcggtgctcaggctctcgcactcggggttgcccagaatccagccggcgatgttg cacttgcccaggtgcaggcgtctttggcggcaagtcagcgatgcttttagtagctggtagtatccgggtctcatcacgt tgtcctcaagcatgcgcaaggtgctttccggttccttttcgtagcagcagggtgtgcaaggcggctgagagcaggggaa 2022279441 tgtagtgtttgccaacaggcacaagaccgggagggcgaggctccactcttcggctccctcaggggtaatttttgtgacg atgtctttgttccacgtcaccacggagagggccgtgcgggcaccttcgttggcccctcctaggacgatggccaccaccc gtcctttgttgtcgaagatcggtctgccgctgtctcccggcttgcctgcacccgtcgggatagtgaaccggcctcctga atactgcactgctccgtgatgccagttatagtacccctcgggtttctcgtgggtaaacttcgaggcatcagacttcatg tgcaccggtatctgtgcacattcaagatcgtatttagacgaccgcttaaaggccagtttagccagatcggcattgtcga tagttcccttcacatgtgctggtttcattactttatcccccaccaggcatgcgtagcccatcactttgccttcatgctt gacttcgaagatgcaatcattttcaattttcatgcacattctctccctacggcctggtttcttcttcttttgagccggc ttcttttgtggtggttgcttcttttgctttgggtcgttttgcggcgcctgcttcttctgcctttgcttcttgtttttcc gatttctgcgaggcttctgttgaggtaccgcgcgcatggtcaatttgttgactgcggagatcagctgggcgagttgccc agcctgcctctgtggacgtggtctaggtctaattacttgaattgtagggcgtggggcccagggtcggggttggtacctt ctgttatagaaagtttgcgtcgggatgaactccat</INSDSeq_sequence> </INSDSeq> </SequenceData> </ST26SequenceListing>
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022279441A AU2022279441A1 (en) | 2014-12-31 | 2022-11-30 | Novel multivalent nanoparticle-based vaccines |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462098755P | 2014-12-31 | 2014-12-31 | |
US62/098,755 | 2014-12-31 | ||
PCT/US2015/068272 WO2016109792A2 (en) | 2014-12-31 | 2015-12-31 | Novel multivalent nanoparticle-based vaccines |
AU2015373928A AU2015373928B2 (en) | 2014-12-31 | 2015-12-31 | Novel multivalent nanoparticle-based vaccines |
AU2020200303A AU2020200303B9 (en) | 2014-12-31 | 2020-01-15 | Novel multivalent nanoparticle-based vaccines |
AU2022279441A AU2022279441A1 (en) | 2014-12-31 | 2022-11-30 | Novel multivalent nanoparticle-based vaccines |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020200303A Division AU2020200303B9 (en) | 2014-12-31 | 2020-01-15 | Novel multivalent nanoparticle-based vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2022279441A1 true AU2022279441A1 (en) | 2023-02-02 |
Family
ID=55168477
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015373928A Active AU2015373928B2 (en) | 2014-12-31 | 2015-12-31 | Novel multivalent nanoparticle-based vaccines |
AU2020200303A Active AU2020200303B9 (en) | 2014-12-31 | 2020-01-15 | Novel multivalent nanoparticle-based vaccines |
AU2022279441A Pending AU2022279441A1 (en) | 2014-12-31 | 2022-11-30 | Novel multivalent nanoparticle-based vaccines |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015373928A Active AU2015373928B2 (en) | 2014-12-31 | 2015-12-31 | Novel multivalent nanoparticle-based vaccines |
AU2020200303A Active AU2020200303B9 (en) | 2014-12-31 | 2020-01-15 | Novel multivalent nanoparticle-based vaccines |
Country Status (11)
Country | Link |
---|---|
US (3) | US11191727B2 (en) |
EP (1) | EP3240567A2 (en) |
JP (3) | JP6655623B2 (en) |
KR (1) | KR102713707B1 (en) |
CN (1) | CN107427571A (en) |
AU (3) | AU2015373928B2 (en) |
BR (1) | BR112017014219A2 (en) |
CA (1) | CA2974346A1 (en) |
IL (2) | IL253187B (en) |
SG (1) | SG11201705264WA (en) |
WO (1) | WO2016109792A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013221187B9 (en) | 2012-02-16 | 2018-01-04 | Vlp Therapeutics, Inc. | Virus like particle composition |
TWI676636B (en) | 2013-07-12 | 2019-11-11 | Vlp醫療股份有限公司 | Virus like particle comprising pd-1 antigen or pd-1 ligand antigen |
EP3906939A1 (en) | 2013-10-11 | 2021-11-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
EP3177720B1 (en) * | 2014-08-08 | 2021-09-22 | VLP Therapeutics, Inc. | Virus like particle comprising modified envelope protein e3 |
SG11201701669PA (en) | 2014-09-11 | 2017-04-27 | Vlp Therapeutics Llc | Flavivirus virus like particle |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
IL253187B (en) * | 2014-12-31 | 2022-07-01 | Us Health | Novel multivalent nanoparticle-based vaccines |
MX2018004916A (en) * | 2015-10-22 | 2019-07-04 | Modernatx Inc | Broad spectrum influenza virus vaccine. |
PL3386484T3 (en) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
US11338033B2 (en) | 2016-09-02 | 2022-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
US20190314486A1 (en) * | 2016-10-21 | 2019-10-17 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
CN108148758B (en) * | 2016-12-05 | 2021-09-17 | 中国科学院大连化学物理研究所 | In-vitro model establishment method for extravillous trophoblast nanoparticle exposure |
WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
CA3058794A1 (en) | 2017-04-04 | 2018-10-11 | University Of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
ES2923133T3 (en) | 2017-08-04 | 2022-09-23 | Hospital For Sick Children | Nanoparticle platform for antibody and vaccine delivery |
KR20200047660A (en) | 2017-09-01 | 2020-05-07 | 다나-파버 캔서 인스티튜트 인크. | Immunogenic peptides specific for BCMA and TACI antigens for the treatment of cancer |
JP7403733B2 (en) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | Method for manufacturing influenza HA split vaccine |
WO2019124557A1 (en) | 2017-12-21 | 2019-06-27 | 株式会社グリーンバイオメッド | Cross-immunizing antigen vaccine and method for preparation thereof |
EP3758747A1 (en) | 2018-02-28 | 2021-01-06 | University of Washington | Self-asssembling nanostructure vaccines |
CN112512566A (en) | 2018-04-03 | 2021-03-16 | 赛诺菲 | Antigenic epstein-barr virus polypeptides |
KR20210034614A (en) | 2018-07-23 | 2021-03-30 | 국립감염증연구소장이 대표하는 일본국 | Composition comprising influenza vaccine |
JP2021532803A (en) * | 2018-08-07 | 2021-12-02 | イーティーエイチ・チューリッヒ | Polypeptides that self-assemble into nanoparticles |
KR102076917B1 (en) * | 2018-10-25 | 2020-02-13 | 연세대학교 산학협력단 | Expression vector system for preparing recombinant self-assembled nanoparticles, and method of using the same |
AU2020219803A1 (en) * | 2019-02-08 | 2021-08-05 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Nanoparticle-based influenza virus vaccines and uses thereof |
TWI776048B (en) * | 2019-04-25 | 2022-09-01 | 財團法人農業科技研究院 | Recombinant protein for preventing swine fever virus infection and composition and cell comprising the same. |
WO2020233685A1 (en) * | 2019-05-21 | 2020-11-26 | 广州市妇女儿童医疗中心 | Intein-mediated nano-carrier and application thereof, and nano preparation capable of simultaneously delivering antigen and immunopotentiator |
CN110354271A (en) * | 2019-05-21 | 2019-10-22 | 广州市妇女儿童医疗中心 | One kind is based on including peptide-mediated nano-carrier modular platform and its construction method and application |
WO2021178971A1 (en) * | 2020-03-06 | 2021-09-10 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccines against sars-cov-2 and other coronaviruses |
BR112022021208A8 (en) * | 2020-04-22 | 2023-02-23 | Medicago Inc | SUPRASTRUCTURE COMPRISING MODIFIED INFLUENZA HEMAGGLUTININ WITH REDUCED INTERACTION WITH SIALIC ACID |
EP4159864A4 (en) | 2020-06-01 | 2024-06-19 | Inthera Inc. | Recombinant expression vector for producing encapsulin-based vaccine, and preparation method therefor |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2022204597A1 (en) * | 2021-03-26 | 2022-09-29 | David Weiner | Dna encoded nanoparticle vaccine against human papillomavirus, and methods of use thereof |
CN115340609B (en) * | 2021-05-12 | 2023-06-13 | 中国农业科学院兰州兽医研究所 | Foot-and-mouth disease virus multi-antigen epitope fusion protein, protein cage nanoparticle and preparation method thereof |
US20240285740A1 (en) | 2021-05-12 | 2024-08-29 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
WO2023015145A1 (en) * | 2021-08-06 | 2023-02-09 | Najit Technologies, Inc. | Multivalent pan-influenza vaccine |
EP4401767A1 (en) | 2021-09-16 | 2024-07-24 | Emergent Product Development Gaithersburg Inc. | Vaccine compositions |
CN114891121B (en) * | 2022-05-11 | 2024-01-19 | 天康制药股份有限公司 | Bivalent virus-like particle vaccine for resisting PEDV and PRV and preparation method thereof |
WO2024167855A1 (en) | 2023-02-06 | 2024-08-15 | Emergent Product Development Gaithersburg Inc. | Influenza hemagglutinin constructs and compositions |
CN116947982B (en) * | 2023-07-12 | 2024-05-14 | 吉林大学 | Three dominant epitope peptide sequences and application thereof in influenza virus vaccine |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
CA2776391C (en) | 2001-10-01 | 2015-03-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
US20050108791A1 (en) | 2001-12-04 | 2005-05-19 | Edgerton Michael D. | Transgenic plants with improved phenotypes |
CN1659187A (en) | 2002-05-10 | 2005-08-24 | 新世纪药品有限公司 | Ferritin fusion proteins for use in vaccines and other applications |
CA2816222A1 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
GB0319797D0 (en) | 2003-08-26 | 2003-09-24 | Leuven K U Res & Dev | Particle size reduction of poorly soluble drugs |
JP5071854B2 (en) | 2005-09-12 | 2012-11-14 | 独立行政法人科学技術振興機構 | Fine particle-protein complex, method for producing the same, semiconductor device, and fluorescent labeling method |
EP1991264B1 (en) | 2006-03-07 | 2015-01-07 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
WO2008087563A2 (en) | 2006-12-29 | 2008-07-24 | Institut Pasteur Of Shanghai | Lentivirus pseudotyped with influenza hemagglutinin and methods of use |
MX2009013008A (en) | 2007-05-31 | 2010-06-09 | Influenza vaccines. | |
US8778847B2 (en) | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
WO2009026397A2 (en) | 2007-08-20 | 2009-02-26 | Fraunhofer Usa, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
RU2540871C2 (en) | 2008-02-01 | 2015-02-10 | Альфа-О Пептидес Аг | Self-assembling peptide nanoparticles effective as vaccines |
JP5382489B2 (en) | 2008-03-29 | 2014-01-08 | 国立大学法人 奈良先端科学技術大学院大学 | Circularly polarized light-emitting nanoparticles |
WO2010036948A2 (en) | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
JP2012521786A (en) * | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | Influenza virus vaccine and use thereof |
KR102115226B1 (en) | 2009-09-22 | 2020-05-27 | 메디카고 인코포레이티드 | Method of preparing plant-derived proteins |
WO2011044152A1 (en) | 2009-10-05 | 2011-04-14 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer | Protection against pandemic and seasonal strains of influenza |
WO2011102900A1 (en) | 2010-02-18 | 2011-08-25 | Technovax, Inc. | Universal virus-like particle (vlp) influenza vaccines |
WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
US9441019B2 (en) | 2011-09-23 | 2016-09-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza hemagglutinin protein-based vaccines |
EP2766030A4 (en) | 2011-10-12 | 2015-09-16 | Univ Washington | Engineered outer domain (eod) of hv gp120 and mutants thereof |
EP3906939A1 (en) | 2013-10-11 | 2021-11-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
DK3148578T5 (en) | 2014-05-27 | 2024-10-14 | Us Health | STABILIZED INFLUENZA HEMAGGLUTIN ORIGINAL REGION TRIMERS AND USES THEREOF |
EP3177720B1 (en) | 2014-08-08 | 2021-09-22 | VLP Therapeutics, Inc. | Virus like particle comprising modified envelope protein e3 |
IL253187B (en) * | 2014-12-31 | 2022-07-01 | Us Health | Novel multivalent nanoparticle-based vaccines |
-
2015
- 2015-12-31 IL IL253187A patent/IL253187B/en unknown
- 2015-12-31 US US15/540,898 patent/US11191727B2/en active Active
- 2015-12-31 SG SG11201705264WA patent/SG11201705264WA/en unknown
- 2015-12-31 EP EP15825772.5A patent/EP3240567A2/en active Pending
- 2015-12-31 JP JP2017534796A patent/JP6655623B2/en active Active
- 2015-12-31 KR KR1020177021112A patent/KR102713707B1/en active IP Right Grant
- 2015-12-31 BR BR112017014219A patent/BR112017014219A2/en not_active Application Discontinuation
- 2015-12-31 WO PCT/US2015/068272 patent/WO2016109792A2/en active Application Filing
- 2015-12-31 AU AU2015373928A patent/AU2015373928B2/en active Active
- 2015-12-31 CN CN201580076324.6A patent/CN107427571A/en active Pending
- 2015-12-31 CA CA2974346A patent/CA2974346A1/en active Pending
- 2015-12-31 IL IL294189A patent/IL294189B1/en unknown
-
2019
- 2019-11-14 JP JP2019206110A patent/JP6957580B2/en active Active
-
2020
- 2020-01-15 AU AU2020200303A patent/AU2020200303B9/en active Active
-
2021
- 2021-10-06 JP JP2021164905A patent/JP7250878B2/en active Active
- 2021-11-04 US US17/519,142 patent/US11938221B2/en active Active
-
2022
- 2022-11-30 AU AU2022279441A patent/AU2022279441A1/en active Pending
-
2024
- 2024-03-25 US US18/615,895 patent/US20240226012A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016109792A8 (en) | 2017-07-27 |
AU2020200303B9 (en) | 2022-09-15 |
JP2022023102A (en) | 2022-02-07 |
SG11201705264WA (en) | 2017-07-28 |
AU2015373928B2 (en) | 2019-10-17 |
IL294189B1 (en) | 2024-08-01 |
AU2020200303A1 (en) | 2020-02-06 |
AU2015373928A1 (en) | 2017-08-10 |
KR102713707B1 (en) | 2024-10-04 |
WO2016109792A3 (en) | 2016-09-01 |
JP6655623B2 (en) | 2020-02-26 |
CA2974346A1 (en) | 2016-07-07 |
US11191727B2 (en) | 2021-12-07 |
US20220054419A1 (en) | 2022-02-24 |
JP6957580B2 (en) | 2021-11-02 |
JP7250878B2 (en) | 2023-04-03 |
AU2020200303B2 (en) | 2022-09-08 |
EP3240567A2 (en) | 2017-11-08 |
IL253187A0 (en) | 2017-08-31 |
JP2018501801A (en) | 2018-01-25 |
IL253187B (en) | 2022-07-01 |
IL294189A (en) | 2022-08-01 |
US20180021258A1 (en) | 2018-01-25 |
JP2020039347A (en) | 2020-03-19 |
US20240226012A1 (en) | 2024-07-11 |
US11938221B2 (en) | 2024-03-26 |
BR112017014219A2 (en) | 2018-03-06 |
CN107427571A (en) | 2017-12-01 |
WO2016109792A2 (en) | 2016-07-07 |
KR20170102905A (en) | 2017-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022279441A1 (en) | Novel multivalent nanoparticle-based vaccines | |
US11793871B2 (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
US10137190B2 (en) | Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins | |
CN113423718A (en) | Nanoparticle-based influenza virus vaccines and uses thereof | |
US11535651B2 (en) | Hepatitis B nanoparticle-based vaccine for influenza virus | |
EA046906B1 (en) | VACCINES AGAINST THE FLU VIRUS AND WAYS OF THEIR APPLICATION |